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8ABSTRACT
Mutations within the cascade of pituitary transcription factors that play a crucial role in its 
development  and  differentiation  have  improved  our  understanding  of  variable 
hypopituitarism  in  children.  The  diagnosis  of  hypopituitarism  is  problematic  as  it  is 
dependent on a series of endocrine tests varying in sensitivity and specificity, compounded 
by evolving hormonal deficiencies.  In order to test the hypothesis that human phenotypes 
are  determined  by  the  neuroanatomy which  is  further  influenced  by  the  position  of the 
abnormal gene within the pituitary developmental cascade, clinical, biochemical, magnetic 
resonance  [MR]  imaging  and  molecular data were  retrospectively analysed  in  subgroups 
from a cohort of 825 patients with variable hypothalamo-pituitary [H-P] abnormalities. The 
major aims were to determine abnormalities on MR imaging that help predict the spectrum 
of hypopituitarism, to assess if genotype determined phenotype and to ascertain the optimum 
test  for  diagnosis  of  hormone  deficiency.  Results  showed  good  structure-function 
relationships  within  the  H-P  axis.  Anterior  pituitary  hypoplasia  and  an  undescended 
posterior pituitary were 6.7 and 33.1  times more prevalent in patients with hypopituitarism 
as compared with those without. These abnormalities were also significantly associated with 
endocrinopathies  in  patients  with  optic  nerve  hypoplasia.  Within  patients  with 
hypopituitarism,  midline  forebrain  defects  [MFD]  and  pituitary  stalk  abnormalities  were 
found to be significantly associated with combined pituitary hormone deficiency as opposed 
to  isolated  GH  deficiency.  GH  was  critical  for  early  postnatal  growth,  which  was  also 
influenced by other pituitary hormones  and MFD.  Regular evaluation of serum thyroxine 
concentration best revealed TSH deficiency, as the TRH test was normal in 23% of patients 
with central hypothyroidism limiting its role as a diagnostic test. A combination of the short 
Synacthen test and 0800-hour serum cortisol concentrations represented the optimal method 
of  investigation  for  ACTH  deficiency.  The  LHRH  test  in  infancy  needs  careful 
interpretation, as responses were gender-specific with significantly exaggerated serum FSH 
concentrations in females. There was a poor genotype-phenotype correlation, particularly in 
patients with mutations in HESX1, PROP1 and SOX3,  both within and between pedigrees, 
indicating a role for other genetic or environmental factors on phenotypic expression.
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27CHAPTER 1
PITUITARY GLAND AND ITS FUNCTION
1.1  INTRODUCTION
The pituitary gland is the central regulator of growth, reproduction and homeostasis.  The 
gland lies within a bony cavity called sella turcica at the base of the brain to  which it is 
attached by the pituitary stalk or infiindibulum [Figure  1.1]. A mature gland consists of the 
adenohypophysis  [anterior and  intermediate  lobes]  and  neurohypophysis  [posterior  lobe]. 
The anterior pituitary secretes growth hormone  [GH],  thyrotrophin or thyroid  stimulating 
hormone  [TSH],  corticotrophin  or  adrenocorticotrophic  hormone  [ACTH],  follicle 
stimulating hormone [FSH], luteinising hormone [LH] and prolactin. The intermediate lobe 
produces  pro-opiomelanocortin  [POMC],  which  is  a  precursor to  melanocyte  stimulating 
hormone  [MSH],  and  endorphins,  and  this  intermediate  lobe  involutes  in  the  adult.  The 
posterior lobe  secretes  arginine  vasopressin  [AVP,  also  called  antidiuretic  hormone]  and 
oxytocin.  The hypothalamus lies in a superior position to the pituitary gland and the link 
between the two organs is critical for normal pituitary gland function.
The  anterior pituitary develops  from oral  ectoderm while  the posterior pituitary develops 
from neural  ectoderm.  Both  lobes  of the  pituitary gland  are  histologically different  as  a 
result of embryological development and function almost as two separate glands.
28Figure 1.1: Magnetic resonance scan of the brain illustrating neuroanatomical 
relations of the pituitary gland.
1.2  THE HYPOTHALAMO-PITUITARY AXIS
Complex  functions  of the pituitary gland  are  mediated  via hormone-signalling pathways 
from  the brain  and  hypothalamus  that  ultimately co-ordinate  complex  signals  to  various 
target  organs.  The  hypothalamus  virtually  surrounds  the  third  ventricle  and  has  neural 
projections  into  the  cerebral  cortex  and  median  eminence.  Various  stimulatory  and 
inhibitory  releasing  hormones  are  secreted  from  hypothalamic  nuclei  that  regulate  the 
hypothalamo-pituitary  [H-P]  -target  gland  axis  [Figure  1.2].  They  include  GH  releasing 
hormone  [GHRH],  a  44-amino  acid  polypeptide  which  stimulates  the  release  of  GH;
29corticotrophin releasing hormone [CRH], a 41-amino acid polypeptide which stimulates the 
releases of ACTH; thyrotrophin releasing hormone [TRH], a tripeptide which stimulates the 
releases of TSH and prolactin; gonadotrophin releasing hormone [GnRH], a decapeptide that 
stimulates the release of FSH and LH; somatostatin, a 14-amino acid peptide which inhibits 
the release of GH; and dopamine, a single amino acid derivative that inhibits the release of 
prolactin. Hormones secreted by the posterior lobe of the pituitary gland are synthesised in 
magnocellular  neurones  of  the  paraventricular  and  supraoptic  nuclei  within  the 
hypothalamus.
Figure 1.2: Hypothalamic nuclei and their stimulatory and inhibitory hormones
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30The hypothalamus is supplied by blood  from the circle of Willis and most venous blood 
drains  into  the vein of Galen.  Blood from the  superior hypophyseal  arteries,  which arise 
from the internal carotid arteries, flows through a capillary plexus in the median eminence to 
enter a sinusoidal network in the pituitary stalk.  Blood passes from these sinusoids into a 
second capillary network plexus in the anterior pituitary.  This venous portal system linking 
these two capillary networks is called the H-P portal system [Figure 1.3]. The infundibulum 
or pituitary stalk carries both, the portal blood with delivery of hypothalamic hormones to 
the anterior pituitary, and neural tracts from magnocellular neurones of the paraventricular 
and supraoptic nuclei within the hypothalamus to the posterior pituitary. Any damage to the 
pituitary stalk can therefore result in anterior and posterior pituitary dysfunction.
Figure 1.3: Neurovascular connections within the infundibulum or pituitary stalk.
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31Several  hypothalamic  hormones  are  initially  synthesised  as  prohormones  according  to 
specific  gene  sequences.  Following  transcription  and  translation  on  the  endoplasmic 
reticulum,  they are transferred to the Golgi  complex where the  final products of enzyme 
action are packaged into granules. These granules then migrate down their axons and their 
contents  are  released  to  the  exterior  by  exocytosis  following  depolarisation  of  nerve 
terminals. Neurosecretory cells of the hypothalamic nuclei also have numerous connections 
with terminals of neurones originating in other parts of the central nervous system secreting 
known neurotransmitters such as noradrenaline, dopamine, acetylcholine, serotonin, opioids 
and y amino-butyric  acid [GABA].  This probably accounts  for the important influence of 
external  stimuli  such  as  environmental  changes,  stress  and  exercise  on  anterior pituitary 
function.
Some hypothalamic hormones such as somatostatin are also found in other parts of the brain 
where it acts as a neurotransmitter or neuromodulator, in the gastrointestinal tract where it 
exerts various inhibitory effects and in the pancreas where it inhibits the release of insulin 
and glucagon.
One characteristic of anterior pituitary hormones is that they are secreted in discrete pulses 
that are associated with pulsatile release patterns of their regulatory hypothalamic hormones. 
The pulsatility is sometimes critical for normal function as observed with GH, FSH and LH. 
If pulsatility of GnRH  is  interrupted or a continuous  infusion administered,  then after an 
initial  increase  of  serum  FSH  and  LH  concentrations,  their  release  is  inhibited.  Other 
hypothalamic  hormones  such  as  CRH  are  secreted  in  circadian  pulses  resulting  in  the 
circadian rhythm of ACTH and cortisol secretion.
321.3 ANTERIOR PITUITARY HORMONES
1.3.1  Introduction
The anterior pituitary or adenohypophysis consists of five different cell types secreting six 
hormones which can be classified arbitrarily as (1) those that have a primary effect on target 
tissues  directly:  two  protein  hormones  with  considerable  homology,  GH  secreted  by 
somatotrophs and prolactin secreted by lactotrophs and (2) those whose primary effect is to 
stimulate other endocrine glands to secrete their hormones including three glycoprotein and 
one polypeptide hormone. TSH secreted by thyrotrophs and gonadotrophins [FSH and LH] 
secreted by  gonadotrophs  are  glycoproteins,  while  ACTH  secreted by  corticotrophs  is  a 
polypeptide  [Table 1.2].
Table 1.1:  Hormones secreted from the anterior lobe of the pituitary gland
Cell type Hormone % Cell 
population
Hypothalamic
hormone
Hypothalamic nucleus 
of synthesis
Somatotroph GH 40-50% GHRH (+) 
Somatostatin (-)
Arcuate,
Anterior periventricular
Thyrotroph TSH 3-5% TRH (+) 
Somatostatin (-)
Paraventricular, 
Anterior periventricular
Corticotroph ACTH 15-20% CRH (+)
AVP -augments CRH
Paraventricular,
Supraoptic
Gonadotroph LH, FSH 10-15% GnRH (+) Arcuate
Lactotroph Prolactin 10-25% TRH (+) 
Dopamine (-)
Arcuate,
Paraventricular
33Figure 1.4: Feedback signals within the hypothalamo-pituitary-target gland axis.
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Hormones  secreted  from  the  anterior  pituitary  regulate  growth,  puberty,  metabolism, 
response to stress, reproduction and lactation. To maintain function, it is essential that the 
pituitary gland and hypothalamic cells receive constant and rapid information about the state 
of  systems  regulated  so  that  the  release  of  hormones  can  be  finely  adjusted  to  the 
requirement of target tissues by these feedback mechanisms [Figure 1.4].
The hormones derived from the anterior pituitary and hypothalamus are peptide or protein 
hormones  requiring  transcription  of a  single  gene  apart  from  the  a  and  (3  subunits  of 
glycoprotein  hormones  [TSH,  LH  and  FSH]  which  are  derived  from  different  genes. 
Hormone synthesis requires transcription followed by post-transcriptional modification by 
excision of introns, translation of messenger ribonucleic acid [mRNA] and post-translational 
modifications, in some cases involving cleavage of the prohormone into fragments.
34Unlike  insulin  and growth  factors,  which bind to transmembrane receptors with inherent 
tyrosine kinase activity [Figure 1.5 (a)], GH and prolactin bind to receptors with intracellular 
molecules  possessing  tyrosine  kinase  activity  [Figure  1.5  (b)].  The  rest  of the  anterior 
pituitary hormones  bind  to  G-protein  coupled  receptors  with  either  a  short  extracellular 
domain e.g. GnRH [Figure 1.5 (c)] or a much longer domain e.g. TSH, LH [Figure 1.5 (d)].
Figure  1.5:  Hormone  receptors  with  (a)  inherent  tyrosine  kinase  [TK]  activity,  (b) 
intracellular  molecules  possessing  TK  activity,  (c)  G-protein  receptors  with  a  short 
extra cellular domain, (d) G-protein receptors with a long extra cellular domain.
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35Binding  of hormones,  such  as  GH  and  prolactin,  to  the  extra  cellular  domain  of their 
receptor results in receptor dimerisation with phophorylation of Janus [JAK] kinases as well 
as  of the  receptor.  This  induces  phosphorylation  of signal  transducers  and  activators  of 
transcription  [STAT]  kinases,  which  translocate  to  the  nucleus  as  dimers,  and  activate 
transcription factors [Figure 1.6].
Figure  1.6:  The  GH  receptor,  its  dimerisation  and  activation  of  the  JAK/STAT 
pathway of signal transduction.
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36Hormone-receptor interactions  of other hormones  induce  dissociation of the  intracellular 
trimeric  G-protein  that  may  either  open  ion  channels  in  the  membrane  or  activate  a 
membrane bound enzyme that  stimulates  [or inhibits]  production of a  second messenger 
such  as  cyclic  adenosine  mono  phosphate  [cAMP]  or  diacylglycerol  and  inositol 
triphosphate.  These  products  then  activate  serine/threonine  kinases  or  phosphatases. 
Activation  of  these  kinases  leads  to  alterations  in  specific  cytosolic  enzyme  activity, 
activation  of  nuclear  transcription  factors  or  initiation  of  a  cascade  of  subsequent 
phosphorylations  on  serine  and  threonine  residues  of protein  kinases  that  can  regulate 
transcription [Figure 1.7].
Figure 1.7: Signal transduction and transcriptional actions of peptide hormones.
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The human GH gene [GH1]  forms part of a cluster of five homologous genes along with 
human chorionic  somatomammotropic hormone pseudogene  1   (CSHP1),  human chorionic 
somatomammotropic hormone  1   [CSH1],  GH2 and human chorionic  somatomammotropic 
hormone 2  [CSH2].  The  gene  is  located  on the  long  arm of chromosome  17  [17q22-24] 
spanning 66.5 kilo bases [Kb]. Its expression is regulated not only by a proximal promoter, 
but also by a locus control region 15-32 Kb upstream of the GH1 gene. Full-length transcript 
from the GH1  gene encodes a  191  amino acid, 22 kilo Dalton [kDa] protein that contains 
two disulphide bridges and accounts for 85-90% of circulating GH. Alternative splicing of 
the mRNA transcript generates a 20 kDa form of GH that accounts for the remaining  10- 
15%. Within both, the proximal promoter and the locus control region, are located binding 
sites for the pituitary-specific transcription factor POU1F1.
In circulation, GH binds to two binding proteins [BP], high affinity GHBP and low affinity 
GHBP. Little is known about the low affinity GHBP, accounting for approximately 10-15% 
of GH binding with a preference for binding to 20kDa GH. On the other hand, high affinity 
GHBP is a 61 kDa glycosylated protein that represents a soluble form of the extra cellular 
domain of the GH receptor that can bind to both 20 and 22 kDa GH and thereby prolong the 
half-life of GH. The end-result is an activation of a number of genes that mediate effects of 
GH.  These  include  early  response  genes  implicated  in  cell  growth,  proliferation  and 
differentiation, and insulin-like growth factor I [IGFI].  IGF1, synthesized in the liver, is a 
single  chain polypeptide  containing  70  amino  acids  sharing  considerable  homology with 
insulin.  IGFI  is  the  main  GH-dependent  growth  factor  and  circulates  bound  to  several 
binding proteins, the principal being IGFBP3, secretion of which is also regulated by GH.
38Measurement of IGFI correlates well with spontaneous GH secretion and is widely used in 
the  diagnosis  of GH  deficiency  [GHD].  However,  its  concentration  is  altered  in  disease 
states such as hypothyroidism, malnutrition, poorly controlled diabetes and chronic diseases.
Apart  from  its  indirect  actions  on  linear  growth  through  the  synthesis  of IGFI,  GH  is 
anabolic,  lipolytic  and  diabetogenic  [Figure  1.8].  It  increases  calcium  absorption  and  is 
believed to improve bone density. Administration of GH results in a reduction in body fat 
and an increase in muscle mass.
Figure 1.8: Major actions of growth hormone.
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39Two hypothalamic hormones regulate GH: GHRH, a 44 amino acid protein that stimulates 
GH secretion, and somatostatin, an inhibitory hormone containing 14 amino acids. Both GH 
and  growth  factors  such  as  IGFI  and  IGFII  exert  negative  feedback  on  hypothalamic 
regulators of GH secretion [Figure 1.9]. Sex steroids such as estrogen and testosterone also 
increase GH secretion, the latter having an indirect effect requiring prior aromatisation.
Recent use of synthetic GH-releasing peptides [GHRP] has led to the identification of a GH 
secretagogue  receptor  [GHSR  type  la].  The  receptor  is  strongly  expressed  in  the 
hypothalamus but specific binding sites for GHRP have also been identified in other regions 
of the  central  nervous  system  and  peripheral  endocrine  and  non-endocrine  tissues.  The 
endogenous ligand for GHSR, Ghrelin, has now been isolated from the stomach and is an 
octynylated  peptide  consisting  of 28  amino  acids.  It  is  expressed  predominantly  in  the 
stomach but smaller amounts are also produced within the bowel, pancreas, kidney, immune 
system,  placenta,  pituitary,  testis,  ovary  and  hypothalamus.  Ghrelin  leads  not  only  to 
secretion  of  GH,  but  also  stimulates  prolactin  and  ACTH  secretion.  Additionally,  it 
influences endocrine pancreatic function and glucose metabolism, gonadal function, appetite 
and behaviour.  It also  controls gastric motility,  acid secretion and has  cardiovascular and 
anti-proliferative  effects.  The  role  of  endogenous  Ghrelin  in  normal  growth  during 
childhood remains unclear. Both Ghrelin and GHRP release GH synergistically with GHRH 
but the efficacy of these compounds as growth-promoting agents is poor.
40Figure 1.9: Feedback mechanism controlling growth hormone secretion,
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41GH is secreted in a pulsatile fashion under the control of the hypothalamus [Figure  1.10]. 
Peak  serum  GH  concentrations  are  achieved  during  sleep.  Secretion  of  hypothalamic 
hormones is further influenced by neurotransmitters and neuropeptides  [Table  1.2].  As a 
result,  GH  secretion  is  also  increased  during  emotional  stress,  exercise,  hypoglycaemia, 
protein meals and prolonged fasting. Pharmacological agents used to increase GH secretion 
include insulin, glucagon, clonidine, L-dopa and propranolol.
Figure 1.10: Endogenous growth hormone pulsatility measured by two assays.
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42Table 1.2: Major factors controlling growth hormone secretion
Stimulation Inhibition
Growth hormone releasing hormone Somatostatin
Hypoglycaemia Hyperglycaemia
Decreased free fatty acids Increased free fatty acids
Starvation Insulin-like growth factor 1
Sleep Senescence
Exercise Growth hormone
Stress Progesterone
Puberty Glucocorticoids
Estrogens P adrenergic agonists
Androgens Serotonin antagonists
a  adrenergic agonists Dopamine antagonists
Serotonin
Dopamine agonists
Pyridostigmine
431.3.3  Thyrotrophin or Thyroid Stimulating Hormone
Thyrotrophin  [TSH]  is  a  glycoprotein  consisting  of two  non-covalently bound chains  of 
amino acids  [a and p]  and is synthesised and stored within the thyrotrophs of the anterior 
pituitary gland.  The a chain consists of 92  amino  acids  and shares homology with other 
pituitary glycoproteins, FSH and LH. The gene encoding TSH a glycoprotein is located on 
chromosome  6ql2-q21.  The  P  chain contains  110  amino  acids  and is  TSH-specific.  The 
gene encoding the TSH p chain is located on chromosome lpl3.
The primary function of TSH is to stimulate the thyroid gland to secrete thyroid hormones; 
triiodothyronine [T3] and thyroxine [T4]. Its actions include stimulation of the iodide pump 
on the cell membrane transporting iodide into the cell, stimulation of synthesis of thyroidal 
storage protein thyroglobulin and stimulation, synthesis  and release of T4 and T3 from their 
complexes with thyroglobulin.
TSH secretion is pulsatile with maximum concentrations attained at night.  Its  secretion is 
stimulated by hypothalamic TRH and inhibited by somatostatin and dopamine. Both thyroid 
hormones  exert  negative  feedback  at  the  pituitary  level  on  TSH  secretion  and  at  the 
hypothalamic  level  on  TRH  [Figure  1.11].  Other  factors  impinging  on  TSH  secretion 
include  estrogen  that  increases  the  number  of TRH  receptors  on  the  thyrotrophs  and  a 
decrease in the ambient temperature acting as a potent stimulator of TSH.
44Figure 1.11: Feedback mechanisms within the hypothalamo-pituitary-thyroid gland 
axis. + positive feedback  - negative feedback.
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Bound and free T4 and T31.3.4  Corticotrophin or Adrenocorticotrophic hormone
Corticotrophin [ACTH] is a 39 amino acid polypeptide with a very short biological half-life 
of approximately 8 minutes. It is synthesised and stored within corticotrophs of the anterior 
pituitary  that  account  for  about  15%  of  the  adenohypophysis.  The  initial  precursor 
prohormone  is  pro-opiomelanocortin  [POMC].  Post-translational  processing  of POMC  is 
species-specific. The POMC gene located on chromosome 2 in humans spans approximately 
12 Kb and consists of 3  exons.  Cleavage of the POMC precursor into biologically active 
peptides is a critical process [Figure 1.12].
Figure 1.12: Synthesis of corticotrophin [ACTH] from pro-opiomelanocortin [POMC].
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46The  main  enzymes  involved  are  prohormone  convertases  [PC],  particularly  PCI  within 
anterior pituitary corticotrophs. PCI  cleaves POMC to generate N-POC and |3 lipotrophin. 
N-POC  is  then  cleaved  to  form  pro-y-melanocyte  stimulating  hormone  [pro-y-MSH],  a 
joining peptide and ACTH. There is further evidence to suggest that another enzyme PC2 
cleaves  ACTH  into  aMSH  and  a  corticotrophin-like  intermediate  lobe  peptide  [CLIP] 
within the intermediate lobe and P lipotrophin is cleaved into P endorphin and y lipotrophin. 
aMSH  plays  an  important  role  as  an  agonist  for  the  melanocortin  1   [MCI]  receptor in 
causing pigment deposition in the hair follicle and as an agonist for the MC4 receptor in the 
hypothalamus where it controls appetite.
Hypothalamic  CRH,  a 41  amino  acid peptide, binds with high affinity to  its  specific cell 
membrane  receptor  [CRHR]  on  the  corticotrophs  to  increase  transcription  of the  POMC 
gene and ACTH synthesis [Figure 1.13]. CRH neurones are also found in other areas of the 
brain including the hypothalamus, brainstem and cerebral cortex. AVP acts synergistically 
with CRH to stimulate ACTH release from corticotrophs.  Various other neurotransmitters 
[serotonin, noradrenaline, neuropeptide Y, interleukins  1   and 6, tumour necrosis factor and 
leukaemia inhibitory factor] are also involved in ACTH secretion. Stressors such as surgical 
stress,  infection,  pain,  acute  illness,  fever,  hypoglycaemia  and  other  pathological  states 
increase  CRH  secretion  resulting  in  a  profound  increase  in  both  ACTH  and  cortisol 
secretion. Exogenous glucocorticoids reverse this effect.
The primary function of ACTH is to stimulate the zona fasciculata and zona reticularis of 
adrenal  glands  to  produce  glucocorticoids,  mainly  cortisol,  and  adrenal  androgens.  Like 
other peptide hormones, ACTH binds to its specific membrane receptor on adrenocortical
47cells to increase the formation of cyclic AMP and activation of various protein kinases. The 
secretion of ACTH  follows a distinct circadian rhythm with peak concentrations in early 
hours of the morning and low concentrations in the late evening. As a result of this, cortisol 
secretion is  also circadian with peak concentrations at around 0800 hours  and a nadir at 
midnight. This rhythm can be disrupted by shifts in day-night patterns.
Figure 1.13: Hypothalamo-pituitary-adrenal axis and its feedback mechanisms;
+ positive feedback; - negative feedback
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481.3.5  Gonadotrophins
The reproductive system is unique due to changes in the secretion of reproductive hormones 
taking place throughout life. Gonadotrophins, FSH and LH, are glycoproteins composed of 2 
subunits, a and (3 [Figure  1.14]. The a-subunit is identical to the a-subunit of TSH  [gene 
encoding the  a-subunit  is  located on chromosome  6ql2-q21]  and the  specific biological 
activity of both hormones resides in the (3-subunit. The gene encoding the FSH (3 chain is 
found  on  chromosome  11 pi 1.2  and  that  of the  LH  p  chain  is  located  on  chromosome 
19ql3.2. The human chorionic gonadotrophin p-subunit has similar biological activity to the 
LH p-subunit.
Figure 1.14: Simplified diagram of the structure and actions of gonadotrophins
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49Pulsatile release of hypothalamic GnRH regulates the secretion of LH and FSH [Figure 1.15 
a  and  b].  GnRH-synthesising  neuronal  migration,  from  their  first  appearance  in  the 
embryonic medial olfactory placode to their final position in the mediobasal hypothalamus, 
is  complete  by  around  the  19th  week  of  gestation  when  pulsatile  GnRH  release  is 
established. Several signalling factors such as anosmin-1 or KAL and FGFR1 are implicated 
in  this  migratory  process.  GnRH  synthesis  and  release  is  also  influenced  by  several 
neuroendocrine factors such as PCI and leptin.
Kisspeptins  are products  of the KiSS-1  gene, which bind to  a G-protein coupled receptor 
known as GPR54. Although KiSS-J was initially discovered as a metastasis suppressor gene, 
recent evidence suggests the kisspeptin/GPR54 system is a key regulator of the reproductive 
system. GnRH neurons are direct targets for regulation by kisspeptins, and KiSS-1 mRNA is 
regulated by gonadal hormones, suggesting that KiSS-1  neurones play an important role in 
feedback regulation of gonadotrophin secretion.
Dopamine also appears to have a regulatory effect on gonadotrophin secretion that is dose 
dependent. Estradiol and progesterone act via both, the pituitary and hypothalamus, to have 
a negative effect on gonadotrophin secretion.  However,  if plasma estradiol concentrations 
are very high for a period greater than approximately 36 hours  in the absence of plasma 
progesterone, a positive feedback influence is exerted with an LH surge as seen in the mid- 
menstrual cycle in females. FSH secretion is also regulated by inhibin, a protein molecule 
secreted by the follicular granulosa cells in the female and Sertoli cells in the male.
50Figure 1.15: Feedback mechanisms within the (a) hypothalamo-pituitary-testicular axis 
and (b) hypothalamo-pituitary-ovarian axis. +positive feedback, - negative feedback.
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51LH  secretion  is pulsatile  in both  sexes but  sexual  dimorphism in physiological  secretory 
patterns  becomes  evident  with  maturity  of the  H-P-gonadal  axis.  There  is  a  surge  in 
gonadotrophin  and  gonadal  steroid  secretion  in  the  neonatal  period,  with  similar 
concentrations to those reached during puberty. Following the first few months of life, the 
gonadotrophin  axis  remains  quiescent  until  puberty  when  concentrations  rise  again.  An 
increased nocturnal LH release following this quiescent phase is the first sign of the onset of 
puberty.  FSH  regulates  gametogenesis  in males  and  females  while  LH  is  thought to  be 
primarily responsible for gonadal steroid secretion.
1.3.6  Prolactin
The chemical structure of prolactin, a protein containing 199 amino acids, has similarity to 
that of GH.  The prolactin gene is situated on chromosome 6  and the hormone is initially 
synthesized  as  a  prohormone.  The  principal  functions  of  prolactin  are  growth  and 
development of breasts, initiation and maintenance of lactation in postpartum women. It also 
plays some role in regulation of gonadal function by stimulating generation of LH receptors 
in gonads  of both  sexes.  Release of prolactin  is  under control  of the hypothalamus  with 
afferent  impulses  from  sensory  receptors,  primarily  around  the  nipples.  The  dominant 
hypothalamic  influence  is  inhibitory  and  the  principal  inhibitory  hormone  is  dopamine 
[Figure  1.16]. Other molecules exerting an inhibitory role are noradrenaline, histamine and 
serotonin acting at either a hypothalamic or pituitary level. TRH in addition to stimulating 
the  release  of TSH  is  also  the  principal  prolactin  stimulatory  hormone.  Thyroxine  and 
estradiol  can  modulate  the  number  of TRH  receptors  in  lactotrophs  thereby  influencing
52prolactin release. Thyroxine, by negative feedback, decreases the number of TRH receptors 
while estradiol increases their availability.  Maternal pituitary gland is the main source of 
serum  prolactin  during  pregnancy  and  the  only  known  clinical  effect  of  prolactin 
hyposecretion in adults is failure of lactation in puerperal women.
Figure  1.16:  Factors  controlling  prolactin  secretion.  +  positive  feedback,  -  negative 
feedback
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531.4 POSTERIOR PITUITARY HORMONES
The posterior pituitary is composed of neural tissue that descends from the floor of the third 
ventricle. It does not synthesise hormones. It consists of axons of neurones with cell bodies 
located in the supraoptic and paraventricular nuclei of the hypothalamus. Posterior pituitary 
hormones, arginine vasopressin [AVP] and oxytocin, are synthesized in the hypothalamus, 
transported  in  the  neurohypophyseal  tract  of the  pituitary  stalk,  stored  in  the  posterior 
pituitary and released in response to neurohypophyseal stimuli.
1.4.1  Arginine Vasopressin
Vasopressin is a basic nonapeptide with a disulphide bridge between cysteine residues  at 
positions  1   and  6.  In  most  mammals,  the  amino  acid  at  position  8  is  arginine.  The 
vasopressin gene lies on chromosome 20 in tandem with the oxytocin gene separated by 8 
Kb  of DNA.  The preprohormone  is  synthesized  in the  magnocellular neurone  cell  body, 
following which the signal peptide is cleaved away. The gene contains 3 exons and encodes 
a polypeptide precursor that consists of a  19 amino acid amino-terminal signal peptide, a 9 
amino acid vasopressin peptide, a di amino acid linker, a 93 amino acid neurophysin peptide 
[NPII],  a  single  amino  acid  linker  and  a  39  amino  acid  carboxyl-terminal  glycopeptide 
copeptin  [Figure  1.17].  The prohormone  folds  and places  A  VP  into  a binding pocket  of 
NPII,  which  protects  AVP  from  proteolysis  and  promotes  high-density  packing  in 
neurosecretory granules  by oligomerisation of AVP-NPII  dimers.  Following formation of 
seven disulphide bonds within NPII,  one  within AVP  and glycosylation  of copeptin,  the 
prohormone  is  packaged  into  neurosecretory granules  and  cleaved  into  product  peptides 
during axonal transport to the posterior pituitary. The mature hormone and NPII are stored
54as  a  complex  in  secretory  granules  within  nerve  terminals  of  the  posterior  pituitary. 
Stimulation of vasopressinergic neurones releases their contents into the circulation.
Figure 1.17: Synthesis and structure of arginine vasopressin (AVP)
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The half-life of AVP is short, approximately 5-15 minutes. AVP acts via three G-protein 
coupled receptors: it achieves its pressor effects via VI  receptors, its main renal effects via 
V2 receptors and it acts via V3 receptors on corticotrophs to secrete ACTH in synergy with 
CRH. Activation of V2  receptors leads to  a biphasic  increase in expression of the water 
channel protein Aquaporin 2. This allows re-absorption of water from the duct lumen along 
an  osmotic  gradient,  with  excretion  of  a  concentrated  urine  [Figure  1.18].  The  main 
regulatory factors  in determining vasopressin secretion are osmotic status, blood pressure 
and circulating volume. Neurotransmitters, dopamine and norepinephrine and angiotensin II 
are also thought to play a role in vasopressin secretion.
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55Figure 1.18: Actions of arginine vasopressin and mechanisms controlling its secretion.
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1.4.2  Oxytocin
The  oxytocin  gene  found  on  chromosome  20  consists  of 3  exons  and  like  vasopressin, 
encodes a polypeptide precursor with an amino-terminal  signal peptide,  oxytocin peptide, 
neurophysin  and  a  carboxy-terminal  peptide.  The  human  oxytocin  promoter  contains 
estrogen-response and interleukin-6 response elements although the significance of these is 
unclear.  The  half-life  of oxytocin  is  short.  It  binds  to  a  G-protein  coupled  receptor  to 
mediate a variety of effects largely concerned with the regulation of lactation, parturition 
and  reproductive  behaviour.  In  humans,  women  lacking  posterior pituitary  function  can 
breast-feed normally, indicating that oxytocin is not necessary for lactation in humans.
56CHAPTER 2
EMBRYOLOGY OF THE PITUITARY GLAND
There has been an explosion in the understanding of the genetic basis of the development of 
hypothalamo-pituitary [H-P] and midline forebrain structures [MFS] over the past 25 years. 
Development of the pituitary gland has been extensively studied in the mouse.  Although 
little is known about pituitary development in humans, it would appear to mirror that seen in 
the  rodent,  as  pituitary  development  is  similar  in  all  vertebrates.  The  anterior  and 
intermediate lobes of the pituitary gland are derived from oral ectoderm whilst the posterior 
pituitary is derived from neural ectoderm (Takuma et al.  1998; Dattani and Robinson 2000; 
Cohen and Radovick 2002).
2.1  STAGES OF PITUITARY DEVELOPMENT
Development of the pituitary gland occurs in 4 distinct stages [Figure 2.1].
(a)  Formation of the pituitary placode from oral ectoderm: Cell types of the pituitary gland 
are derived from the most anterior midline portion of the embryo in a region contiguous with 
the anterior neural ridge.  The anterior neural ridge is displayed ventrally to  form the oral 
epithelium which gives rise to the roof of the oral cavity. Onset of pituitary organogenesis 
coincides  with  a  thickening  [the  pituitary  placode]  in  the  roof of the  oral  ectoderm  at 
embryonic day (E) 8.5, corresponding to 4-6 weeks gestation in humans.
57(b) Formation of rudimentary Rathke’s pouch:  Invagination of the oral  ectoderm forms a 
rudimentary pouch and evagination of the ventral diencephalon forms the posterior pituitary. 
The pituitary placode makes contact with the floor of the ventral diencephalon. Apposition 
between the rudimentary Rathke’s pouch and neural ectoderm of the diencephalon is critical 
to normal development and is maintained throughout early pituitary organogenesis.
(c) Formation of definitive Rathke’s pouch:  The rudimentary Rathke’s pouch deepens and 
folds on itself until it closes forming a definitive pouch. The infundibulum or pituitary stalk 
is formed by evagination of the posterior part of the presumptive diencephalon.
(d) Formation of the adult pituitary gland: The definitive pouch is completely detached from 
the oral cavity. Spatial and temporal differentiation of various cell types within the pituitary 
gland results in the development of individual hormone secreting cells in a sequential order.
Complex genetic interactions dictate normal pituitary development. A cascade of signalling 
molecules  and  transcription  factors  plays  a  crucial  role  in  organ  commitment,  cell 
proliferation,  cell  patterning  and  terminal  differentiation  and  the  final  product  is  a 
culmination of this coordinated process [Figure 2.2]. Initially, cells within the primordium of 
the pituitary gland are competent to differentiate into all cell types. Following expression of 
the earliest markers of pituitary gland development (e.g. Hesxl), further signalling pathways 
are  established  from  within  the  gland  and  ventral  diencephalon  that  direct  these  cells 
towards terminal differentiation into mature hormone secreting cell types.
58Figure 2.1: Stages of rodent pituitary development:
a) Oral ectoderm
b) Rudimentary pouch
c) Definitive pouch
d) Adult pituitary gland
I,  infundibulum;  NP,  neural  plate;  N,  notochord;  PP,  pituitary placode;  OM,  oral  membrane;  H,  heart;  F, 
forebrain; MB,  midbrain;  HB, hindbrain;  RP,  Rathke’s pouch; AN,  anterior neural pore; O, oral cavity;  PL, 
posterior lobe; OC, optic chiasm; P, pontine flexure;  PO, pons;  IL, intermediate lobe; AL, anterior lobe;  DI, 
diencephalon; SC, sphenoid cartilage. [Taken from Sheng HZ, Westphal H  1999. Trends in Genetics,  15: 236- 
240].
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59Figure  2.2:  Transcription  factors  and  signalling  molecules  involved  in  anterior 
pituitary development in the mouse.
E,  embryonic  day;  1   signalling  molecules  from  the  ventral  diencephalon;  2 transcription 
factors and genes within the pituitary gland. Revised from Watkins-Chow DE, Camper SA 
1998 Trends in Genetics, 14:284-290
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60Signalling molecules and transcription factors are expressed sequentially at critical periods 
of pituitary development and expression of many of these factors is attenuated subsequently 
[Figure 2.3]. Genes that are expressed early are implicated in organ commitment but are also 
implicated in repression and activation of downstream target genes that have specific roles 
in directing the cells towards a particular fate. Spontaneous or artificially induced mutations 
in  the  mouse  have  led  to  significant  insights  into  human  pituitary  disease.  Mutations 
involved specifically in human H-P disease are listed in Table 2.1.
Figure 2.3: Schematic representation of the pituitary developmental cascade with 
sequential expression of pituitary transcription factors and genes.
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61Table 2.1: Genetic disorders of hypothalamo-pituitary development in humans.
Gene Phenotype Inheritance
Isolated Hormone Abnormalities
GH1 Isolated GH deficiency AR, AD
GHRHR Isolated GH deficiency AR
TSH beta Isolated TSH deficiency AR
TRHR Isolated TSH deficiency AR
TPIT Isolated ACTH deficiency AR
GnRHR Hypogonadotrophic hypogonadism (HH) AR
PCI ACTH deficiency, hypoglycaemia, HH, obesity AR
POMC ACTH deficiency, obesity, red hair AR
DAX1 Adrenal hypoplasia congenital and HH XL
CRH CRH deficiency AR
KALI Kallman syndrome, renal agenesis, synkinesia XL
FGFR1 Kallman syndrome cleft lip and palate, facial dysmorphism AD, AR
Leptin HH, obesity AR
Leptin-R HH, obesity AR
GPR54 HH AR
FSH beta Primary amenorrhea, defective spermatogenesis AR
LH beta Delayed puberty AR
AVP-NPII Diabetes insipidus AR, AD
Combined pituitary hormone deficiency
POU1F1 GH, TSH and prolactin deficiencies AR, AD
PROP1 GH, TSH, LH, FSH, PRL and evolving ACTH deficiencies AR
Specific Syndrome
HESXl Septo-optic dysplasia AR, AD
LHX3 GH, TSH, LH, FSH, PRL deficiencies, limited neck rotation AR
LHX4 GH, TSH, ACTH deficiencies with cerebellar abnormalities AD
SOX3 Hypopituitarism and mental retardation XL
GLI2 Holoprosencephaly and multiple midline defects AD
SOX2 Anophthalmia, hypopituitarism, learning difficulties, 
esophageal atresia
AD
GLI3 Pallister-Hall syndrome AD
PITX2 Rieger syndrome AD
R receptor; AR autosomal recessive; AD autosomal dominant; XL X-linked; 
HH hypogonadotrophic hypogonadism
622.2  EARLY DEVELOPMENTAL GENES
2.2.1  Morphogenetic signals (Bmp, Fgf, Shh,  Wnt)
Extrinsic  molecules  within  the  ventral  diencephalon  and  surrounding  structures,  such  as 
bone morphogenetic proteins 2 and 4  [Bmp 2,  4],  fibroblast growth factor 8  [Fgf8],  sonic 
hedgehog [SM], wingless [Wnt4], thyroid transcription factor [Ttfl; also called NAx2.7], and 
molecules involved in Notch signalling play critical roles in early organogenesis (Dasen and 
Rosenfeld 2001; Rizzoti and Lovell-Badge 2005).  Recent studies in the mouse have shown 
that  a  close  interaction  between  oral  ectoderm  and neural  ectoderm  is  critical  for  initial 
development  of the  pituitary  gland.  Rathke’s  pouch  develops  in  a  two-step  process  that 
requires at least two sequential inductive signals from the diencephalon. First, induction and 
formation of the rudimentary pouch is dependent upon Bmp4, and secondly, FgfS activates 
key regulatory genes, Lhx3 and Lhx4, that are essential for subsequent development of the 
rudimentary pouch into  a definitive pouch.  Both Bmp4 and Fgf%  are present only in the 
diencephalon and not in Rathke’s pouch.  Murine mutations within Nkx2.1, only expressed 
in the presumptive ventral diencephalon, can cause severe defects in the development of not 
only the diencephalon but also the anterior pituitary gland.  Conditional deletion of Rbp-J, 
which encodes the major mediator of the Notch pathway,  leads  to conversion of the late 
[Pitl]  lineage  into  the  early  [corticotroph]  lineage.  Notch  signalling  is  required  for 
maintaining  expression  of Propl,  which  is  required  for  generation  of the  Pitl  lineage. 
Attenuation of Notch signalling is necessary for terminal differentiation in Pitl  cells  and 
maturation and proliferation of the GH-producing somatotroph (Zhu et al. 2006). There have 
been no reported mutations of these early morphogenetic signals in humans.
632.2.2  Hesxl
Hesxl  is one of the earliest markers of the pituitary primordium,  suggesting that it has a 
critical role in early determination and differentiation of the pituitary gland. It is also called 
Rpx  [Rathke’s  pouch  homeobox]  and  is  a member of the  paired-like  class  of homeobox 
genes (Thomas et al.  1995; Hermesz et al.  1996; Dattani et al.  1998; Thomas et al. 2001). 
Hesxl is a transcriptional repressor, although its downstream targets are as yet unknown. A 
highly conserved region in the N-terminus  of Hesxl,  the  engrailed homology domain,  is 
crucial  for  its  strong  repressor  function.  The  gene  is  first  expressed  during  mouse 
embryogenesis  in  a  small  patch  of cells  in  the  anterior  midline  visceral  endoderm  as 
gastrulation  commences.  Hesxl  continues  to  be  expressed  in  the  developing  anterior 
pituitary until  El2,  when  it  disappears  in  a  spatiotemporal  sequence  that  corresponds  to 
progressive pituitary cell differentiation. Extinction of Hesxl  is important for activation of 
other downstream genes such as Propl. It has been suggested that Hesxl and Propl function 
as opposing transcription factors and that a careful temporal regulation of their expression is 
critical for normal pituitary development. Premature expression of Propl can block pituitary 
organogenesis  whereas  prolonged  expression  of  Hesxl  can  block  Propl-dependent 
activation. There is also evidence to suggest that Propl activation is itself a prerequisite for 
extinction of Hesxl. Lhx3 is also important for maintenance of Hesxl expression.
Targeted disruption of Hesxl in the mouse revealed a reduction in the prospective forebrain 
tissue,  absence  of developing  optic  vesicles,  markedly  decreased  head  size  and  severe 
microphthalmia  reminiscent  of the  syndrome  of septo-optic  dysplasia  [SOD]  in  humans. 
Other abnormalities included absence of the optic cups, the olfactory placodes and Rathke’s 
pouch,  reduced  telencephalic  vesicles,  hypothalamic  abnormalities  and  aberrant
64morphogenesis of Rathke’s pouch.  In 5% of null mutants, the phenotype was characterized 
by  complete  lack  of  the  pituitary  gland.  In  the  majority  of  mutant  mice,  they  were 
characterized by  formation  of multiple  oral  ectodermal  invaginations  and hence  multiple 
pituitary glands.
Mutations  in  HESX1  in  humans  were  first  reported  in  two  siblings  with  SOD  and 
subsequently  other  mutations  have  been  shown  to  present  with  varying  phenotypes 
characterized by isolated GH  deficiency  [IGHD],  combined pituitary hormone  deficiency 
[CPHD] and SOD (Dattani et al.  1998; Brickman et al. 2001; Thomas et al. 2001; Carvalho 
et al. 2003; Tajima et al. 2003; Cohen et al. 2003; Sobrier et al. 2005; Sobrier et al. 2006).
2.2.3  Pitxl and Pitx2
Pitxl and Pitx2 are paired-like homeobox genes expressed in the fetal pituitary and in most 
cells of the adult pituitary gland. These genes play an important role in the development of 
Rathke’s pouch and the anterior pituitary gland.
In the mouse, Pitxl is initially expressed in the first branchial arch mesenchyme at E9 and 
then throughout the oral  epithelium lining the  roof of the  buccal  cavity  and  in Rathke’s 
pouch ectoderm.  Pitxl  expression continues throughout development in all regions of the 
anterior pituitary and overlaps with that of Lhx3  and appears to be required for sustained 
expression of the latter. A T-box factor, Tpit, present only in POMC expressing cells within 
the pituitary is essential for initiating POMC cell differentiation and for activating POMC 
transcription synergistically with Pitxl. Pitxl also appears to modulate steroidogenic factor 
1  [sfl\ activity in gonadotrophs, activation of the GH promoter and synergistic activation of
65the  prolactin  promoter  with  Pitl.  Mice  that  are  rendered  deficient  in  Pitxl  demonstrate 
abnormalities  within the hindlimb  and palate.  Gonadotrophs  and thyrotrophs  are reduced 
with an increase in the concentration of ACTH transcripts and peptide in corticotrophs.  In 
adults, PITX1 is specifically expressed at higher levels in cells of the a-glycoprotein subunit 
lineage and a fraction of POMC-expressing cells. Most corticotrophs in humans however do 
not express PITXl.
Pitx2 is first expressed in mouse embryo in the oral epithelium and oral ectoderm. At E9.5 
Pitx2 is expressed in the developing Rathke’s pouch  in  addition to  mesenchyme near the 
optic  eminence,  basal  plate of the  central  nervous  system,  forelimbs  and domains  of the 
abdominal cavity. It appears to be required for pituitary development shortly after formation 
of the committed pouch. It may be required for one or more anterior pituitary cell types or 
may act in concert with other transcription  factors.  It is  also  expressed  in lungs,  kidney, 
testes  and  tongue.  Additionally,  Pitx2  is  implicated  in  left-right  asymmetry  since  it  is 
expressed in the lateral plate mesoderm and then continues to be expressed asymmetrically 
in several organs that are asymmetric with respect to left-right axis of the embryo. There are 
at  least  3  isoforms  of Pitx2.  Pitx2a  and  Pitx2b  are  expressed  in  the  adult  pituitary  in 
thyrotrophs, gonadotrophs, somatotrophs and lactotrophs but not corticotrophs, where Pitxl 
is highly expressed. However, Pitx2c is expressed in all five cell lineages.
To date, no mutations have been described within PITX1 in humans. Mutations in PITX2 are 
associated with Rieger syndrome in humans (Semina et al. 1996).
662.2.4  Lhx3 and Lhx4
Lhx3  and Lhx4 belong to the LIM family of homeobox  genes that are expressed early in 
Rathke’s  pouch.  At least 3  different isoforms  of Lhx3 have been described in mammals, 
each  with  distinct  expression  patterns  and  transcriptional  properties  (Bach  et  al.  1995; 
Zhadanov et al. 1995; Schmitt et al. 2000).
Lhx3 is detected in the developing nervous system. Lhx3a isoform is first expressed at E8.5 
in  the  mouse  embryo  whilst  Lhx3b  is  first  expressed  at  E9.5.  Subsequently,  Lhx3  is 
expressed in the anterior and intermediate lobes of the pituitary gland, ventral hindbrain and 
spinal  cord.  Maintenance  of  Lhx3  persists  in  the  adult  pituitary  gland  suggesting  a 
maintenance function for one or more of the anterior pituitary cell types. Lhx3 activates a 
glycoprotein subunit unit  [aGSU]  promoter and together with Pitl  acts  synergistically to 
activate TSH-P and prolactin promoters and the Pitl  enhancer. Lhx3 is one of the earliest 
markers for cells that are destined to form the anterior and intermediate lobes and continued 
expression  is  essential  for  formation  of  gonadotrophs,  thyrotrophs,  somatotrophs  and 
lactotrophs.  In Lhx3 null mutant mice,  Rathke’s pouch  is  initially formed  but then fails to 
grow and Hesxl expression is switched off early. There is failure of expression of aGSU,  P 
subunit of TSH,  GH  and  Pitl  transcripts.  Specification  of corticotroph  cell  lineage  does 
occur, although there is failure of POMC cell proliferation.
Human  mutations  in  LHX3  are  associated  with  GH,  TSH,  prolactin,  and  gonadotrophin 
deficiencies with a neck phenotype characterized by limited neck rotation (Netchine et al. 
2000).
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Like  Lhx3,  Lhx4  is  expressed  throughout  the  invaginating  pouch  at  E9.5.  Subsequent 
expression  at El2.5  is  restricted to  the  future  anterior lobe.  Its  expression is  reduced by 
E l5.5  (Sheng et al.  1997). Null mutants of Lhx4 show formation of Rathke’s pouch with 
expression of aGSU, (3 subunit of TSH, GH and Pitl transcripts, demonstrating that various 
anterior pituitary  cell  lineages  are  specified  although  their numbers  are  reduced.  Lhx3~/~ , 
Lhx4~/~  double mutant  mice show a more severe phenotype than either single mutant with an 
early arrest of pituitary development, thereby suggesting that these two genes may act in a 
redundant manner during early pituitary development (Sobrier et al. 2004).
LHX4 mutations in humans, reported in only one pedigree to date, resulted in GH, TSH and 
ACTH deficiencies with cerebellar hypoplasia (Machinis et al. 2001).
2.3  TERMINAL CELL DIFFERENTIATION GENES
Terminal pituitary cell  differentiation is  a  culmination  of a  complex  interaction between 
extrinsic  signalling  molecules  and  transcription  factors  such  as  Lhx3,  Lhx4,  Sox  genes, 
GATA2, Isll, Propl and Pitl. GATA2 encodes a transcription factor that is important in the 
differentiation of gonadotrophs and thyrotrophs. Other transcription factors involved in the 
maturation  of  gonadotroph  lineage  include  S/1  and  Dax 1.  Pitl  and  Propl  are  best 
characterised in terms of function in both humans and mice.
682.3.1 Propl
Propl  [Prophet of Pitl] is a pituitary-specific paired-like homeodomain transcription factor 
first expressed in the dorsal portion of Rathke’s pouch  at El0-10.5  followed by maximal 
expression at E12 and subsequent extinction by El5.5 (Somson et al.  1996). It is believed to 
be required for expression of Pitl, the critical lineage-determining transcription factor, since 
there is a failure of determination of Pitl lineages, lack of Pitl gene activation and absence 
of progression to mature cells in the Ames dwarf mice who harbour a homozygous missense 
mutation in the Propl  gene (Parks  et al.  1999). Propl  is  also  important in regulating the 
expression of Hesxl, the lineage-inhibiting transcription factor. Beta-catenin acts as a binary 
switch by interacting with Propl to simultaneously activate expression of Pitl and to repress 
Hesxl, acting via TLE/Reptin/HDACl co-repressor complexes (Olson et al. 2006).
Homozygous Ames dwarf mice exhibit severe proportional dwarfism, hypothyroidism and 
infertility  and  the  emerging  anterior  pituitary  gland  is  reduced  in  size  by  about  50% 
displaying  an  abnormal  looping  appearance.  The  adult Ames  dwarf mouse  exhibits  GH, 
TSH and prolactin deficiency resulting from a severe reduction of somatotroph, lactotroph 
and caudomedial thyrotroph lineages. Additionally these mice have reduced gonadotrophin 
expression correlating with low plasma LH and FSH concentrations.
The  size  of  the  pituitary  gland  on  magnetic  resonance  [MR]  imaging  is  reduced 
considerably.  Recent  reports  suggest  that  Propl-deficient  fetal  mouse  pituitary  retains 
mutant cells in the perilumenal area of Rathke's pouch that fail to differentiate. The mutant 
pituitary then exhibits enhanced apoptosis and reduced proliferation (Ward et al. 2005). At 
postnatal  day  11,  apoptosis-independent  caspase-3  activation  occurs  in  thyrotrophs  and
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caspase-3 expression (Ward et al. 2006).
Humans  with  mutations  in  PROP1  characteristically  have  GH,  TSH,  prolactin  and 
gonadotrophin deficiencies suggesting a role for PROP1  in gonadotroph differentiation in 
humans (Wu et al.  1998). The phenotype also includes evolving ACTH deficiency in some 
patients.
2.3.2  Pitl
Pitl  [called POU1F1 in humans] is a pituitary specific transcription factor belonging to the 
POU homeodomain family. It has also been called GH factor 1   as it was first identified as a 
regulator of GH1 transcription. Apart from GH1, Pitl binding sites have also been identified 
in promoters  of the prolactin  and  TSH  (3-subunit  genes.  Pitl  is  expressed relatively late 
during pituitary development  [El3.5  in the mouse]  and its expression persists throughout 
life. Pitl is also essential for the development of somatotrophs, lactotrophs and thyrotrophs 
in the anterior pituitary. Transcripts first appear in cells within the caudomedial region of the 
anterior pituitary at  E14.5,  followed by detection of the protein within  somatotrophs  and 
lactotrophs  and  subsequent  expression  of  GH1  and  prolactin  genes  on  El6  and  E l7 
respectively. Pitl dependent thyrotrophs arise on El5.5.
In the  Snell  dwarf mouse,  a recessive point mutation results  in  absence  of somatotrophs, 
lactotrophs and thyrotrophs. A similar phenotype results in the Jackson dwarf mouse, which 
harbours  a  recessive  null  mutation  of  Pitl.  Apart  from  its  role  in  proliferation  and
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found in promoter regions of the GHRHR and the Pitl  gene itself. Data suggest that auto 
regulation  of Pitl  is  required  to  sustain Pitl  gene  expression  once  the  Pitl  protein  has 
reached a critical threshold (Li et al. 1990; Andersen and Rosenfeld 2001).
Humans  with mutations  in POU1F1  characteristically present with a pituitary phenotype 
characterized by GH, TSH and prolactin deficiencies (Tatsumi et al. 1992).
2.3.3. Sox3
Sox3 is a single-exon gene located on the X-chromosome in all mammals. It contains a high 
mobility group [HMG] box and is believed to be the gene from which the testis-determining 
gene SRY evolved. It is closely related to Soxl and Sox2 and all 3 genes belong to the Soxbl 
subgroup and are expressed throughout the central nervous system. Sox genes are expressed 
in the neuroepithelial progenitor and stem cells from the earliest stages with considerable 
overlap in their expression patterns. Over-expression in the fish leads to hypoplasia in other 
tissues.
Duplications of Xq26-27 and mutations in SOX3 have been implicated in variable 
hypopituitarism and mental retardation in humans (Hamel et al. 1996; Hoi et al. 2000; 
Solomon et al. 2002; Laumonnier et al. 2002).
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CONGENITAL HYPOPITUITARISM
3.1  INTRODUCTION
Hypopituitarism  encompasses  a  group  of  disorders  with  variable  aetiologies.  Hormone 
dysfunction may occur in isolation, combined with other pituitary hormone deficiencies or 
associated with extra-pituitary features.  The reported incidence of GH  deficiency  [GHD], 
isolated or combined with other pituitary hormone deficiencies is between 1   in 4,000 to 1  in 
10,000 live births, the majority of cases being idiopathic in origin (Lacey and Parkin 1974; 
Vimpani  et al.  1977;  Rona and Tanner  1977).  The exact incidence of combined pituitary 
hormone deficiency [CPHD] is unknown. Familial CPHD may account for 5-30% of cases 
of  hypopituitarism  (Phillips  and  Cogan  1994).  Idiopathic  hypopituitarism  is  generally 
associated with a male to female preponderance. Clinically, the phenotype is highly variable, 
both in severity and in the number of hormone deficiencies. The onset of clinical features 
may be early in the neonatal period often with a stormy perinatal course or later with growth 
failure. Isolated GHD [IGHD], by far the commonest endocrinopathy, presents with growth 
failure and short stature.  The root of the problem appears to  lie within the hypothalamus 
rather  than  the  pituitary  gland  in  many  patients  with  hypopituitarism.  Additionally,  the 
evolution  of  hormone  deficiencies  with  time  is  now  a  well-recognised  feature  of 
hypopituitarism.  Evolving endocrinopathies are observed more commonly in patients with 
septo-optic  dysplasia (SOD),  autosomal  dominant  familial  GHD  (type  II)  and in patients 
with mutations in PROP1 and HESXl.
123.2  ISOLATED HORMONE DEFICIENCY
3.2.1  Growth hormone [GH] deficiency
IGHD occurs in four well-described familial forms, as shown in Table 3.1, and described in 
detail below.
Table 3.1: Types of isolated growth hormone deficiency [IGHD].
Inheritance Type Phenotype Gene Nature of mutations
AR IA Short stature, 
anti GH antibodies
GH1 Deletions, amino acid 
substitutions
IB Short stature.
No anti GH antibodies
GH1 / 
GHRHR
Splice site mutations, 
amino acid substitutions
AD II Short stature. 
No antibodies
GH1 Splice site mutations, 
missense mutation 
[R183H]
XLR III Short stature with 
? learning difficulties 
? agammaglobulinemia
Unknown 
? SOX3
AR, autosomal recessive; AD, autosomal dominant; XLR, X-linked recessive
733.2.1.1  IGHD Type IA
Patients with IGHD type IA have complete absence of GH and lack tolerance to exogenous 
GH treatment with production of human GH [hGH] antibodies. They present with early and 
profound growth failure, a characteristic facial appearance of a large vaulted forehead and a 
small nose with a depressed nasal bridge, and a markedly reduced adult height.  Serum GH 
concentrations are undetectable or extremely low on provocation testing.
The exact prevalence of this disorder is unclear as sporadic cases may go unrecognised. All 
families  reported  to  date  with  IGHD  type  IA  are  consanguineous  with  an  autosomal 
recessive  mode  of inheritance.  There  is  marked  heterogeneity  in  the  phenotype  of these 
patients in addition to a considerable variability in antibody production and response to hGH 
treatment even within families with the same mutation.
The  majority of patients  with  IGHD  type  LA have  large  deletions  within  the  GH1  gene 
(Phillips,  III  et  al.  1981).  However,  micro  deletions  and point  mutations  have  also  been 
described.  Patients  with  larger  deletions  (>7.6  Kb)  respond  better  to  GH  treatment  as 
compared with those with smaller deletions. Recombinant human IGF1  [rhIGFl] treatment 
has also been used, particularly in patients with a poor initial response to hGH treatment and 
production  of high  antibody titres.  With  improvements  in recombinant technology,  purer 
forms  of  rhGH  can  now  be  produced  which  may  alleviate  the  problem  of  antibody 
production to some extent. Table 3.2 lists deletions and mutations within GH1 reported to 
date.
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Mutation Anti GH antibodies Type
Gross deletions
6.7 Kb gross deletion IA
7.0 Kb gross deletion v IA
7.6 Kb gross deletion V/x IA
45.0 Kb gross deletion V IA
Double (GH1; CSH1, GH2, CSH2) V IA
Micro deletions
ClOdel micro deletion IA
IVS3 18 base pair del micro deletion II
2 base pair deletion S54del X IA
[Compound heterozygote with 6.7Kb dell
Point mutations
W7X nonsense mutation V IA
E4X nonsense mutation X IA
W20X nonsense mutation X IA
P89L missense mutation X II
R183H missense mutation X II
VI10F missense mutation X II
R77C missense mutation X II
Splice site mutations
E3+1 G>T X II
E3+5 A>G X II
IVS2 - 2 A>T X II
IVS3+1 G>A X II
IVS3+1 G>C X II
IVS3+2 T>C X II
IVS3+5 G>A X II
IVS3+5 G>C X II
IVS3+6 T>C X II
IVS3+6 T>G X II
IVS3+28 G>A X II
IVS4+1 G>C X IB
IVS4+1 G>T X IB
IVS4+5 G>C X II
production of anti GH antibodies; X, no production of anti GH antibodies.
753.2.1.2  IGHD Type IB
This disorder is also associated with a prenatal onset of IGHD, but is milder than IGHD type 
IA,  with  detectable  concentrations  of  GH  after  provocation  testing.  The  condition  is 
inherited  as  an  autosomal  recessive  trait.  Children  present  with  short  stature  and  a poor 
growth velocity with a good response to exogenous hGH treatment with no formation of GH 
antibodies. IGHD type IB is manifest due to either homozygous splice site mutations within 
the GH1 gene or mutations within the GHRH receptor gene (GHRHR).
The human GHRHR gene consists of 13 exons spanning approximately 15Kb, and has been 
mapped to chromosome 7pl5. It encodes a protein containing 423 amino acids. The receptor 
is a G-protein coupled receptor  with a high binding affinity for GHRH. The expression of 
GHRHR  is  up  regulated  by  POU1F1.  GHRHR  is  also  required  for  proliferation  of 
somatotrophs and therefore plays an important role in anterior pituitary development.
The  first reported cases  of GHRHR  mutations  were  found in  two  first  cousins,  from the 
Indian subcontinent, who were found to have a G>T substitution leading to a stop codon and 
a severely truncated protein lacking membrane spanning domains and an inability to bind to 
GHRH (Wajnrajch et al.  1996).  Since then,  several patients with GHRHR mutations have 
been reported, including splice site mutations (Carakushansky et al. 2003) [Table 3.3].
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Mutation_____________________________________________________________
Point mutations________________________________________________________
E72X nonsense mutation 
L144H missense mutation
F242C missense mutation (compound heterozygote with L144H)
A222E missense mutation
H137L missense mutation (compound heterozygote with del 1140-1144)
K329E missense mutation (compound heterozygote with promoter region mutation) 
Q43X missense mutation (compound heteozygote with splice site mutation)
A176V missense mutation
R357C missense mutation________________________________________________
Splice site mutations____________________________________________________
IVS1+1G— »A 
IVS7 + 1G-*C
IVS12 + 2T->A________________________________________________________
Small deletions________________________________________________________
Del 1121-1124
Del 1140-1144_________________________________________________________
Promoter region________________________________________________________
- 124 A> C
3.2.13  IGHD Type II
This  condition  is  inherited  in  an  autosomal  dominant  manner.  The  patients  present  with 
short stature and respond well to exogenous hGH treatment with no formation of antibodies. 
IGHD type II is most commonly a result of splice site mutations in intron III (IVSIII) within 
the GH1  gene [See Table 3.2].  In addition, four missense mutations (R77C, R183H, P89L 
and VI10F) have also been implicated in IGHD type II. More recently, mutations in an exon 
splice  enhancer  within  exon  3  of the  GH1  gene  have  been  associated  with  autosomal 
dominant GHD (Moseley et al. 2002).  Splice site mutations lead to the production of two 
alternatively spliced GH molecules,  20kDa and  17.5kDa hGH.  The  17.5kDa form of GH 
generated as a result of the skipping of exon 3 and subsequent loss of amino acids 32-71 has
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consequent deleterious effect on pituitary somatotrophs. In a murine model of this dominant 
negative mutation, there is evolution of the phenotype with later failure of prolactin, TSH 
and gonadotrophin secretion (McGuinness et al. 2003). Patients presenting with a splice site 
mutation within the first 2 base pairs of intervening sequence 3 (5'IVS +1/+2 bp) leading to 
a  skipping  of exon  3  were  found  to  be  more  likely  to  present  at  follow-up  with  other 
pituitary hormone deficiencies (Mullis et al. 2005). The development of multiple hormonal 
deficiencies is not age dependent and there is a clear evidence of variability in the onset, 
severity  and  progression,  even  within  the  same  family.  A  detailed  analyses  of different 
mutations  identified  in  IGHD  type  II  showed  different  mechanisms  of  secretory 
pathophysiology at a cellular level resulting in a different extent of co-localization  and a 
different effect on GH secretion. This might be caused by different folding or aggregation 
problems  necessary  for  sorting,  packaging  or  secretion  through  the  regulated  secretory 
pathway (Salemi et al. 2005).
3.2.1.4  IGHD Type III
The disorder is inherited in an X-linked recessive manner. In addition to GHD, patients may 
also  manifest agammaglobulinaemia.  No  abnormalities have been documented within the 
GH1  gene  and the  exact mechanism  for the phenotype  is  as  yet unknown.  Mutations  in 
SOX3 associated with X-linked mental retardation and GHD (Laumonnier et al. 2002) may 
account for some patients although the association with agammaglobulinaemia suggests the 
involvement of other genes.
783.2.2  Thyrotrophin [TSH] deficiency
Isolated  central  hypothyroidism,  characterized  by  deficient  TSH  secretion  resulting  in 
reduced concentrations of thyroid hormones, is a very rare disorder. It is most often sporadic 
although  familial  cases  have been reported.  The  reported prevalence  is  1   in  50,000  live 
births. Neonates may present with non-specific  symptoms  such as lethargy, poor feeding, 
prolonged  hyperbilirubinaemia  and cold  intolerance.  Central  hypothyroidism  is  generally 
milder  than  primary  hypothyroidism,  where  a  more  severe  phenotype  characterised  by 
coarse facies and severe mental retardation may be characteristic.
Dacou-Voutetakis et al first reported a homozygous nonsense mutation in exon 2 of the TSH 
p-subunit  gene  in  three  children  affected  by  congenital  TSH-deficient  hypothyroidism 
within  two  related  Greek  families  (Dacou-Voutetakis  et  al.  1990).  Affected  individuals 
showed symptoms  of severe mental  and growth retardation.  This mutation gave rise to  a 
truncated peptide including only the first  11  of 118  amino  acids of the mature TSH beta- 
subunit peptide.
Collu et al were the first to report an inactivating mutation of the TRH receptor gene as a 
cause for isolated central hypothyroidism in a patient with short stature and delayed bone 
maturation. Although he had a subnormal intelligence quotient, this was possibly related to 
the low socio-economic  status as the intelligence quotients of unaffected sibs was  similar 
(Collu et al.  1997). The mutation resulted in a failure of TRH binding to its receptor and a 
consequent failure of TSH and prolactin secretion.
793.2.3  Corticotrophin [ACTHJ deficiency
Isolated congenital ACTH deficiency is rare. Patients usually present in the neonatal period 
with  non-specific  symptoms  such  as  poor  feeding,  failure  to  thrive  and  hypoglycaemia. 
More acute signs of adrenal  deficiency include vascular collapse,  shock and bradycardia. 
Serum  aldosterone  secretion  is  controlled  by  the  renin-angiotensin  system  and  hence 
abnormalities  in  salt  excretion  are  unusual.  Females  rely  on  adrenal  androgens  for  the 
development of pubic and axillary hair and women lack both if they are ACTH deficient.
Krude  et  al  first described two  patients with mutations  in the  POMC  gene  (Krude  et  al. 
1998). Both patients presented with early-onset ACTH deficiency, obesity and red hair due 
to  lack  of  aMSH.  Symptoms  of  hypoglycaemia  and  cholestasis  resolved  with 
hydrocortisone treatment.  A compound heterozygous mutation in PCI  in  a female patient 
with extreme early-onset obesity and ACTH deficiency with defective processing of other 
prohormones,  abnormal  glucose  homeostasis  and  hypogonadotrophic  hypogonadism  has 
been described  (O'Rahilly  et  al.  1995;  Jackson  et  al.  1997).  More  recently,  a  child with 
ACTH deficiency, red hair and a severe enteropathy was found to harbour mutations in PCI 
(Jackson et al.  2003). Twelve independent mutations have been identified in  TPIT,  with a 
recessive  mode  of  inheritance,  resulting  in  severe  ACTH  deficiency,  profound 
hypoglycemia associated with seizures in some cases and prolonged cholestatic jaundice in 
the  neonatal  period.  Neonatal  deaths  have  been  reported  in  25%  of families  with  TPIT 
mutations,  in  a  large  series,  suggesting  that  isolated  ACTH  deficiency  may  be  an 
underestimated cause of neonatal death (Lamolet et al. 2001; Vallette-Kasic et al. 2005).
803.2.4  Gonadotrophin deficiency
Hypogonadism  may  be  due  to  abnormalities  within  the  H-P  axis  [hypogonadotrophic 
hypogonadism (HH)]  or within the gonad itself [hypergonadotrophic hypogonadism].  It is 
rare condition with an incidence variably reported from  1   in  10,000 to  1   in 86,000 and is 
four times more common in males (Fromantin et al.  1973; Filippi 1986). HH is particularly 
heterogeneous with a phenotype, in males, ranging from undescended testes at birth, absent 
pubertal development alone, to normal puberty but infertility at the other extreme. Overall, 
there is a low prevalence of genital abnormalities at birth in these patients suggesting that 
maternal  human  chorionic  gonadotrophin may also play a  significant role  in  testosterone 
secretion by the fetus.
An  association  between  isolated  HH  and  anosmia,  Kallman  syndrome  [KS],  was  first 
reported by Maestre de San Juan and Kallman described the genetic basis to this disorder. 
Mutations  in  the KALI  gene  result  in  an  X-linked  inheritance  of KS  (Bick  et  al.  1992; 
Hardelin et al.  1993). Anosmia is a result of agenesis of olfactory bulbs,  development of 
which  is  closely linked to  that of GnRH  secreting neurones.  Although  these patients  are 
capable  of synthesising  and  secreting  a normal  GnRH  protein,  the  abnormal  location  of 
GnRH neurones results  in an inability of GnRH to reach the pituitary gland to  stimulate 
gonadotrophs. Other features such as mirror movements, renal aplasia, high-arched palate, 
deafness  and pes  cavus  are  associated with  this  disorder  (Hardelin  et  al.  1993).  Loss  of 
function mutations in FGFR1  are thought to be responsible for autosomal dominant  [and 
rarely recessive] forms of KS. These patients have a milder phenotype and may have adult- 
onset HH. They may also have abnormalities such as a cleft lip or palate.
81Disrupted  GPR54  signalling  causes  HH  in  rodents  and  man.  Recently,  a  homozygous 
missense mutation was identified within the gene in a highly consanguineous pedigree of 
patients  with  HH  (de Roux  et al.  2003).  A  second patient was  found to be  a compound 
heterozygote and, since, several pedigrees have been identified that harbour deletions within 
this gene. Mutations or targeted disruptions in its ligand kisspeptin-1  also cause autosomal 
recessive  HH  in  humans  and  mice.  Central  or  peripheral  administration  of  kisspeptin 
potently  stimulates  the  H-P-gonadal  axis,  increasing  circulating  serum  gonadotrophin 
concentrations in a number of animal models underlying the importance of kisspeptin and its 
receptor in the secretion of gonadotrophins.
DAX-1  [dosage sensitive sex reversal, adrenal hypoplasia congenita critical region on the X 
chromosome]  mutations  in humans  cause  HH  and  adrenal  hypoplasia  congenita  that  can 
result in a severe neonatal adrenal crisis. More often, HH presents itself at puberty (Tabarin 
et  al.  2000).  The  condition  is  inherited  as  an  X-linked  disorder.  DAX1  is  a transcription 
factor that is expressed in several tissues including the hypothalamus and pituitary gland and 
closely  interacts  with  SF1,  another  transcription  factor  critical  for  adrenal  and  gonadal 
development,  acting  as  a  repressor  of  SFI.  Duplications  of DAX1  result  in  persistent 
Mullerian structures and XY sex reversal suggesting that the gene acts in a dosage sensitive 
manner similar to the SOX3 gene.  Females with duplications of DAX1  are phenotypically 
normal.
Inactivating mutations  of the  GnRH receptor gene  (GnRHR)  were  first reported  in  1997. 
Since then  seven  different pedigrees with  GnRHR  mutations  with  a varying phenotypes, 
ranging from complete hypogonadism with undescended testes at birth to those who present 
with mild pubertal delay, have been described (de Roux et al.  1997). Mutations in GnRHR
82are rare but patients with milder phenotypes harbouring mutations may not,  as  yet,  have 
been identified.
Leptin is a secretory product of the adipocyte, which acts as a satiety factor and also plays 
an important role in several neuroendocrine functions at a hypothalamic level. Mutations in 
leptin  and  its  receptor  are  associated  with  obesity,  marked  hyperphagia,  metabolic 
abnormalities  and  HH  (Montague  et  al.  1997;  Farooqi  et  al.  1999).  Mutations  in PCI 
associated with defective processing of prohormones also result in HH (Jackson et al. 1997).
3.2.5  Prolactin deficiency
Isolated prolactin deficiency is extremely rare (Kauppila et al.  1987).  More  commonly it 
occurs in combination with other anterior pituitary hormone deficiencies, sporadically or in 
patients with POU1FI and PROP1 mutations.
3.2.6  Central Diabetes Insipidus
Central  diabetes  insipidus  [DI]  is  most  often  acquired  and  congenital  causes  are  rare. 
Familial central DI is an autosomal dominant disorder of AVP secretion. Affected patients 
present  with  polyuria  and  polydipsia,  usually  within  the  first  10  years  of life.  Neonatal 
manifestations  are  uncommon  suggesting that the  pathophysiology of familial  central  DI 
involves  progressive  postnatal  degeneration  of AVP-producing  magnocellular  neurones. 
During infancy, common clinical features include hyperthermia, vomiting, failure to thrive
83and constipation. Overt hypertonic dehydration occurs only if the patient is unable to obtain 
water. Food consumption is decreased leading to loss of weight and poor growth.
A number of mutations have been described in children with central DI in the A VP-NPII 
gene. These include signal peptide mutations with a decreased ability of the signal peptidase 
to initiate removal of the signal peptide from the preprohormone (Ito et al.  1993). A second 
group  of mutations  occurs  within  the  AVP  or  amino-terminal  domain  of  NPII-coding 
sequence  interfering with binding of AVP to NPII or in  folding of NPII  (Bahnsen et  al. 
1992).  A  third  group  of mutations  results  in  the  synthesis  of  a  truncated  neurophysin 
molecule (Nagasaki et al. 1995). All mutations may lead to abnormal folding and processing 
of the preprohormone.  The mutant protein  may then  accumulate  within  the  endoplasmic 
reticulum killing cells by interfering with the orderly processing of other essential proteins. 
Hence, heterozygous mutations within the A VP-NPII gene may result in production of an 
abnormal  preprohormone  that  cannot  be  processed  properly  destroying  AVP-processing 
neurones. A pedigree with autosomal recessive DI has also been described.
Other  causes  include  Wolfram  syndrome,  an  autosomal  recessive  condition  with  DI, 
diabetes  mellitus,  optic  atrophy  and  sensorineural  deafness.  The  WFS1  gene,  on 
chromosome 4, encodes an 890 amino acid glycoprotein, wolframin, and is predominantly 
localised in the  endoplasmic  reticulum.  Mutations  in  WFS1  underlie  Wolfram syndrome. 
Mutations  have  been  reported  to  date  over  the  entire  coding  region  and  are  typically 
inactivating,  suggesting that a loss of function causes the disease phenotype  (Cryns et al. 
2003). DI may also be a feature of midline disorders such as SOD and holoprosencephaly 
[HPE].
843.3  COMBINED PITUITARY HORMONE DEFICIENCY [CPHD]
3.3.1  Idiopathic CPHD
Most patients with CPHD do not have a known underlying etiology and are classified as 
having  idiopathic  disease.  The  condition  is  highly  variable  with  respect  to  clinical 
presentation. Even if hypopituitarism is not recognized in the immediate postnatal period, a 
careful history at the time of diagnosis may indicate the presence of perinatal symptoms.
Craft et al have suggested a causal relationship between gestational-perinatal complications 
[65%]  and  hypopituitarism  with  risk  factors  such  as  prematurity,  gestational  bleeding, 
complications  of delivery,  fetal  distress  or  asphyxia  (Craft  et  al.  1980).  It  is  difficult  to 
differentiate  whether  hypothalamo-pituitary  defects  are  actually  responsible  for  these 
perinatal complications or whether perinatal problems themselves lead to hypopituitarism. 
The discovery of pituitary transcription factors, mutations of which can lead to abnormalities 
of hypothalamo-pituitary  [H-P]  morphology,  suggests that the  former may be  the case  at 
least in some patients. The fact that many males with hypopituitarism are bom with genital 
abnormalities such as undescended testes and a micropenis also suggests that, in some cases 
at least, hypopituitarism is of prenatal onset.
853.3.2  Non-Syndromic Genetic CPHD
3.3.2,1  Mutations in PROP1
Human PROP1 gene has been mapped to chromosome 5q and is a member of the paired-like 
homeobox  gene  family.  The gene  spans  3 Kb  and consists  of 3  exons  encoding a protein 
product of 226  amino  acids.  The DNA binding homeodomain consists  of 3  alpha helical 
regions and most mutations reported to date affect this region.
Wu et al first reported mutations in PROP1  in four unrelated pedigrees with an endocrine 
phenotype consistent with GH, TSH, prolactin, LH and FSH deficiencies (Wu et al.  1998). 
To  date,  22  distinct  mutations  have  been  identified  in  over  170  patients  [Figure  3.1], 
suggesting  that  mutations  in  PROP1  are  the  most  common  cause  of  CPHD,  in 
approximately  50%  of  familial  cases  (Cogan  et  al.  1998;  Deladoey  et  al.  1999).  The 
incidence  in  sporadic  cases  is,  however,  much  lower  (Cogan  et  al.  1998].  Affected 
individuals exhibit recessive inheritance. The most common PROP1  mutation (50%-72%) 
detected in multiple unrelated families is a 2 base pair [bp] deletion within exon 2 resulting 
in a frame shift at codon  101  and has been referred to as 301-302delAG and 296delGA in 
different reports (Wu et al.  1998; Fofanova et al.  1998; Mendonca et al.  1999; Deladoey et 
al.  1999). This probably represents a mutational hot spot (Cogan et al.  1998) and along with 
the  150delA mutation accounts for approximately 97% of all mutations in PROPL
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The timing of initiation and severity of hormonal deficiencies in patients with mutations in 
PROP1  is  highly  variable.  The  spectrum  of  gonadotrophin  deficiency  can  range  from 
hypogonadism and lack of puberty, to spontaneous pubertal development with subsequent 
arrest,  and  infertility  (Parks  et  al.  1999).  Individuals  with  mutations  in  PROP1  exhibit 
normal  ACTH  and  hence  cortisol  concentrations  in  early  life  but  often  demonstrate  an 
evolving cortisol deficiency associated with increasing age (Mendonca et al.  1999; Agarwal 
et al. 2000; Asteria et al. 2000; Pemasetti et al. 2000; Riepe et al. 2001), although it has also 
been described in a 7 year old patient (Agarwal et al. 2000). The underlying mechanism for 
cortisol  deficiency  is  unknown,  especially  as  PROP1  is  not  expressed  in  corticotrophs, 
although it appears to be required for maintenance of the corticotroph population. Various
87hypotheses have been postulated such as a gradual attrition of corticotrophs or an expanding 
pituitary and its subsequent involution (Asteria et al. 2000), although there appears to be no 
correlation between involution of the pituitary gland and development of ACTH deficiency.
Pituitary morphology  in  patients  with  mutations  in PROP1  is  variable.  Most  individual 
reports have documented a normal pituitary stalk and posterior lobe, with a small or normal 
anterior pituitary on MR scanning. However, in some cases, an enlarged anterior pituitary 
has also been reported (Wu et al.  1998; Mendonca et al.  1999; Vallette-Kasic et al. 2001). 
Longitudinal analyses of anterior pituitary size have revealed that a significant number of 
patients demonstrate pituitary enlargement in early childhood with subsequent involution in 
older patients (Riepe et al. 2001; Voutetakis et al. 2004). Pituitary enlargement consists of a 
mass lesion interposed between the anterior and posterior lobes, possibly originating from 
the intermediate lobe (Voutetakis et al. 2004).
To  date,  the  underlying  mechanism  leading  to  pituitary  gland  enlargement  remains 
unknown.  The  only  biopsy  report  of the  “tumour”  was  non-specific  with  presence  of 
amorphous material, no signs of apoptosis and no recognisable cells. Prolonged expression 
of HESX1  or LHX3 and hence of undifferentiated precursor cells that remain viable for a 
longer time  have  been  implicated  (Somson  et  al.  1996).  A  recent report  suggesting  that 
Prop7-deficient fetal mouse pituitary retains mutant cells in the perilumenal area of Rathke's 
pouch that fail to differentiate and exhibit enhanced apoptosis and reduced proliferation may 
be a possible explanation (Ward et al. 2005).
8833.2.2 Mutations in POU1F1
The human POUIFI gene has been localised to chromosome 3pll  and consists of 6 exons 
spanning  17Kb. It encodes a 291  amino acid protein with a molecular mass of 33kD.  The 
protein has three functional domains: a transactivation domain, a POU specific domain and a 
POU homeodomain. The POU specific and POU homeodomains are both critical for high 
affinity DNA-binding on GH and prolactin promoters.
The  first  mutation  within POUIFI was  identified  by  Tatsumi  et  al  in  a  child  with  GH, 
prolactin and profound TSH deficiency (Tatsumi et al.  1992). The patient was homozygous 
for a nonsense mutation in POUIFI  resulting in a truncated protein of 171  amino  acids. 
Since then, a total of 27 mutations within POUIFI have been described [22 recessive, five 
dominant]  in  over  60  patients,  all  with  a  broadly  similar  phenotype  of GH,  TSH  and 
prolactin  deficiency  [Figure  3.2]  (Cohen  and  Radovick  2002).  Although  the  majority  of 
mutations within POUIFI are recessive, the heterozygous point mutation R271W appears to 
be a “hotspot” for mutations within POUIFI (Cohen et al.  1995), and has been identified in 
several unrelated patients of different ethnic backgrounds (Ohta et al.  1992; Radovick et al. 
1992;  Okamoto  et  al.  1994;  Holl  et  al.  1997;  Aarskog  et  al.  1997;  Ward  et  al.  1998; 
Rodrigues Martineli et al. 1998).
The spectrum of hormone deficiency varies considerably in patients with mutations within 
POUIFI. MR imaging demonstrates a small or normal anterior pituitary with no other extra- 
pituitary abnormalities. Deficiency of GH, prolactin and TSH is more profound in patients 
harbouring  mutations in POUIFI than in patients with PROP1 mutations [Table 3.4].
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Table 3.4: Differences in phenotype due to mutations in POUIFI, PROP1 and LHX3.
Phenotype PROP1 POUIFI LHX3
Presentation Delayed Congenital Congenital
GH Deficient Deficient Deficient
TSH Deficient Deficient Deficient
Prolactin Deficient Deficient Deficient
LH, FSH Deficient Normal Deficient
ACTH May evolve Normal Normal
Pituitary size H, N, E H, N H, N, E
Extra-pituitary phenotype Nil Nil Short cervical spine
H hypoplastic; N normal; E enlarged
903.3.3  Syndromic CPHD
33.3.1  Septo-optic dysplasia
Septo-optic dysplasia [SOD] is a rare congenital heterogeneous anomaly with a prevalence 
ranging from 6.3-10.9 per 100,000 (Tomqvist et al. 2002; Patel et al. 2006). The condition is 
defined by presence of any two of three features:  midline forebrain defects  [MFD],  optic 
nerve hypoplasia  [ONH]  and hypopituitarism.  Approximately 30%  of patients with  SOD 
manifest the complete clinical triad, 62% of patients have some degree of hypopituitarism, 
and 60% have an absent septum pellucidum (Arslanian et al.  1984; Morishima and Aranoff 
1986). The condition is equally prevalent in males and females. ONH may be unilateral or 
bilateral; the latter is more common.
Pituitary dysfunction  may manifest  as  endocrine  deficits  varying  from IGHD  to  CPHD. 
Decrease  in  growth  rate  as  a  result  of  GHD  is  often  the  commonest  feature,  with 
hypoglycaemia,  polyuria  and  polydipsia  being  less  common.  Either  sexual  precocity  or 
failure  to  develop  in puberty may occur.  Abnormal  hypothalamic  function with diabetes 
insipidus [DI] may be a feature. The endocrinopathy may evolve with a progressive loss of 
endocrine function over time. Gonadotrophin secretion may be retained in the face of other 
pituitary  hormone  deficiencies  (Nanduri  and  Stanhope  1999).  Commencement  of  GH 
treatment in patients with SOD may be associated with accelerated pubertal maturation.
Neurological  deficits  range  from  global  retardation  to  focal  deficits  such  as  epilepsy  or 
hemiparesis. Other n  euro  anatomical abnormalities can include a eavum septum pellucidum, 
cerebellar hypoplasia,  schizencephaly  and  aplasia  of the  fornix.  An  association  between
91SOD and other congenital anomalies such as digital abnormalities has been reported (Pagon 
and Stephan 1984; Orrico et al. 2002; Harrison et al. 2004).
Both genetic and environmental factors have been implicated in the etiology of the condition 
(Wales and Quarrell  1996;  Rainbow et al.  2005).  As  forebrain and pituitary development 
occurs as early as 3-6 weeks gestation in the human embryo, any insult at this critical stage 
of development  could  account  for  the  features  of  SOD.  There  has  been  an  increased 
understanding of the genetic basis of this condition led by the discovery of Hesxl. HESX1 
maps  to  chromosome 3p21.1  -  3p21.2,  and  its  coding region  spans  1.7Kb  with  a highly 
conserved genomic organization consisting of four coding exons. The 185-amino acid frame 
is  highly conserved compared with  the  mouse.  The  first homozygous  missense  mutation 
[Argl60Cys] was found in the homeobox of HESX1 in two siblings with SOD (Dattani et al. 
1998).  The  overall  frequency  of  HESX1  mutations  in  SOD  has,  however,  been  low 
suggesting that mutations in other known or unknown genes may contribute to this complex 
disorder.
Environmental  agents  such  as  viral  infections,  vascular  or  degenerative  changes  and 
exposure  to  alcohol  or  drugs  have  also  been  implicated  in  the  etiology  of  SOD.  The 
condition  presents  more  commonly  in  children  bom  to  younger  mothers  and  clusters  in 
geographical areas with a high frequency of teenage pregnancies (Murray et al. 2005; Patel 
et al. 2006).
923.3.3.2  Holoprosencephaly
Abnormal cleavage of the forebrain leads to holoprosencephaly  [HPE].  Three types have 
been  identified:  alobar,  semilobar  and  lobar.  The  condition  is  also  associated with other 
anomalies such as nasal and ocular defects, abnormalities of the olfactory nerves and bulbs, 
corpus callosum, hypothalamus and pituitary gland. Phenotypes can be highly variable and 
the  pituitary  abnormality  most  commonly  associated  with  HPE  is  DI,  although  anterior 
pituitary hormone deficiencies may be associated with the condition.
Major advances have recently been made in understanding the aetiology of this condition. 
At least twelve chromosomal regions on eleven chromosomes contain genes implicated in 
HPE.  Autosomal  recessive  and  dominant  forms  of the  condition  have  been  described. 
Mutations in various genes such as SHH, ZIC2,  TG1F and SIX3 have now been implicated 
in this condition. Three GLI genes have been implicated in the mediation of SHH signals. 
Heterozygous  mutations within  GLI2 were  identified  in  seven  of 390  patients  with HPE 
(Roessler et al. 2003). The phenotype and penetrance was variable, with the parent carrying 
a  mutation  but  showing  no  obvious  phenotype  in  some  cases.  In  all  affected  patients, 
pituitary gland function was abnormal, accompanied by variable craniofacial abnormalities.
Other features included post-axial polydactyly, single nares, single central incisor and partial 
agenesis of the corpus callosum.
933.3.3.3  Neck abnormalities
Homozygous mutations in LHX3 have currently been identified in five patients from three 
unrelated consanguineous families (Netchine et al. 2000; Sobrier et al. 2004; Bhangoo et al. 
2006).  Patients  presented  with  an  endocrine  phenotype  similar  to  that  observed  in 
individuals with mutations in PROP1 with a deficit in all anterior pituitary hormones except 
ACTH. Hypopituitarism was additionally associated in all patients with a short rigid cervical 
spine with limited head rotation and trunk movement. Pituitary morphology on MR scanning 
was  variable  in  these  patients,  as with  mutations  in  PROP!,  ranging  from  a  small  to  a 
markedly enlarged anterior pituitary not evident in a previous MR scan, to a recent report of 
a hypointense lesion with a “microadenoma” (Bhangoo et al. 2006).
3.33.4  Cerebellar Abnormalities
Probands  with  a  mutation  within  LHX4,  only  reported  in  one  three  generation  family, 
presented  with  GH,  TSH  and  ACTH  deficiency  (Machinis  et  al.  2001).  MR  imaging 
revealed anterior pituitary hypoplasia, an undescended posterior pituitary, an absent pituitary 
stalk,  a poorly  formed  sella  and pointed  cerebellar  tonsils,  suggesting that LHX4  tightly 
coordinates  brain  development  and  skull  shape.  Haploinsufficiency  of LHX4  results  in 
defective regulation of POUIFI and downstream activation of GH1 expression, providing a 
mechanism  at  the  molecular  level  in  patients  with  mutations  in  LHX4  (Machinis  and 
Amselem 2005). However, ACTH deficiency observed in these patients cannot be explained 
by this mechanism suggesting that other Z/£Y4-dependent pathways may exist independent 
of POUIFI in the developing pituitary gland.
943.3.3.5  Hypopituitarism and mental retardation
A  number  of  pedigrees  have  been  described  with  X-linked  hypopituitarism  involving 
duplications of Xq26-q27 (Hamel et al.  1996; Hoi  et al.  2000;  Solomon et al. 2002).  The 
phenotype  is  that  of  variable  mental  retardation  and  hypopituitarism.  All  duplications 
encompass  the SOX3  gene.  Further implication  of SOX3  in  hypopituitarism comes  from 
identification of patients with hypopituitarism and an expansion of a polyalanine tract within 
the gene (Laumonnier et al. 2002).
3.3.3.6  Rieger Syndrome
Mutations  within  PITX2  or  R1EG  are  associated  with  Rieger  syndrome,  an  autosomal 
dominant condition with anomalies of the anterior chamber of the eye,  dental hypoplasia, 
protuberant umbilicus,  mental  retardation and variable pituitary abnormalities  in humans. 
All mutations identified within PITX2 to date are heterozygous, affecting the homeodomain 
of the  gene,  although none  of the  patients with  these  mutations  presented with  pituitary 
hormone deficiencies (Cohen and Radovick 2002).
3.3.3.7  Oth er Midline A bn ormalities
Other conditions associated with hypopituitarism include Pallister-Hall syndrome,  Fanconi 
anaemia,  solitary  single  central  incisor,  cleft  lip/palate  and  ectrodactyly-ectodermal 
dysplasia-clefting syndrome.
953.4  DIAGNOSIS OF HYPOPITUITARISM
Normal secretion of a hormone is dependent upon the presence of an intact H-P-target gland 
axis. The axis can be stimulated to test for hormone deficiency and can be suppressed to test 
for hormonal excess and this forms the basis for several pituitary stimulation tests. Various 
pharmacological  and physiological  agents have been used to  stimulate the  axis  and have 
been extensively studied.  Laboratory evaluation of the H-P-target gland axis is performed 
for the diagnostic evaluation of the patient presenting with symptoms suggestive of pituitary 
insufficiency or to evaluate patients at risk of developing hypopituitarism such as those with 
ONH and midline forebrain defects [MFD].
Children with congenital abnormalities of the H-P axis are at risk of serious morbidity. It is 
important to  establish the diagnosis quickly in order to  avoid the risk of hypoglycaemia, 
adrenal crisis, delayed mentation and even mortality. In spite of the serious consequences of 
this disorder and a multitude of tests available, diagnosis of hypopituitarism in infants and 
children  is  still  problematic.  To  add to  this,  patients  have  markedly variable phenotypes 
ranging from IGHD to CPHD, with evolution of hormone deficiency, that makes a precise 
definition of the underlying abnormality difficult.
Once the diagnosis of hypopituitarism has been made, appropriate mutational screening is an 
important  adjunct  to  assessment  and  management  of the  patient.  Not  only  does  genetic 
screening provide a better understanding of the pathophysiological process but it can also 
help in management of the patient as observed in those with IGHD type II and those with 
mutations in PROP1.
963.5  OBJECTIVES OF THE PRESENT STUDY
The hypothesis of the present study was that the phenotype of a patient with hypopituitarism 
is determined by the morphology of hypothalamo-pituitary and midline forebrain structures, 
which  is  further  influenced by position  of the  abnormal  gene  within  the  developmental 
cascade.
The major aims of the study were as follows:
1)  to define possible structure -  function relationships within the hypothalamo-pituitary 
axis in order to determine risk factors associated with hypopituitarism,
2)  to determine if birth size and growth in infancy are influenced by the endocrine and 
neuroanatomical phenotype,
3)  to  establish  if phenotype  correlated  with  genotype  in  patients  with  a  molecular 
genetic cause of hypopituitarism and
4)  to ascertain the optimal test for the diagnosis of specific hormone deficiency.
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PATIENTS AND METHODOLOGY
4.1  PATIENT RECRUITMENT AND STUDY COHORT
Eligibility  criteria  for  inclusion  into  the  study  were:  (1)  patients  with  congenital 
hypopituitarism  or  (2)  patients  “at-risk”  of  hypopituitarism  including  those  with 
developmental  defects  of  the  eye  [e.g.  optic  nerve  hypoplasia]  or  midline  facial 
dysmorphism. Patients with a later confirmation of an alternative diagnosis not related to a 
pituitary pathology or those with acquired hypopituitarism were excluded from the study.
825 patients with a male: female ratio of 1.8:1  satisfied the eligibility criteria. The majority 
of patients had sporadic disease with 109 familial cases belonging to 73 unrelated pedigrees. 
Clinical  data  and blood  [or DNA]  of patients  recruited  in  the  study,  from June  1998  to 
December 2004, were obtained in two ways depending on the referral centre:
(1)  directly  from  268  patients  (32.5%  of  patients)  referred  to  the  London  Centre  for 
Paediatric Endocrinology (LCPE), based at Great Ormond Street Hospital for Children 
and  University  College  London  Hospitals.  LCPE  is  a  tertiary  referral  centre  for  the 
diagnosis  and  management  of  complicated  forms  of  hypopituitarism.  Patients  are 
generally referred by their local Paediatrician or General Practitioner and occasionally, 
have had a brief initial assessment prior to referral to the endocrinology department,
98(2) by the referring doctor of a patient evaluated at another national (232 patients, 28.1%) or 
international  (325  patients,  39.4%)  hospital.  Clinical  data  were  obtained  through  a 
proforma that was  supplied to  each caring physician,  paediatrician or endocrinologist 
[Appendix I]. The proforma was completed and forwarded along with the patient’s blood 
or DNA sample for mutational screening of pituitary transcription factors.
The study cohort consisted of the following broad endocrine phenotypes:
(1)  patients with isolated hormone deficiencies
a.  isolated growth hormone deficiency (IGHD, n=325)
b.  isolated thyrotrophin [TSH] deficiency (n=2)
c.  isolated gonadotrophin deficiency (n=7)
d.  isolated diabetes insipidus (n=7)
(2)  patients with combined pituitary hormone deficiency [CPHD, n=399] and
(3)  patients “at-risk” of hypopituitarism but normal endocrinology to date
a.  optic nerve hypoplasia (n=68)
b.  microphthalmia / anophthalmia (n=2)
c.  midline facial dysmorphism (n=l 5)
994.2  STUDY GROUPS
Various subgroups from the above cohort were analysed in order to achieve the objectives.
(1)  Determine  structural  abnormalities  on  neuroimaging  associated  with 
hypopituitarism:
The  endocrinology  and  findings  on  magnetic  resonance  [MR]  imaging  of  170  of 268 
patients referred to a single endocrine centre [LCPE] were retrospectively analysed in order 
to identify structural abnormalities associated with hypopituitarism. Patients were selected if 
they had undergone baseline pituitary function testing and MR imaging at a single centre to 
exclude inter-observer variation. As MR imaging and / or endocrine tests were not available 
in 98 patients, they were excluded from analysis.
(2)  Determine factors influencing birth size and early growth:
Length, weight and body mass index of patients from birth to 2 years of age or onset of GH 
treatment  (whichever  was  earlier),  with  congenital  GHD,  isolated  or  as  CPHD,  were 
analysed  retrospectively  in  order  to  ascertain  if birth  size  and  postnatal  growth  were 
influenced by the severity of the endocrine and neuroanatomical phenotype.  Patients were 
selected if sufficient growth data (at least three data points)  from birth to 2 years of age, 
from a single  endocrine centre  [LCPE]  were available.  44 of 268 patients from the study 
cohort met the selection criteria.
100(3)  Determine genotype-phenotype correlation:
Based  on  studies  in  mice  and  reported  mutations  in  humans,  patients  were  selected  for 
appropriate mutational  screening  [Table 2.1].  All patients were  screened for mutations  in 
HESX1  given  the  phenotypic  variability  associated  with  these  mutations.  Patients  with 
IGHD [without developmental defects of the eye or midline structures]  were screened for 
mutations in GHJ,  GHRHR and selected patients for PROP],  LHX3, LHX4 and POU1F1. 
Patients with CPHD [without developmental defects of the eye and midline structures] were 
screened for mutations in POU1F1, PROP1, LHX3 and LHX4 depending on the hormonal 
phenotype. Patients with a X-linked inheritance of hypopituitarism were screened for SOX3 
mutations.
Table 4.1: Mutational screening of appropriate candidate genes within study cohort.
Gene Number of patients screened
HESX1 825
PROP1 233
LHX3 233
LHX4 233
POU1F1 129
GH1 103
GHRHR 103
SOX3 76
101(4)  Determine the optimal test for specific hormone deficiency:
As tests performed for the diagnosis of GHD have been extensively studied and some of the 
controversies surrounding its diagnosis resolved by guidelines set by the Growth Hormone 
Research society and National Institute for Clinical Excellence, only tests performed for the 
diagnosis of other anterior pituitary hormone deficiencies were analysed.
a.  Thyrotrophin [TSH] deficiency: Unstimulated serum thyroxine and TSH concentrations 
in patients investigated at a single endocrine centre [LCPE] with central hypothyroidism 
[CH, n=54] were analysed retrospectively. In order to determine whether TSH releasing 
hormone [TRH] tests have a role to play in the diagnosis and in differentiating between 
“pituitary” and “hypothalamic” CH, TRH-stimulated TSH responses were analysed in 30 
of 54 patients.
b.  Corticotrophin [ACTH] deficiency: To assess the usefulness of the short Synacthen test 
[SST]  as  a  marker  of  endogenous  cortisol  secretion,  serum  cortisol  concentrations 
obtained after the SST were compared prospectively with those obtained on spontaneous 
secretion  in  28  consecutive  patients  investigated  for  ACTH  deficiency  at  a  single 
endocrine centre [LCPE] from March 2002 to June 2004.
c.  Gonadotrophin  deficiency:  Peak  serum  follicle  stimulating  hormone  [FSH]  and 
luteinising hormone [LH] concentrations in 30 consecutive patients, at a single endocrine 
centre [LCPE], who underwent a LH releasing hormone [LHRH] stimulation test within 
18  months  of birth,  were prospectively analysed  to  ascertain  usefulness  of the  test  in 
infancy and assess gender-specific responses.
1024.3  ASSESSMENT  OF  PATIENTS  REFERRED  DIRECTLY  TO  THE 
LONDON CENTRE FOR PAEDIATRIC ENDOCRINOLOGY [LCPE]
4.3.1  Clinical Evaluation
268 patients were referred to LCPE directly. Parents or patients were given the information 
sheet [Appendix II] prior to obtaining an informed written consent for participation in the 
study and obtaining a blood sample for genomic analysis [Appendix III]. Ethical committee 
approval was obtained from the Institute of Child Health Research and Ethics Committee. 
Clinical  information  obtained  from  the  parent  and  from  admission  notes  included  birth 
details  [antenatal history, mode of delivery,  gestation, history of perinatal complications], 
family details [parental ages and heights, relevant family history], age at puberty and final 
adult height if relevant.  Birth size  [height and weight]  measurements were obtained from 
individual patient held records. Data were recorded on to the proforma [Appendix I].
4.3.2  Endocrine Evaluation
4,3.2.1  Pituitary function testing
Dynamic tests to assess pituitary function were performed in day care planned investigation 
units by nurses based on standardized protocols shown in Appendix IV. Children between 0- 
12 years of age were admitted to the Programmed Investigation Unit at Great Ormond Street 
Hospital for Children and those over 12 years of age were admitted to the Adolescent Unit at 
University  College  London  Hospitals.  Tests  performed  and  “cut-off’  levels  used  for 
diagnosis of individual pituitary hormone deficiency at LCPE are shown in Table 2.2. Blood 
samples from patients were also collected at the same time for genetic analysis.
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Hormone Primary Test Diagnostic “cut-off’ value Alternative test
Growth
Hormone
- Glucagon provocation (<12 years)
- Insulin induced hypoglycaemia (>12 years)
- Serum IGF1, IGFBP3
- Peak GH <20mU/L
- Peak GH <20mU/L
- < 2SD below mean for age and sex
- Overnight GH profile
Thyrotrophin - Free thyroxine (FT4) or total thyroxine (TT4)
- Serum TSH
- FT4 <12.0 pmol/L or TT4 <65 nmol/L 
with serum TSH concentration <5 mU/L.
- TRH stimulation
Corticotrophin - Standard Synacthen test
- Glucagon provocation (< 12 years)
- Insulin induced hypoglycaemia (> 12 years)
Peak serum cortisol < 540 nmol/L - 24 hour cortisol profiles
- Low dose Synacthen test
- Serum ACTH
Gonadotrophins - LHRH test (if age appropriate) Absent LH and FSH response
Prolactin - Serum prolactin - < 100 mU/L
(elevated serum prolactin > 500 mU/1)
- TRH test
Arginine
Vasopressin
- Early morning plasma and urine osmolalities
- Water deprivation and DDAVP tests
- inappropriate osmolalities that respond 
to DDAVP treatment
IGF1, insulin like growth factor 1; IGFBP3, insulin like growth factor binding protein 3
10443.2.2 Measurement of  plasma hormone concentration
Hormones and metabolites were measured in the biochemistry departments at LCPE as a 
service  provision.  Unless  otherwise  stated,  hormone  concentrations  are  expressed  in  SI 
units.
Samples for GH, FT4 or TT4, TSH, cortisol, LH, FSH and prolactin were analysed on the 
IMMULITE  2000  analyser  as  a  chemiluminescent  immunometric  analysis  (Diagnostic 
Products, Gwynedd, UK). IMMULITE 2000 is a continuous random-access analyser with a 
processing throughput of 200 tests per hour and has been designed specifically for optimum 
efficiency and consolidation in medium - and high-volume laboratories. The IMMULITE 
2000  software  package  offers  information  management  from  remote  test  ordering  to 
sophisticated  analysis  of results.  Workflow  enhancing  features  such  as  primary  tube 
sampling,  automatic  reflex  testing  and  on-board  dilution  have  been  incorporated  for 
optimum  efficiency.  The  system's  open  architecture  also  accommodates  interfacing  to 
laboratory automation  systems.  The  IMMULITE  system uses  assay-specific  antibody or 
antigen coated plastic beads as the solid phase, alkaline phosphatase-labelled reagent and a 
chemiluminescent enzyme substrate. The bead is housed in a proprietary test unit. This unit 
serves  as  the  reaction  vessel  for the  immune  reaction,  incubation,  washing process  and 
signal  development.  The  IMMULITE  system  automates  the  entire  assay process.  After 
incubating the patient  sample with the  alkaline phosphatase reagent,  the  liquid reaction 
mixture in the test unit is rapidly separated from the bead, the bead is washed and the test 
unit is spun at a high speed in its vertical axis.
105The fluid contents (sample, reagent and wash solution) are transferred to a coaxial waste 
chamber in the Test Unit. The bead is left with no residual unbound label. The bound label 
is then quantified with a dioxetane substrate, which produces light. A photo multiplier tube 
detects light emission and the systems computer generates printed reports for each sample. 
Performance data for various hormones on the IMMULITE 2000 is shown in Table 4.2.
IGF1  and IGFBP3 were analysed on the Diagnostics Systems Laboratories 5600 ACTIVE 
and 6600 ACTIVE  [Oxon,  UK]  respectively.  Principles  of analysis were  same  for both 
metabolites.  Analyte to be measured was  sandwiched between two  antibodies.  The  first 
antibody is  immobilized to  the inside wall  of the tube  and the  other is radiolabeled for 
detection. Both assays are immunoradiometric assays. There are 3 reagents used for IGF1 
analysis: IGF1  in buffer, I125 labeled anti IGF1  and anti IGF1  immunoglobulin. The assay 
has a sensitivity value for the lowest limit of detection at 0.80 ng/ml (27 pg/ml). The intra- 
assay coefficients  of variation were  3.4%  and  1.5%  at  concentrations  of 9.4  ng/ml  and
263.6  ng/ml respectively. The inter-assay coefficients of variation were 8.2% and 3.7% at 
concentrations of 10.4 ng/ml and 155.9 ng/ml respectively. The reagents used for analysis 
of IGFBP3  were  IGFBP3  in  a  protein-based  buffer  and  I125  labeled  goat  anti-IGFBP3 
polyclonal antibody. Lowest limit of detection was 0.5 ng/ml and intra-assay coefficients of 
variation  were  1.8%  and  3.9%  at  concentrations  of  82.73  ng/ml  and  7.35  ng/ml 
respectively. Inter-assay coefficients of variation were 1.9% and 0.6% at concentrations of 
76.9 ng/ml and 8.03 ng/ml respectively.
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Hormone Concentration CV Sensitivity Antibody Reagent Volume Incubation Calibration
Intra­
assay
Inter­
assay
of blood (cycles) range
GH
(mU/L)
7.8
5.1
3.5%
4.2%
6.5%
6.6%
0.03 Murine MC Rabbit PC 25 pL 1  X30 Upto 120
TSH
(mU/L)
0.021
68
19%
5%
23.8%
5.7%
0.01 Murine MC Goat PC 75 pL 1  X30 Upto 75
FSH
(U/L)
6.8
103
2.9%
3/1%
4.1%
7.9%
0.1 Murine MC Murine MC 50 pL 1  X30 Up to 170
LH
(U/L)
0.15
170
13.1%
3.5%
23.9%
7.1%
0.05 Murine MC Goat PC 75 pL 1  X30 Up to 200
Prolactin
(mU/L)
98
3280
2.2%
2.3%
6.9%
7.9%
3.2 Murine MC Goat PC 25 pL 1  X30 Up to 3000
Cortisol
(nmol/L)
91.4
859
6.1%
7.4%
8.2%
9.4%
5.5 Rabbit PC Cortisol 10 pL 1X30 28-1380
FT4
(pmol/L)
8.6
65.9
7.5%
5.2%
9%
7.7%
3.9 Murine MC 3 reagents1 10 pL 2X30 3.9-77.2
GH,  growth hormone;  TSH, thyrotrophin;  FSH,  follicle stimulating hormone;  LH, luteinising hormone;  FT4,  free thyroxine;  CV,
coefficient of variation; MC, monoclonal; PC, polyclonal;1, 2 reagents - ligand labeled T4 labeled, one reagent- anti-ligand in buffer.
1074.3.3  Ophthalmologic Evaluation
Detailed  ophthalmologic  evaluation  for  the  presence  of  ONH  was  carried  out  by  the 
paediatric  ophthalmologists  in  patients  with  visual  disturbances.  Examination  by 
ophthalmologists  included  an  examination  of  the  optic  disc  by  direct  and  indirect 
ophthalmoscopy, presence of pigmentary halo, comparison of the optic disc diameter with 
blood  vessels  and  with  the  macula.  Visual  acuity  was  tested  in  older  children.  Where 
indicated,  patients  also  underwent  an  electroretinogram  and  visual  evoked  responses 
following fundoscopy to confirm ONH.
4.3.4  Magnetic resonance imaging
Data on neuroanatomy were obtained following MR imaging using a  1.5  Tesla Siemens 
Magnetom Symphony scanner. T1 and T2 weighted high-resolution slices through the H-P 
axis  (T1  sagital  3mm  slices,  T1  and T2  coronal  3mm  slices)  were  obtained before  and 
following gadolinium contrast. The Siemens Magnetom Symphony scanner is an advanced 
high speed, short bore imaging system. It has a short [1.6 meter] length and a 60 cm inside 
diameter  with  a  flared  120  cm  opening.  Details  noted  included  anterior  pituitary 
morphology,  position  of the posterior pituitary  signal,  presence  and  morphology of the 
optic  nerves,  optic  chiasm,  pituitary  stalk  and  midline  structures  such  as  the  septum 
pellucidum and corpus callosum and were reported by a single paediatric neuroradiologist.
1084.4  MOLECULAR ANALYSIS
Genomic  DNA  was  extracted  from  peripheral  lymphocytes  by  salt  extraction  using 
standard methods. Coding and splice donor/acceptor regions of the relevant candidate genes 
were amplified by polymerase chain reaction using flanking primer pairs.
HESXJ,  LHX4,  GHRHR  and  GH1  were  analysed  using  a heteroduplex  protocol  on  the 
MegaBACE  1000  (Amersham  Biosciences,  Buckinghamshire,  UK),  according  to 
manufacturer’s  recommendations.  POU1F1  and  PROP1  were  analysed  using  single 
stranded  conformational  polymorphism  analysis  [CleanGel  SSCP  kit,  Amersham 
Biosciences,  Buckinghamshire,  UK].  LHX3  was  analysed  using  dHPLC  WAVE 
[Transgenomic  Ltd.,  Cheshire,  UK],  optimized  and  run  according  to  manufacturers’ 
instructions.  Duplications of the SOX3 locus were analysed by interphase Flourescent In 
Situ Hybridization using a human genomic BAC  clone, bA51C14,  containing the SOX3 
gene.  Candidates  that  screened  positive  were  directly  sequenced  using  BigDye  v3.1 
[Applied  Biosystems,  Warrington,  UK)  and  analysed  on  the  MegaBACE 1000  using 
Sequencher  (Ann  Arbor,  Michigan,  USA].  The  mutations  were  confirmed  by  repeat 
polymerase chain reaction and direct sequencing in both orientations.
Mutational screening for genes causing isolated hormone deficiencies other than IGHD or 
for GLI2, GLI3, PITX1 and SOX2 was not included in the present study.
1094.5  STATISTICAL ANALYSIS
Data  manipulation  was  performed  using  the  Microsoft  ®  Excel  2000  spreadsheet
[Microsoft Corp., USA] and statistical analysis performed using the SPSS  13 for Windows 
statistical  package  [SPSS  Inc.,  Illinois,  USA].  A  probability  [p]  value  of  <0.05  was 
regarded as significant.
Data are presented in this study as mean ± standard deviation (SD). In situations where the 
distribution was highly skewed, the median was used to describe the overall measure of the 
center, with the range quoted.
The height and weight of patients were measured at the time of initial presentation and 
subsequently  by  a  single  auxologist  with  an  intra-observer  co-efficient  of variation  of
0.15% and 0.1% at lengths of 75 cms and 100 cms respectively.  Height, weight and body 
mass index [BMI, weight in kilograms -5 - (length in meters)2] were expressed as standard 
deviation scores  [SDS]  to allow comparisons to be made between sexes and at different 
ages using current reference data (Freeman et al. 1995).
A  statistical  significance  test measures  the  strength of evidence,  which  the  data  sample 
supplies for, or against, some proposition of interest. This proposition is known as a “null 
hypothesis”  since it usually relates to there being no difference between groups or “a no 
effect”  of  treatment.  The  unpaired-samples  student  t-test  was  applied  to  ascertain 
statistically  significant  differences  between  two  groups  of parametric  data.  It  computes 
differences between values of two variables for each case and tests the hypothesis whether 
the samples are compatible with a population difference in means of zero.
110For  3  or  more  groups  of parametric  data,  analysis  was  performed  using  the  One-way 
Analysis of Variance  [ANOVA]  to test the null hypothesis that there was no  significant 
difference between groups. The One-Way ANOVA procedure produces a one-way analysis 
of variance for a quantitative dependent variable by a single factor [independent] variable. 
This  technique  is  an  extension  of the  two-sample  t-test.  The  ANOVA  test  determines 
whether  the  means  of  groups  differ  by  more  than  could  be  expected  by  chance.  A 
probability value <0.05 shows that at least one of the group samples has a mean value that 
was  unlikely to  have  risen  by chance  if the population  that  the  groups  were  randomly 
sampled from had identical means.
The  ANNOVA  was  followed  by  Least  Significant  Difference  [LSD]  Post  Hoc  test  to 
determine that differences exist among means. Examination of group confidence intervals 
indicated which of the groups was different.
The one-way ANOVA Contrast was used to partition the between-groups sums of squares 
into trend components and to  specify a priori  contrasts.  The test partitions the between- 
groups sums of squares into trend components in order to test for a trend of the dependent 
variable across the ordered levels of the factor variable. Employing user-specified a priori 
contrasts were then tested by the t-statistic. The order of the coefficients corresponded to 
the ascending order of the category values of the factor variable. The first coefficient on the 
list corresponded to the lowest group value of the factor variable and the last coefficient 
corresponded to the highest value.  This test was used particularly to compare a variable 
across different phenotypic states to assess the level of severity.
IllWhen the data were categoric, it was summarized as the proportions [or percentages] of the 
total falling into each category. When comparing the proportions having a feature in two 
different groups, a 2X2 frequency table followed by the Pearson’s Chi-square test was used 
to  analyse  the  data.  Odds  ratio  were  used  as  an  estimate  of  relative  risk  when  the 
occurrence of the factor  was rare.
In order to quantify the relationship between two continuous variables, a scatter plot of the 
data was  first produced.  The raw data were  examined and variables, which had skewed 
distributions,  underwent  logarithmic  transformation  before  analysis  to  normalize  the 
distributions  and  reduce  skewness  on  correlations.  Correlation  analysis  was  performed 
using Pearson’s correlation  coefficient with  a null  hypothesis value of zero  or no  linear 
association.
Test  performance  was  assessed  using  principles  outlined  by  Sox  (Sox,  Jr.  1986). 
Performance of a test when compared to another or a “gold standard” test can be considered 
under two circumstances assuming that both tests are performed on different days and are 
independent:
(1)  the  “rule-in”  scenario,  when  both  tests  need  to  be  positive  for  a  diagnosis 
maximising specificity but possibly missing many treatable individuals,
(2)  the “rule-out” scenario, when both tests need to be negative to exclude abnormality 
possibly resulting in misdiagnoses by falsely labelling normal  children.
Given the potentially fatal consequences of missing a diagnosis, the “rule-out” approach 
was  considered  safer  although  clinically this  would place  an  onus  on  a  clinician to 
reassess all individuals at a later stage.
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STRUCTURAL BRAIN ABNORMALITIES ASSOCIATED WITH
HYPOPITUITARISM
5.1. INTRODUCTION
The  spectrum of hypopituitarism  [growth hormone  deficiency (GHD)  in  isolation or as 
combined pituitary hormone  deficiency  (CPHD)]  is  highly variable,  both  in  its  clinical 
phenotype  and  abnormalities  within  the  hypothalamo-pituitary  [H-P]  axis  on  magnetic 
resonance [MR] imaging. With the advent of MR imaging technology, it is now possible to 
relate  neuroanatomy  in  patients  with  hormone  deficiencies  to  the  likely  underlying 
pathophysiological  process.  The  causal  relationship  between  gestational-perinatal 
complications and hypopituitarism due to traumatic injury to the pituitary stalk has been 
suggested previously (Craft et al. 1980; Fujisawa et al. 1987; Kikuchi et al. 1988; Triulzi et 
al.  1994).  However, it is difficult to differentiate whether perinatal insults such as breech 
delivery lead to hypopituitarism by traumatic disruption of the pituitary stalk or whether 
hypopituitarism with structural H-P defects result in an increased prevalence of perinatal 
complications.  Identification  of  structural  abnormalities  on  imaging  in  patients  with 
mutations  in  pituitary  transcription  factors  suggests  that  the  latter  is  more  likely.  MR 
imaging abnormalities in patients with mutations in PROP1 and HESX1 are more variable 
as  compared  with  mutations  in  GH1,  GHRHR,  PIT  I,  LHX3  and LHX4,  although  the 
number of patients reported to date with mutations in LHX3 and LHX4 are small. Overall, 
incidence of mutations  within genes  known to be implicated in hypopituitary states has
113been  low  indicating  that  mutations  in  other  unknown  transcription  factors  may  be 
responsible (Sloop et al. 2000; Osorio et al. 2002).
GHD with midline forebrain defects [MFD] such as those observed within the phenotypic 
spectrum of septo-optic dysplasia [SOD] and holoprosencephaly [HPE] are more likely to 
present with hypothalamic abnormalities leading to diabetes insipidus, precocious puberty 
and  a propensity for weight  gain  in  later  life  (Hoyt  et  al.  1970;  Huseman  et  al.  1978; 
Arslanian  et al.  1984;  Izenberg et  al.  1984;  Roessmann et  al.  1987;  Hanna  et al.  1989; 
Yukizane  et  al.  1990;  Fitz  1994).  Abnormalities  on  imaging  such  as  an  undescended 
posterior pituitary,  absent  septum pellucidum  and  cerebral  hemispheric  abnormalities  in 
patients with optic nerve hypoplasia [ONH] have been suggested to increase the prevalence 
of endocrine abnormalities and neurodevelopmental deficits (Miyamoto et al. 2001; Lange 
et  al.  2003;  Birkebaek  et  al.  2004).  This  can be particularly useful  as  identifying these 
structural  abnormalities  in patients  diagnosed  with  ONH  may  suggest  the possibility of 
hypopituitarism and a lower threshold for investigation. Additionally,  hypopituitarism in 
ONH  may  evolve  several  years  after  the  initial  diagnosis  (Stanhope  et  al.  1984). 
Neuroimaging has also helped to identify those patients with isolated GHD  [IGHD]  who 
continue to be GHD as adults as the finding of an undescended posterior pituitary has been 
suggested as a specific marker of permanent GHD (Maghnie et al. 2004).
The  aim  of this  part  of the  study  was  to  assess  if there  were  good  structure-fimction 
relationships within the H-P axis and to identify abnormalities on MR imaging following 
gadolinium injection that predict endocrine dysfunction in a large cohort of patients.
1145.2  PATIENTS AND METHODS
Patients  were  recruited  into  the  study  if they  had  undergone  full  clinical  assessment, 
pituitary  function  evaluation  and  MR  imaging,  at  a  single  endocrine  centre  [LCPE]. 
Genomic analysis for appropriate candidate genes [GH1, HESX1, POU1F1, PROP1, LHX3, 
LHX4, SOX3J depending on the phenotype was performed in all patients. Where indicated, 
the paediatric ophthalmologist evaluated patients with visual problems such as blindness, 
decreased visual acuity,  strabismus or nystagmus.  MR imaging was reviewed by a single 
paediatric  neuroradiologist.  137  children  with  hypopituitarism  [Appendix  V-l]  and  33 
children [Appendix V-2] with normal endocrinology, serving as a “control” group, met the 
selection  criteria.  The  children  within  the  “control”  group  with  normal  endocrinology 
continued in clinical follow up as they had evidence of ONH on clinical examination and 
might  be  considered  “at-risk”  of developing  endocrine  dysfunction  in  the  future.  All 
individuals within this “control” group had abnormal  MR imaging. A number of patients 
had extra-pituitary abnormalities as shown in Table 5.1.
The study was divided into 3 sections for further analysis:
1.  Identify abnormalities on MR imaging predictive of endocrine dysfunction:
Group  A:  124  of  137  patients  with  hypopituitarism  who  demonstrated  abnormal  MR 
imaging [patients 14-137, Appendix V-l]
Group  B:  “Control”  group,  33  children  with  abnormal  MR  imaging  but  normal 
endocrinology [patients 138-170, Appendix V-2].
2.  Identify abnormalities on MR imaging predictive of CPHD over IGHD:
Patients with hypopituitarism [n=137] were selected for this part of the study and divided 
based on their endocrinology into:
115Group C: 44 patients with IGHD [patients 1-5 and 14-52, Appendix V-2]
Group D: 93 patients with CPHD [patients 6-13 and 53-137, Appendix V-2]
3.  Identify abnormalities on MR imaging predictive of endocrine dysfunction in 
cohort of patients with ONH
Group E: 51 of 137 hypopituitary patients with ONH [Appendix V-2, patients 46-96]
Group B: “Control” group [n=33] with ONH but normal endocrinology [patients  138-170, 
Appendix V-3]
Table 5.1: Extra-pituitary abnormalities in study cohort.
Abnormality Patient Number
Eye abnormalities
Entropion 149
Pigmentary retinal dystrophy 13, 53, 75
Coloboma 52, 168, 170
Unilateral microphthalmia 52, 168
Closed funnel retinal detachments 96
Optic nerve hypoplasia 46-96, 138-170
Systemic abnormalities
Congenital heart disease 6, 83, 85, 122, 147, 152
Persistent hyperinsulinaemia hypoglycaemia of infancy 55
Cleft lip and/or palate 47, 168
Situs inversus 106
Deafness 76, 77, 93, 152
Anosmia 76
Digital abnormalities 51
Other neuroradiological abnormalities
Polymicrogyria 122, 139, 142
Cerebral cysts 74, 76, 117, 155
Lipoma rostrum 169
Macrocephaly 60,104,110
Craniosynostosis 162
1165.3  RESULTS
5.3.1  Identify abnormalities on MR imaging predictive of endocrine dysfunction
The results of MR imaging of 124 patients with hypopituitarism [group A] were compared 
with the MR imaging of 33 patients with normal endocrinology [“control” group B]. There 
were no significant differences between the male: female ratio, gestational age or mode of 
delivery between patients in both groups [Table 5.2, page 121]. 51 of 124 patients in group 
A had evidence of ONH.
All patients within group A demonstrated at least one structural abnormality of the H-P axis 
as  compared  with  76%  of group  B  patients  and  this  difference  was  statistically highly 
significant  [Table  5.3,  page  122].  The  risk  of an  undescended  posterior  pituitary  was 
significantly greater in patients in group A as compared with group B [p<0.0001, odds ratio 
(OR)  33.05,  95% confidence interval (Cl) 4.38,  249.45],  as only one patient in group B 
demonstrated  this  abnormality.  Anterior  pituitary  hypoplasia  was  also  observed  in  a 
significantly greater number of patients in group A as compared with group B [p=0.0001, 
OR 6.78, 95% Cl 2.63,  16.98]. Prevalence of an abnormal pituitary stalk was however not 
significantly  different  between  patients  in  group  A  [54%]  and  group  B  [48.5%].  The 
presence  of an undescended posterior pituitary  [n=46]  was  significantly  [p=0.0001,  OR 
3.69] greater in patients with an abnormal stalk [n=83] as compared to those with a normal 
stalk [18 of 73]. MFD were, however, observed in a significantly greater number of patients 
in group B as compared with group A. These differences were statistically significant for 
abnormalities of the corpus callosum [p=0.001, OR 0.27,  95% Cl 0.12, 0.62] but not the 
septum pellucidum.
117To summarise, the odds ratios suggest a 33 times greater risk of an undescended posterior 
pituitary  and  a  6.7  times  greater  risk  of anterior  pituitary  hypoplasia  in  patients  with 
hypopituitarism as  compared with  those  without  endocrine  abnormalities  in  a  cohort  of 
patients with abnormal neuroimaging.
5.3.2  Identify abnormalities on MR imaging predictive of CPHD over IGHD
The cohort of 137 patients with hypopituitarism was further analysed to identify risk factors 
on neuroimaging that predict the endocrine spectrum with respect to development of IGHD 
[n=44,  group  C]  or  CPHD  [n=93,  group  D].  There  was  a  2.1:1  male  to  female 
preponderance within the cohort.  Although males were more  commonly affected within 
both groups as well, there were no significant gender differences between the 2  groups. 
The male to  female ratio was  significantly different between patients with ONH  [n=51, 
1.1:1] and those without [n=86, 3.3:1].
Patients with CPHD presented significantly earlier than those with IGHD [Table 5.4, page 
123]. Within patients with CPHD, GH, TSH, ACTH and gonadotrophin deficiencies were 
found in 99%, 82%, 78.5% and 69% of patients tested.  18 patients had diabetes insipidus 
[DI],  14  of  whom  had  ONH.  Prevalence  of  both  DI  and  ACTH  deficiency  were 
significantly [p=0.0001, p<0.00001 respectively] greater in patients with ONH [relative risk 
2.5,  4.1  respectively]  as  compared  with  those  without  ONH  [relative  risk  0.3,  0.5 
respectively]. The posterior pituitary was undescended in only 39% of patients [n=7] with 
DI; it was enlarged in one patient [patient 92] and was normally sited in the remaining 10 
patients.
118Five patients were found to harbour mutations in pituitary transcription factors and genes. 
Patients 36  and 40 with IGHD were found to have mutations in  GH1.  The MR scan of 
patient 36 revealed an empty pituitary sella with extension of chiasmatic cistern into the 
sella, while that of patient 40 revealed anterior pituitary hypoplasia. Patient 43, with IGHD 
and MR scan revealing anterior pituitary hypoplasia, an undescended posterior pituitary and 
a hypoplastic stalk and had a mutation in HESX1. Patient 117 with CPHD had a mutation in 
PROP1  and an MR scan characterized by a massively enlarged anterior pituitary. Patient 
112  with  CPHD  and  anterior  pituitary  hypoplasia  had  a  mutation  in  POU1F1.  These 
patients  are further discussed in Chapter 7  in  sections  7.6,  7.3,  7.4  and  7.5  respectively 
along with a larger cohort of patients with a molecular genetic cause of hypopituitarism.
The MR scan was normal in 11% (n=5) of patients with IGHD and 9% (n=8) of patients 
with CPHD [Table 5.5, page  124]. All 5 patients with IGHD [patients  1-5] have reached 
their end of growth, been re-tested with an insulin induced hypoglycaemia test and been 
found  to  have  IGHD  as  adults.  The  presence  of  anterior  pituitary  hypoplasia,  an 
undescended  posterior  pituitary  or  abnormalities  with  the  septum  pellucidum  were  not 
significantly  [p=0.192,  p=0.055,  p=0.056  respectively]  different  between  patients  with 
IGHD and CPHD,  although the  latter two  abnormalities were more common in patients 
with CPHD. However, abnormalities of the corpus callosum and pituitary stalk were both 
significantly greater in patients with CPHD as compared with IGHD  [p=0.008, OR 6.13, 
95% Cl 1.37, 37.44; p=0.006, OR 2.84, 95% Cl 1.33, 6.0 respectively]. Overall, prevalence 
of any one MFD was most significantly associated with CPHD occurring 5.5 times greater 
in patients with CPHD as compared with IGHD.
1195.3.3  Identify abnormalities on MR imaging predictive of endocrine dysfunction in 
cohort of patients with ONH
ONH was present in 51  patients with hypopituitarism  [group E] and 33 “controls”. Male: 
female ratio  [1.5:1] was not significantly different between both groups  [Table 5.6, page 
125]. Bilateral ONH was observed in the vast majority [n=72, 85.5%] of patients with no 
significant differences between group E (88%) and group B (82%).  Within group E, IGHD 
was present in only 7 of 51 patients and the majority presented with CPHD [n=44]. Within 
patients in group E; GH, TSH, ACTH, gonadotrophin and AVP deficiencies were present in 
47  [48  tested  to  date,  98%],  36  [71%],  42  [82%],  14  [34  tested to  date,  45%]  and  14 
[27.5%] patients respectively. 3 patients have as yet not had GH provocation testing due to 
a normal growth pattern and normal serum IGF1 and IGFBP3 concentrations to date. ONH 
was confirmed on MR imaging in all patients. 34% of patients had ONH with structural H- 
P abnormalities, 10% had ONH with MFD and 56% patients had ONH, MFD and structural 
H-P  abnormalities  within the  entire  cohort.  Prevalence  of anterior pituitary hypoplasia 
[p<0.0001, OR 28.44,  95% Cl 3.61, 224.27]  and an undescended posterior pituitary was 
significantly greater  [p=0.0004,  OR 7.64,  95% Cl 2.22,  26.31]  in patients in group E  as 
compared with group B [Table 5.7, page 126]. However, prevalence of septum pellucidum, 
corpus callosum or pituitary stalk abnormalities did not significantly differ between both 
groups. The pituitary stalk was absent in 23 patients and hypoplastic in 10 patients within 
group E, but no patient in group B demonstrated an absent stalk (p<0.001), although it was 
hypoplastic in 17 patients. All patients in group E demonstrated at least one H-P structural 
abnormality  as  compared  with  76%  of patients  in  group  B  and  these  differences  are 
statistically significant [Table 5.7, page 126].
120Table 5.2: Clinical characteristics of patients with hypopituitarism [group A] and normal endocrinology [group B].
Group A Group B Probability value (p)
Number of patients 124 33
Male: female ratio 2.1:1 1.2:1 0.158
Gestational age (weeks) 38.8 ±3.1 37.913.6 0.243
Assisted deliveries 34% 25% 0.879
Endocrinology
GH deficiency 119/120 tested (99%) 0
TSH deficiency 70 (56.5%) 0
ACTH deficiency 70 (56.5%) 0
Gonadotrophin deficiency 37/93 tested (40%) 0
Diabetes insipidus 16(13%) 0
Serum prolactin (mU/L) 5061569 3761448 0.259
121Table 5.3: Differences in magnetic resonance imaging in patients with hypopituitarism [group A] and normal endocrinology
[group B].
Probability 
value (p)
Odds ratio 
(Group A/Group B)
95% Cl
Group A Group B
Lower Upper
Number of patients 124 33
Undescended posterior pituitary 63 (51%) 1  (3%) <0.0001 33.05 4.38 249.45
Anterior pituitary hypoplasia 109 (88%) 20 (61%) 0.0001 6.68 2.63 16.98
Absent / hypoplastic stalk 67 (54%) 16 (48.5%) 0.797 1.11 0.51 2.39
Absent septum pellucidum 25 (20%) 13 (39%) 0.222 0.39 0.17 0.89
Absent / hypoplastic corpus callosum 23 (18.5%) 15 (45.5%) 0.001 0.27 0.12 0.62
Any one hypothalamo-pituitary defect 124 (100%) 25 (76%) <0.0001
Any one midline forebrain defect 42 (34%) 20 (61%) 0.005 0.33 0.33 0.73
122Table  5.4:  Clinical  characteristics  of patients  with  isolated  growth  hormone  deficiency  [IGHD,  group  C]  and  combined 
pituitary hormone deficiency [CPHD, group D].
Group C Group D Probability value (p)
Number of patients 44 93
Male: female ratio 2.7:1 1.9:1 0.404
Age at diagnosis (years) 5.4 ±3.4 2.7 ±3.3 <0.0001
Gestational age (weeks) 39 ± 2 38 ±4 0.309
Assisted deliveries 32% 34% 0.584
Optic nerve hypoplasia 7 (16%) 44 (47%) 0.0004
Endocrinology
GH deficiency 44 (100%) 85/86 tested (99%)
TSH deficiency 0 76 (82%)
ACTH deficiency 0 73 (78.5%)
Gonadotrophin deficiency 0 40/58 tested (69%)
Diabetes insipidus 0 18 (19.4%)
Serum prolactin (mU/L) 314 ±272 579 ± 622 0.024
123Table 5.5: Differences in magnetic resonance [MR] imaging in patients with isolated growth hormone deficiency [IGHD, group
C] and combined pituitary hormone deficiency [CPHD, group D].
Group C Group D Probability 
value (p)
Odds ratio 
(Group D/Group C)
95% Cl
Lower Upper
Number of patients 44 93
Normal MR scan 5(11%) 8 (9%) 0.607
Absent / hypoplastic corpus callosum 2 (4.5%) 21 (23%) 0.008 6.125 1.367 37.436
Absent / hypoplastic stalk 14 (32%) 53 (57%) 0.006 2.839 1.334 6.045
Absent septum pellucidum 4 (9%) 21 (23%) 0.056 2.917 0.936 9.092
Undescended posterior pituitary 15 (34%) 48 (52%) 0.055 2.062 0.980 4.341
Anterior pituitary hypoplasia 38 (86%) 71 (76%) 0.192 0.499 0.173 1.439
Any one hypothalamo-pituitary defect 39 (89%) 85 (91%) 0.607 1.362 0.419 4.433
Any one midline forebrain defect 5(11%) 37 (40%) 0.001 5.514 1.859 14.284
124Table 5.6: Clinical characteristics in patients with optic nerve hypoplasia: group E, patients with hypopituitarism; group B,
control group with normal endocrinology.
Group E Group B Probability value (p)
Number of patients 51 33
Male: female ratio 1.1:1 1.2:1 0.886
Age at diagnosis (years) 2.6 ±3.0 1.8 ±1.8 0.327
Gestational age (weeks) 39 ±3.5 38 ±3.6 0.399
Assisted deliveries 37.5% 25% 0.809
Bilateral ONH 45 (88%) 27 (82%) 0.412
Endocrinology
GH deficiency 47/48 tested (98%) 0
TSH deficiency 36 (71%) 0
ACTH deficiency 42 (82%) 0
Gonadotrophin deficiency 14/31 (45%) 0
Diabetes insipidus 14 (27.5%) 0
Serum prolactin (mU/L) 655 ± 626 376 ±448 0.044
125Table 5.7: Differences in magnetic resonance [MR] imaging in patients with optic nerve hypoplasia: group E, patients with
hypopituitarism; group B, control group with normal endocrinology.
Probability 
value (p)
Odds ratio 
(Group E/Group B)
95% Cl
Group E Group B
Lower Upper
Number of patients 51 33
Undescended posterior pituitary 24 (47%) 1  (3%) <0.0001 28.444 3.608 224.272
Anterior pituitary hypoplasia 47 (92%) 20(61%) 0.0004 7.638 2.217 26.308
Absent / hypoplastic stalk 33 (65%) 16 (48.5%) 0.229 1.725 0.707 4.211
Absent septum pellucidum 23 (45%) 13 (39%) 0.606 1.264 0.519 3.077
Absent / hypoplastic corpus callosum 18 (35%) 15 (45.5%) 0.352 0.655 0.268 1.600
Any one hypothalamo-pituitary defect 51 (100%) 25 (76%) 0.0002
Any one midline forebrain defect 35 (69%) 20 (61%) 0.450 1.422 0.569 3.550
1265.4 DISCUSSION
MR scanning was normal in only 13 of 137 patients with hypopituitarism. Abnormalities on 
MR  imaging  were  not  only  restricted  to  patients  with  endocrinopathies  but  were  also 
observed in patients with ONH without any endocrine dysfunction [group B], comparable 
with  other  reports  (Stanhope  et  al.  1984;  Traggiai  and  Stanhope  2002;  Birkebaek  et  al. 
2003).  MR  abnormalities  noted  included  anterior  pituitary  hypoplasia  [78%],  an 
undescended  posterior pituitary  [38%],  an  abnormal  [absent/hypoplastic]  stalk  [49%],  an 
absent  septum pellucidum  [22%]  and  an  abnormal  [absent/hypoplastic]  corpus  callosum 
[22%]. Patients with ONH and normal endocrinology served as a “control” group to assess 
abnormalities on MR imaging associated with hypopituitarism. Although this is not ideal, it 
is not easy to identify a true control group from the general population for MR imaging and 
endocrine tests. All patients with ONH within this study demonstrated abnormalities of the 
H-P or MFS or both. This may suggest a selection-bias as the prevalence and incidence of 
MR abnormalities and endocrine problems depends on the referral rate from ophthalmologic 
and/or radiological departments.
In patients with abnormal imaging, there was a significantly greater prevalence of structural 
abnormalities within the H-P axis as opposed to MFD in patients with hypopituitarism on 
the whole [group A] and within the subgroup of patients with ONH [group E], as compared 
with controls with normal endocrinology [group B], in keeping with recent reports (Traggiai 
and Stanhope 2002; Birkebaek et al. 2003). Anterior pituitary hypoplasia occurred 6.7 and
7.6  times  more  commonly in patients  with  endocrine  dysfunction  in  the  large  cohort  of 
patients with hypopituitarism [group A] and in the subgroup of patients with ONH [group E] 
as  compared  with  “controls”.  An  undescended  posterior pituitary  was  most  likely to  be
127associated with endocrine dysfunction as it occurred 28-33 times more commonly in patients 
with hypopituitarism as compared with those with normal endocrinology.
60%  of the  patients  with  ONH  within  this  study  had  evidence  of endocrinopathies  in 
keeping  with  other  studies  (Acers  1981;  Costin  and  Murphree  1985;  Zeki  et  al.  1992; 
Brodsky and Glasier  1993;  Sorkin  et al.  1996;  Birkebaek et al.  2003).  The frequency of 
abnormalities  of septum pellucidum  (43%),  posterior pituitary  (30%)  and pituitary  stalk 
(59%) in patients with ONH were also in keeping with other series (Brodsky and Glasier 
1993; Birkebaek et al. 2003). 61% of ONH patients without endocrine dysfunction [group 
B]  demonstrated  anterior  pituitary  hypoplasia.  As  findings  from  this  study  indicate  that 
anterior pituitary hypoplasia is associated with endocrine dysfunction, continued assessment 
and follow-up of these patients is necessary as evolving hypopituitarism is known in patients 
with ONH (Stanhope et al. 1984; Traggiai and Stanhope 2002).
Several  previous  studies  have  attempted  to  suggest  risk  factors  in  patients  with 
hypopituitarism that help predict the development of CPHD  over IGHD with conflicting 
results (Maghnie et al.  1999; Bozzola et al. 2000; Osorio et al. 2002; Maghnie et al. 2003). 
Evidence  provided  in  this  study  suggests  an  increased  severity  of abnormalities  on  MR 
imaging  in  patients  with  CPHD.  Although  the  association  of an  undescended  posterior 
pituitary was two times greater in patients with CPHD as compared with IGHD, in keeping 
with similar observations from earlier reports (Pellini et al.  1990; Chen et al.  1999; Bozzola 
et  al.  2000),  the  differences  in  prevalence  of  this  abnormality  were  not  statistically 
significant between groups. The association between abnormalities, of the corpus callosum 
and of the pituitary stalk with CPHD was 6.13 times and 2.84 times greater than with IGHD
128[p=0.008, OR 6.13, 95% Cl  1.37, 37.44]. Anterior pituitary hypoplasia however was noted 
in  a  slightly  greater  number  of patients  with  IGHD  as  compared  with  CPHD  although 
differences were not statistically significant. Overall, MFD were 5.5 times more prevalent in 
patients with CPHD as compared with IGHD. In contrast to a recent report by Osorio et al, 2 
patients with IGHD without ONH also demonstrated MFD (Osorio et al. 2002).
Birth trauma has been implicated in the development of pituitary stalk abnormalities leading 
to pituitary dysfunction (Craft et al. 1980). Earlier reports also suggest that transection of the 
pituitary  stalk  leads  to  an  “ectopic”  posterior  pituitary  (Campbell  and  Harris  1957;  el 
Gammal et al.  1989; Osorio et al. 2002). The presence of an undescended posterior pituitary 
was observed with a relative risk of 1.76 in patients with an absent or hypoplastic pituitary 
stalk  as  compared  with  that  of  0.48  in  patients  with  a  normal  stalk  with  statistically 
significant  [p=0.0001]  differences.  The incidence  of assisted  deliveries was not however 
significantly different in patients with hypopituitarism [37.5%] as compared with those with 
normal  endocrinology  [25%],  both  of whom  demonstrated  pituitary  stalk  abnormalities, 
suggesting that stalk abnormalities are more likely to be a developmental defect rather than 
traumatic or ischaemic injury, at least in some patients.
There  was  no  correlation between  the posterior pituitary position  and  DI.  A  total  of 18 
patients had DI; 10 with an undescended, 7 with a normal and one with an enlarged posterior 
pituitary. None of the 9 patients in whom the posterior pituitary was not visualized had DI 
although this association has been reported previously (Sorkin et al.  1996). 78% of patients 
with DI had ONH, and both, ACTH deficiency and DI were found to be more common in 
hypopituitary patients with ONH as compared with hypopituitary patients without ONH.
129The  present  study  found  a  greater  male  to  female  preponderance  in  patients  with 
hypopituitarism on the whole  [93:44]  and significantly  [p=0.004]  greater in hypopituitary 
patients without ONH [66:20] as compared with hypopituitary patients with ONH [27:24]. 
In future studies, identification of mutations in genes such as SOX3 leading to an X-linked 
inheritance of hypopituitarism (Solomon et al. 2002) may elucidate the genetic basis for this 
male preponderance in  patients with presumed “idiopathic disease”. A  high prevalence of 
extra-pituitary malformations  in these patients  adds  support to  a genetic  aetiology in the 
pathogenesis of hypopituitarism (Simon et al. 2006).
Data from this study suggest a good relation between structure and function with the H-P 
axis. Abnormalities of the anterior and posterior pituitary were most likely to be associated 
with  endocrine  dysfunction  as  they  occurred  6.68  and  33.05  times  more  commonly  in 
patients  with  endocrinopathies  as  compared  with  those  without.  These  MR  imaging 
abnormalities were also most likely to be associated with abnormal endocrine function in 
patients with ONH.  In  contrast,  presence of MFD was most likely to  be  associated with 
CPHD  in  patients  with  hypopituitarism  as  they  occurred  5.5  times  more  commonly  in 
patients with CPHD as compared with IGHD.
130CHAPTER 6
INFLUENCE OF THE ENDOCRINE PHENOTYPE AND 
NEUROANATOMY ON BIRTH SIZE AND EARLY GROWTH
6.1  INTRODUCTION
Fetal growth is largely influenced by maternal nutrition and placental function. Insulin and 
insulin-like  growth  factors  I  and  II  [IGFI  and  II]  play  important roles  as  final  common 
mediators (Sara and Carlsson-Skwirut 1986; Milner and Hill 1989; Liu et al.  1993; Baker et 
al.  1993),  as  exemplified by patients  with growth hormone  [GH]  resistance  (Laron et al. 
1993),  IGFI  deficiency (Woods et al.  1996), and insulin insensitivity (Longo et al. 2002), 
all  of  whom  have  impaired  intra-uterine  growth.  Although  these  factors  have  been 
implicated  in  regulation  of early postnatal  growth,  mathematical  modelling  and  clinical 
observations suggest that nutrition is the principal regulator of rapid weight gain and linear 
growth  in  infancy  and  this  is  independent  of GH  (Karlberg  et  al.  1987).  This  theory  is 
further  supported  by  studies  that  report  normal  birth  size,  weight  and  linear  growth  in 
infancy in children who later develop GH deficiency [GHD] (Lovinger et al. 1975; Karlberg 
and Albertsson-Wikland 1988). The suggestion that growth in infancy is independent of the 
classic postnatal endocrine growth factors is also supported by the observation that severe 
postnatal growth failure is observed in patients with abnormal hypothalamic neuroanatomy 
such as in Prader-Willi syndrome and diencephalic syndrome of infancy, despite normal or 
even elevated serum GH concentrations (Swaab et al.  1995;  Swaab  1997;  Poussaint et al. 
1997).
131Recent  studies  have  challenged  this  assumption  suggesting  that  congenital  GHD  is 
associated with impaired growth in-utero leading to reduced birth size and growth failure 
within the first year of life (Albertsson-Wikland et al.  1990; Gluckman et al.  1992; Wit and 
van Unen 1992; Niklasson et al.  1994; De Luca et al.  1995; Pena-Almazan et al. 2001). GH 
deficient patients with congenital midline forebrain defects [MFD] such as those observed 
within  the  phenotypic  spectrum  of  septo-optic  dysplasia  [SOD]  and  holoprosencephaly 
[HPE] may have both pituitary and hypothalamic abnormalities (Fitz 1983; Lam et al. 1986; 
Yukizane  et  al.  1990;  Fitz  1994),  and  this  raises  the  possibility that  these  patients  may 
demonstrate more severe growth abnormalities compared with GH deficient patients without 
widespread  neuroanatomical  defects.  Patients  with  MFD  are  also  known  to  exhibit  an 
increased propensity for weight gain later in life (Hoyt et al.  1970; Ishihara 1983; Arslanian 
et al. 1984; Izenberg et al. 1984).
In this chapter, the effect of GH alone and the additional effects of other pituitary hormone 
deficiencies and neuroanatomical defects, on antenatal and postnatal growth were assessed 
retrospectively.
6.2  PATIENT SELECTION AND METHODS
The  present  study  was  performed  retrospectively  in  patients  with  congenital  GHD,  in 
isolation or as combined pituitary hormone deficiencies [CPHD], who presented to a single 
endocrine centre, the London Centre for Paediatric Endocrinology [LCPE].  Patients were 
selected if sufficient growth data (at least three data points) were available from birth up to 2 
years of age or onset of GH treatment, whichever was earlier. 44 of 268 patients recruited 
from LCPE met the selection criteria.
132Patients  [male:  female  ratio  1.4:1]  were  divided  into  3  groups  of increasing  phenotypic 
complexity depending on the neuroanatomy and endocrinology:
Group A, GHD patients with no other pituitary hormone deficiencies or midline defects 
[Appendix V-3],
Group B, GHD patients with CPHD but with no midline defects [Appendix V-4],
Group C, GHD patients with CPHD and midline defects [Appendix V-5].
Abnormalities of the optic nerves,  septum pellucidum, corpus callosum and HPE were all 
included as midline defects in group C.
Parameters analysed were length, weight and body mass index [BMI, weight in kilograms -s- 
(length in meters)2]. Birth measurements were obtained from records of individual patients. 
Data regarding birth weight were available in all patients and birth length in 37/44 patients. 
Subsequent  weights  and  lengths  were  measured  by  the  same  auxologist  with  an  intra­
observer co-efficient  of variation of 0.15%  and 0.1%  at  lengths  of 75  cms  and  100 cms 
respectively.
17 patients were started on GH treatment between the ages of 6 months and 2 years. In the 
statistical  analysis  of anthropometric  data at each study point,  patients who were  already 
commenced on GH treatment were excluded from the cohort. Growth data at 6,  12,  18 and 
24 months were therefore analysed in 44, 42, 33 and 27 patients respectively. There was no 
bias introduced by omitting those patients on treatment, as analysis of variance demonstrated 
no  significant  (p=0.3)  differences  in  auxological  terms  between  patients  starting  GH 
treatment earlier compared with those who received treatment at a later age.
1336.3  RESULTS
6.3.1  Patient characteristics
12 patients (27%) belonged to group A,  10 patients (23%) were in group B and 22 patients 
(50%) were in group C. Patient details of the 3 groups are shown in Table 6.1. The overall 
male  to  female  ratio  was  59%:  41%  and  there  were  no  statistically  significant  sex 
differences  between  groups.  There  were  no  significant  differences  in  gestational  ages  of 
patients between 3  groups, ruling out errors in interpretation of birth length. Prevalence of 
assisted deliveries and of postnatal complications was significantly different between the 3 
groups, being greatest in patients with CPHD [groups B and C]. No patient from Group A 
[with IGHD] presented with neonatal hypoglycemia.
Mean age at initial presentation was significantly (p<0.05) different between the 3  groups 
and earliest in group C. Thirty-two patients had evidence of CPHD [Groups B and C]. There 
were no significant differences in the prevalence of thyrotrophin [TSH] and corticotrophin 
[ACTH]  deficiencies  between  these  2  groups  [group  B,  TSH  deficiency  90%  ACTH 
deficiency 70%; group C, TSH deficiency 91% ACTH deficiency 91%]. The age at onset of 
GH treatment was significantly (p<0.0001) earlier in patients with CPHD [groups B and C] 
as compared with patients with IGHD. No patient in Group A received GH treatment within 
2 years of age as compared with 40% of patients in Group B and 59% of patients in Group 
C.
134Table 6.1: Clinical characteristics of cohort analysed to assess effects of GH, other pituitary hormone deficiencies and midline 
brain defects on birth size and growth in early infancy. Group A, isolated growth hormone deficiency and no midline defects; 
Group B, combined pituitary hormone deficiency [CPHD] but no midline defects; Group C, CPHD and midline defects.
Group Male:
female
Age at presentation Assisted deliveries Gestation Postnatal complications Neonatal hypoglycemia
A (n=12) 7:5 3.0 ±1.6 16.7% 38.6 ±2.0 8% 0%
B (n=10) 6:4 1.1 ±1.0 70% 38.0 ± 2.4 80% 70%
C (n=22) 13:9 0.4 ± 0.6 36.4% 39.7 ±2.5 73% 59%
P= 0.997 0.001 0.002 0.147 0.0003 0.001
p, probability value [ANOVA]
1356.3.2  Serum growth hormone concentrations
GH provocation tests were performed in 38 of 44 patients.  6 patients with CPHD did not 
undergo provocation testing. One patient had a serum GH concentration of 3.0 mU/L at the 
time  of spontaneous  hypoglycemia  and the remaining  5  patients  had  undetectable  serum 
IGFI  and  IGFBP3  concentrations  with  a  poor  growth  velocity  and  CPHD.  Serum  GH 
concentrations did not show a significant correlation with birth length (r=-0.08, p=0.7), birth 
weight (r=-0.08, p=0.6) or age at induction of GH treatment (r=0.12, p=0.5). There were no 
significant differences between peak serum GH concentrations in patients of the 3  groups. 
Peak serum GH  concentrations  in patients with neonatal hypoglycemia (7.9 ± 5.3  mU/L) 
were  not  significantly  different  from  those  in  patients  without  hypoglycemia  (7.4  ±5.3 
mU/L; p=0.8).  GH concentrations were not significantly lower in patients with (6.6 ±5.4 
mU/L)  and without (10.3  ± 6.5 mU/L; p=0.08)  anterior pituitary hypoplasia.  Mean serum 
IGFI  and  IGFBP3  concentrations  (n=18)  were  -4.6  ±  2.9  SDS  and  -0.3  ±1.0  SDS 
respectively.
6.3.3  Anthropometry
Mid-parental height was significantly (p=0.006) different between the 3 groups, shortest in 
group A patients.  In spite of this, patients in group A had a greater birth length SDS than 
those in Group C although differences did not reach statistical significance [Table 6.2].
Length SDS decreased in all patients within 6 months of birth.  The greatest decrease was 
observed in patients in group B as compared with those in group A or group C (p=0.03).
136There were significant differences in birth weight SDS between the 3  groups.  Patients in 
group C were significantly [p=0.009] heavier than those in group A [Table 6.3] and overall, 
patients with CPHD [groups B and C] were significantly heavier [p<0.05] than those with 
IGHD [Group A].
BMI SDS at birth was significantly greater in group C as compared with group A and group 
B [Table 6.4]. Patients in Group C continued to have significantly (p<0.05) greater weight 
and  BMI  SDS  as  compared with patients  in  Group  A  at  12,  18  and  24  months  of age. 
Overall,  BMI  was  significantly  greater  [p<0.05]  at  all  study  points  in  CPHD  patients 
[Groups B and C] as compared with patients with IGHD.
Table  6.2:  Comparison  of length  SDS  at  birth,  6,  12,  18,  and  24  months.  Group A, 
isolated growth hormone deficiency and no midline defects;  Group B, combined pituitary 
hormone deficiency [CPHD] but no midline defects; Group C, CPHD and midline defects.
Length (SDS) at months
0 6 12 18 24
Group A n= 11
-0.5 ±1.3
12
-2.2 ± 1.3
12
-2.8 ± 1.4
12
-3.3 ±1.6
12
-3.7 ± 1.6
Group B n= 9
-0.5 ±1.3
10
-3.0 ±1.8
9
-3.7 ±2.2
7
-4.0 ± 2.2
6
-2.7 ±3.6
Group C n= 17
-0.9 ±1.3
22 
-2.3 ±1.8
21
-2.8 ± 2.0
14
-3.2 ±1.8
9
-3.2 ±2.2
137Table  6.3.'Comparison  of weight  SDS  at  birth,  6,  12,  18,  and  24  months.  Group  A, 
isolated growth hormone deficiency and no midline defects;  Group B,  combined pituitary 
hormone deficiency [CPHD] but no midline defects; Group C, CPHD and midline defects.
Weight (SDS) at months
0 6 12 18 24
Group A n= 12
-1.1 10.81
12
-2.6 ±1.0
12
-2.7 ±1.11
12
-3.2 ± 1.21
12
-3.3 ± 1.61
Group B n= 10
-0.5 ± 1.4
10
-1.9 ± 1.5
9
-1.9 ±2.3
7
-1.7 ±2.9
6
-2.1 ±3.2
Group C n= 22 
-0.1 ±0.9
22
-1.4 ±2.3
21
-0.9 ± 2.4
14
-0.8 ± 2.4
9
-1.0 ±2.5
1  probability value, p<0.05 for group A compared with group C.
Table 6.4: Comparison of BMI SDS at birth, 6,12,18, and 24 months. Group A, isolated 
growth hormone deficiency and no midline defects; Group B, combined pituitary hormone 
deficiency [CPHD] but no midline defects; Group C, CPHD and midline defects.
BMI (SDS) at months
0 6 12 18 24
Group A n= 11
-1.0 ± l.l1
12
-1.8 ± 1.53
12
-1.2 ± 1.31 ,3
12
-1.3 ± 1.41 ,3
12
-0.9 ± 1.51
Group B n= 9
-0.4 ± 2.52
10
-0.1 ±1.5
9
+0.7 ± 2.2
7
+1.4 ±2.1
6
+0.5 ± 2.3
Group C n= 17
+1.2 ± 1.3
22 
-0.5 ± 2.2
21
+0.9 ± 1.6
14
+1.3 ±2.0
9
+1.2 ±1.9
1   "  ''      1 1 1 1   1     i  ■   I   ■ ■   .11  I   .1 1   —
probability value, p<0.05 for  group A compared with group C;  group B compared with group C; 
3  group A compared with group B
1386.4  DISCUSSION
Mean birth weight, length and BMI SDS in this study population were -0.4, -0.9 and +0.1 
SDS respectively (Mehta et al.  2005b).  These observations were in agreement with other 
reports of reduced birth weight and length in GHD patients (Albertsson-Wikland et al. 1990; 
Gluckman et al.  1992; Niklasson et al.  1994; De Luca et al.  1995; Rappaport et al.  1997; 
Huet et al.  1999;  Wasniewska et al.  2000). A comparative analysis of various  studies on 
birth size in patients with congenital GHD is shown in Table 6.5.
CPHD patients  [Groups  B  and C]  were bom with a lower length SDS  as compared with 
IGHD  patients  although  differences  were  not  statistically  significant.  Birth  weight  was 
however significantly greater in patients with CPHD as compared with patients with IGHD. 
Although IGHD patients had significantly shorter parents than those of CPHD patients, they 
were  bom  lighter  but  longer  than  the  latter.  It  is  possible  that  co-existing  hormonal 
deficiencies may be contributory factors  for the differences  in birth size between patients 
with CPHD and IGHD. ACTH deficiency is known to result in an increased gestational age 
that  may  lead  to  differences  either  real,  as  weight  gain  continues,  or  artefactual,  as 
comparison of birth size is made with postnatal standards of growth. However, there were 
no  significant  differences  in the gestational  ages  of patients with  [39.2  ± 2.6 weeks]  and 
those without  [38.6  ± 2.0 weeks]  ACTH  deficiency.  Apart  from the  endocrine  spectrum, 
neuroanatomic  factors  also  appeared  to  influence  birth  size  as  demonstrated  by  CPHD 
patients with midline defects who were bom with a lower length SDS but greater weight 
SDS and BMI SDS than CPHD patients without midline defects.
139Table 6.5: Comparisons of birth size in various studies in patients with congenital growth hormone deficiency.
Present
study
Niklasson 
et al
(Niklasson 
et al. 1994)
Wasniewska 
et al
(Wasniewska 
et al. 2000)
DeLuca 
et al
(De Luca et 
al. 1995)
Huet 
et al 
(Huet 
et al. 
1999)
Rappaport 
et al
(Rappaport 
et al. 1997)
Pena-Almazan 
et al
(Pena-Almazan et 
al. 2001)
Gluckman 
et al
(Gluckman 
et al. 1992)
Albertsson 
Wikland et al 
(Albertsson- 
Wikland et al. 
1990)
n=44 n=220 n=12 n=16 n=59 n=49 n=46 n=52 n=220
Weight -0.4 -0.6 -1.0 -1.0 -0.3 0.18 -0.5 -0.6
Length -0.9 -0.9 -2.0 -2.1 -0.9 -0.9 0.4 -0.8 -0.9
140Reduced length SDS was evident within 6 months of age in all study groups with a greater 
effect on linear growth as compared with weight, in keeping with other studies confirming 
the  role  of  GH  in  maintaining  normal  early  growth  (Albertsson-Wikland  et  al.  1990; 
Gluckman et al.  1992; De Luca et al. 1995; Pena-Almazan et al. 2001). There was a greater 
decrease in weight SDS as compared with length SDS in patients with IGHD resulting in a 
reduced BMI. These findings were surprising, given that GH is lipolytic, and GHD would 
therefore be expected to lead to relative obesity with an increase in BMI. A reduction in lean 
body mass could also contribute to the decreased weight SDS. Nutritional intake was not 
formally assessed in patients but it was reported to be normal. There was a greater reduction 
in length SDS observed in CPHD as compared with IGHD patients postnatally. Patients with 
CPHD  continued  to  have  a  greater  BMI  postnatally  in  spite  of optimization  of serum 
thyroxine concentrations.  84.4% of CPHD patients also had ACTH deficiency. There were 
no  significant  differences  in  the  prevalence  of TSH  and  ACTH  deficiencies  in  CPHD 
patients  with  or  without midline  defects.  In  spite  of this,  CPHD  patients  with  midline 
defects [group C] had both greater weight and length SDS than those without these defects 
[group B].
Although the precise aetiology of pituitary dysfunction in conditions with midline defects 
such  as  HPE  and  SOD  is  unknown,  abnormal  hypothalamic  neuroanatomy  has  been 
postulated  in  the  latter  (Huseman  et  al.  1978;  Lam  et  al.  1986;  Roessmann  et  al.  1987; 
Yukizane  et  al.  1990).  Less  severe  effect  on  linear  growth  in  these  patients  could  be 
explained  by  an  increased  weight  gain  and  hyperphagia  secondary  to  a  hypothalamic 
abnormality. It remains to be established whether the early increase in BMI in these patients 
in some way predisposes these patients to obesity in later life.
141No patient with IGHD reported in this study presented with hypoglycemia, although this has 
been  reported  in  a  minority  of cases  (Esberg  and  Jacobsen  1996).  Concomitant  ACTH 
deficiency  was  evident  in  the  majority  of  patients  with  CPHD  who  presented  with 
hypoglycemia,  although patients without ACTH deficiency also presented with low serum 
blood glucose concentrations implying a possible role for other pituitary hormones such as 
TSH apart from other metabolic factors in glucose homeostasis.
Present  data  suggest  that  GH  has  a  minimal  effect  on  birth  size  but  is  critical  for 
maintenance  of postnatal  growth.  Due  to  the  evolving  nature  of hypopituitarism and  the 
heterogeneity in the present cohort of patients, one cannot exclude some degree of overlap 
between the three groups. However, trends within these data suggest that growth during the 
intrauterine  and  infancy  periods  is  influenced  by  the  complexity  of  the  hypopituitary 
phenotype as reflected by the presence of other pituitary hormone deficiencies and structural 
brain defects.
142CHAPTER 7
GENOTYPE-PHENOTYPE CORRELATION IN PATIENTS WITH A 
MOLECULAR GENETIC CAUSE OF HYPOPITUITARISM
7.1  INTRODUCTION
Extrinsic  and  intrinsic  signalling gradients  determine the  expression patterns of pituitary- 
specific  factors  in  the  developing  anterior  pituitary  gland.  Initially,  pituitary  gland 
commitment from the oral ectoderm occurs in response to inductive signals from the ventral 
diencephalon. Eventually, there is a sequential appearance of terminally differentiated cells, 
with  gonadotrophs,  thyrotrophs,  somatotrophs,  lactotrophs  and  corticotrophs  located 
ventrally to dorsally.
Mutations in many intrinsic pituitary transcription factors have been identified in humans 
with  hypopituitarism,  with  or  without  extra-pituitary  manifestations,  as  shown  earlier  in 
Chapter 2, Table 2.1. These include POU1F1  (Tatsumi et al.  1992) and PROP1  (Wu et al. 
1998), mutations of which result in non-syndromic combined pituitary hormone deficiency 
[CPHD]. Mutations within PROP1  are associated with deficiencies of thyrotrophin [TSH], 
prolactin,  growth  hormone  [GH],  follicle  stimulating  hormone  [FSH]  and  luteinising 
hormone [LH] (Duquesnoy et al.  1998; Wu et al. 1998; Deladoey et al.  1999; Vallette-Kasic 
et al.  2001)  and have been reported to represent the commonest cause of familial CPHD. 
The phenotype is variable with respect to severity of hormone deficiency, age at the onset of 
puberty,  adrenal  function  and  even untreated  final  height  (Arroyo  et  al.  2002).  Evolving 
corticotrophin [ACTH]  deficiency has been described in a number of patients (Agarwal et
143al. 2000; Pemasetti et al. 2000), as well as anterior pituitary hyperplasia (Parks et al.  1999; 
Mendonca  et  al.  1999;  Riepe  et  al.  2001;  Voutetakis  et  al.  2004).  POU1F1  [murine 
orthologue  P/77]  was  the  first  pituitary-specific  transcription  factor  to  be  identified.  In 
humans,  mutations  within  POU1F1  were  first  described  in  1992  by  three  independent 
groups  (Tatsumi  et al.  1992; Ohta et al.  1992;  Pfaffle et al.  1992;  Radovick et al.  1992). 
Mutations within POU1F1  are  associated with GH, prolactin and TSH  deficiencies, with 
variable pituitary hypoplasia. Deficiencies of GH and prolactin are generally complete. TSH 
deficiency is more variable although in the majority, hypothyroidism is early and profound.
Mutations in LHX3 (Netchine et al. 2000) and LHX4 (Machinis et al. 2001) result in CPHD 
with a similar endocrine phenotype as in patients with mutations in PROP1. Homozygous 
mutations  in  LHX3  have  currently  been  identified  in  5  patients  from  3  unrelated 
consanguineous families, all with a deficit in all anterior pituitary hormones except ACTH, 
as  well  as  a  short  rigid,  cervical  spine  with  limited  head  rotation  and  trunk  movement 
(Netchine et al. 2000; Sobrier et al. 2004; Bhangoo et al. 2006). Pituitary morphology was 
variable  ranging  from  anterior pituitary hypoplasia with  a normal  posterior pituitary  and 
normal midline forebrain structures [MFS] on MR imaging to an abnormality similar to that 
observed in patients with PROP1 mutations characterized by an enlarged anterior pituitary 
(Netchine et al. 2000). One patient has been reported with a  hypointense lesion within the 
anterior pituitary consistent with a microadenoma (Bhangoo et al. 2006). Mutations in LHX4 
have been reported in only one pedigree with GH, TSH and ACTH deficiencies (Machinis et 
al. 2001). MR scanning revealed anterior pituitary hypoplasia with an undescended posterior 
pituitary and an absent pituitary stalk. Additional manifestations included a poorly formed 
sella turcica and pointed cerebellar tonsils.
144Mutations  in  HESX1  in  humans  have  been  shown  to  present  with  varying  phenotypes 
characterized by IGHD, CPHD and the syndrome of septo-optic dysplasia [SOD] (Dattani et 
al. 1998; Brickman et al. 2001; Thomas et al. 2001; Carvalho et al. 2003; Tajima et al. 2003; 
Cohen  et  al.  2003).  The  overall  frequency of HESX1  mutations  in  SOD  is however low 
suggesting  that  mutations  in  other known  or  unknown  genes  contribute  to  this  complex 
disorder.  Recently  a  recessive  mutation  has  been  identified  in  two  siblings  from  a 
consanguineous  family  who  presented  with  a  severe  phenotype  including  CPHD,  a 
coloboma of the right optic nerve with unilateral blindness and a left-sided diaphragmatic 
hernia  and  aortic  coarctation  (in  one  patient  only)  (Sobrier  et  al.  2005).  Results  of MR 
imaging are also highly variable with regards to H-P morphology and abnormalities of MFS.
More  recently,  mutations  within  GLI2,  GLI3,  SOX3  and  SOX2  have  been  identified  in 
patients  with variable hypopituitarism.  Mutations within PITX2  or RIEG are  found to be 
associated with Rieger syndrome, although none manifested pituitary hormone deficiencies 
(Cohen and Radovick 2002). Mutations within GLI2 have been identified in 7 patients with 
holoprosencephaly (Roessler et al. 2003) with a variable phenotype. In all affected patients, 
pituitary gland function was abnormal accompanied by variable craniofacial abnormalities, 
post-axial polydactyly, single nares, single central incisor and partial agenesis of the corpus 
callosum.  Mutations in GLI3 result in Pallister-Hall syndrome. A number of pedigrees have 
been  described  with  X-linked  hypopituitarism  involving  duplications  of  Xq26-q27 
containing the SOX3 gene (Hamel et al.  1996;  Hoi et al. 2000;  Solomon et al. 2002). The 
phenotype  is  of variable  mental  retardation  and  hypopituitarism.  Further  implication  of 
SOX3  in  hypopituitarism  came  from  identification  of  patients  with  expansion  of  a 
polyalanine tract within the gene (Laumonnier et al. 2002). Mutations in SOX2 have recently
145been  reported  resulting  in  a  phenotype  of  anophthalmia,  hypopituitarism,  learning 
difficulties and esophageal atresia (Kelberman et al. 2006).
Approximately 5-30% of patients with IGHD have a presumed genetic basis to the disorder, 
with  an  affected  first  degree  relative.  Genes  that  have  currently  been  implicated  in  the 
aetiology  of  GHD  include  GH1,  GHRHR,  HESX1  and  possibly  mutations  in  other 
transcription factors  [PROP1,  POU1F1] that present with variable phenotypes.  Mutations 
within GH1  and GHRHR are usually associated with non-syndromic IGHD in the presence 
of a normal or hypoplastic anterior pituitary, with a normally sited posterior pituitary on MR 
scanning. However, Osorio et al. recently described a patient with GH1 gene deletion with 
an undescended posterior pituitary (Osorio et al. 2002).  Recent studies have also revealed 
novel insights into the aetiology and pathogenesis of autosomal dominant type II IGHD. In 8 
out  of 57  patients  with  type  II  IGHD,  additional  hormonal  [partial  TSH  and/or  ACTH] 
deficiencies were documented (Mullis et al.  2005).  Mutations in GHRHR in patients with 
IGHD with extreme short stature suggest that GHRHR mutations may be a more common 
cause of IGHD than previously suspected.
Documentation of the detailed phenotype in patients with mutations in pituitary transcription 
factors, in conjunction with studies from mice with targeted disruption of these genes, will 
yield  better  insights  into  pituitary  development.  This  part  of the  study  investigated  the 
prevalence of individual  mutations  in  large  numbers  of patients  with  hypopituitarism,  to 
document  detailed  endocrine  and  neuroradiological  phenotypes  and  to  investigate  if 
genotype could predict the phenotype.
1467.2  PATIENTS AND SELECTION
The broad phenotypes of patients screened for mutations within candidate genes is shown in 
Table 7.1  All  825 patients recruited into the study were screened for mutations in HESX1 
given the variability of phenotypes associated with these mutations. The remaining patients 
were  selected  for  mutational  analysis  of appropriate  candidate  genes  based  on  previous 
animal  studies.  Patients  with  IGHD  were  screened  for  mutations  in  GH1  and  GHRHR. 
Patients whose neuroimaging revealed abnormalities of MFS, the posterior pituitary or the 
pituitary stalk or those with anterior pituitary enlargement, were excluded from analysis for 
GH1  and GHRHR.  Patients with sporadic IGHD but without MFD were also screened for 
PROP1,  LHX3  and  POU1F1.  Patients  with  CPHD  were  screened  for  mutations  within 
POU1F1, PROP1, LHX3 and LHX4, depending on their phenotype based on studies from 
animal  models.  Patients  with  a  X-linked  inheritance  of  variable  hypopituitarism  were 
selected for SOX3  screening.  Mutation screening of GLI2,  SOX2,  GLI3 or genes causing 
isolated hormone deficiency other than IGHD were not performed as a part of this study.
Mutations in GH1, POU1F1, PROPJ, HESX1  and SOX3 were found in 48 patients (5.8%) 
within the entire cohort. No mutations were found in LHX3, LHX4 or GHRHR within this 
study group.
147Table 7.1: Broad endocrine spectrum of patients screened for mutations in pituitary transcription factors and genes causing 
developmental defects of the pituitary, eye and midline structures.
Gene Number of 
patients screened
Familial
cases
Number of patients with 
isolated deficiencies of
CPHD Number of patients with 
normal endocrinology with
GH TSH Gn AVP Midline dysmorphism Eye defects
HESX1 825 109 325 2 7 7 399 15 70
PROP1 /LHX3/LHX4 233 44 79 1 0 0 153 0 0
POU1F1 129 24 48 1 0 0 80 0 0
SOX3 76 13 28 0 0 0 48 0 0
GH1/GHRHR 103 32 103 0 0 0 0 0 0
GH, growth hormone; TSH, thyrotrophin; Gn, gonadotrophin; AVP, arginine vasopressin; CPHD, combined pituitary hormone 
deficiencies
1487.3  MUTATIONS WITHIN HESX1
7.3.1  Patient phenotypes
Six patients  [5 males,  1   female],  from the cohort of 825 patients screened, were found to 
harbour mutations within HESX1 yielding a frequency of 0.7%.  There were 4 familial and 2 
sporadic  cases  from 4 unrelated  families  [Table 7.2, page  152].  One patient was referred 
directly to LCPE whilst the remaining 5 patients were followed up at other endocrine centres 
within UK. Two patients [pedigree I] were of Asian origin and the others were Caucasian. 
Mean age at diagnosis of hypopituitarism was 4.3 ±2.5 years. The reason for referral in all 
patients was poor growth and short stature with height SDS ranging from -2.8 to -3.9 SDS.
Sequencing  of HESX1  revealed  a  homozygous  R120C  mutation  in  both  siblings  from 
pedigree I. Sequencing of exon 4 from the parents, who were first cousins, revealed that they 
were  heterozygous  for  the  point  mutation  but  did  not  exhibit  any  abnormal  features 
consistent  with  an  autosomal  recessive  mode  of  inheritance.  A  heterozygous  S170L 
mutation in HESX1  resulting in the substitution of a serine residue by leucine in a highly 
conserved region  at  the  carboxy-terminal  end of the homeodomain was  identified in two 
brothers from pedigree II and in patient III. DNA binding studies confirmed a reduction in 
DNA binding by the mutant protein. A novel heterozygous missense mutation at a highly 
conserved residue  (E149K)  was  identified  in HESX1  in patient  IV.  His  mother,  son  and 
brother appear to be unaffected carriers of the mutation. Functional studies revealed that the 
mutation led to disruption of HESX1 function.
149CPHD [GH, TSH, ACTH, gonadotrophin] was demonstrated in both siblings from pedigree 
I with the homozygous R120C mutation whilst the remaining 4 patients with heterozygous 
mutations had IGHD.  These latter 4 patients  [II. 1, II.2,  III,  IV]  demonstrated an evolving 
severity  of GHD  with  serum  GH  concentrations  at  initial  diagnosis  of  14.5  mU/L  (3.8 
years), 20.4 mU/L (1.0 year),  1.1 mU/L (6.0 years) and 4.2 mU/L (6.3 years), and at repeat 
testing of 6.5mU/L (5.3 years),  14.5 mU/L (9.0 years), 0.9mU/L (18.0 years) and 1.2 mU/L 
(22 years). Longitudinal serum GH concentrations were not available in patients 1.1 and 1.2.
Evolution  of other pituitary hormone  deficiencies  was  not  demonstrated  in patients  with 
IGHD.  Patient IV with IGHD was initially suspected to have gonadotrophin deficiency in 
view of a hypoplastic scrotum and a small penis. A luteinising hormone releasing hormone 
test  [LHRH]  test  performed  at  12.5  years  of  age  revealed  peak  serum  FSH  and  LH 
concentrations of 2 U/L and 8 U/L. He was commenced on Sustanon replacement treatment 
until 17 years of age. At the end of puberty, however, his testicular sizes were 15-20 mis and 
a  serum testosterone  concentration  off Sustanon replacement treatment was normal  (13.4 
nmol/L). He was subsequently proven fertile with the birth of a normal male child. Patient
1.1  also had genital abnormalities with glandular hypospadias and gonadotrophin deficiency.
MR imaging was normal in both patients from pedigree II apart from the finding of kinked 
optic nerves in patient II. 1   [Table 7.3, page  153].  The remaining 4 patients demonstrated 
several  abnormalities  on  MR  imaging  including  anterior  pituitary  hypoplasia  (100%), 
hypoplastic pituitary sella (75%), undescended posterior pituitary (100%), abnormal corpus 
callosum (25%), absent septum pellucidum (50%), pituitary stalk abnormalities (100%) and 
ONH (50%). Neuroimaging revealed the diagnosis of SOD in both siblings from pedigree I
150with all 3  features of the syndrome: optic nerve hypoplasia, an absent septum pellucidum 
and  hypopituitarism  with  abnormal  H-P  morphology,  although  there  were  no  visual 
abnormalities clinically [Figure 7.1  B and C]. Additionally patient 1.1  demonstrated partial 
agenesis  of  the  corpus  callosum,  whereas  patient  1.2  had  hypogenesis  of  the  corpus 
callosum. In contrast to patients from pedigree I, patient II. 1  with normal H-P morphology, 
normal MFS but kinked optic nerves had clinical evidence of ONH. He also demonstrated 
extra-pituitary manifestations and was mildly dysmorphic with small hands and feet, simian 
creases and syndactyly of the 2nd and 3rd toes bilaterally. Patients III [Figure 6.1 D] and IV 
did not reveal abnormalities of the MFS or optic nerves on imaging. Digital abnormalities 
were however observed in Patient IV who had small bilateral supernumerary digits requiring 
excision.
Figure 7.1:
Magentic resonance imaging 
in patients with mutations in 
HESX1.
A, normal scan;
B, patient 1.1;
C, patient 1.2;
D, patient III.
151Table 7.2: Clinical and endocrine data of patients with mutations in HESX1
Ethnic origin Sex At Diagnosis Endocrinology Mutation
Age Height Peak FT4 Unstimulated
(years) (SDS) GH
(mU/L)
Cortisol
(nmol/L)
LH
(U/L)
FSH
(U/L)
(pmol/L) TSH
(mU/L)
PRL
(mU/L)
1.1 Asian M N/A N/A 3.0 40 UND UND 4.7 UND N/A R120C
1.2 Asian F N/A N/A UND 13 UND UND <5 0.2 N/A R120C
II. 1 Caucasian M 3.8 -3.9 14.5 1052 N/A N/A 1051 4.4 155 S170L
II.2 Caucasian M 1.0 -3.6 20.4 N N N N N N S170L
III Caucasian M 6.0 -2.8 1.1 920 N N 17.1 2.7 252 S170L
IV Caucasian M 6.3 -3.7 4.2 N 8.0 2.0 N N N E149K
M, male; F, female; GH, growth hormone; TSH, thyrotrophin; FSH, follicle stimulating hormone; LH, luteinising hormone; AP, 
anterior pituitary; PP posterior pituitary; SP, septum pellucidum; CC, corpus callosum; ON, optic nerves; N/A, not available; D, 
deficient; H, hypoplastic; N, normal; U, undescended; P, partial; A, absent; K, kinked;1  total thyroxine, UND, undetectable
152Table 7.3: Magnetic resonance [MR] imaging in patients with mutations in HESX1
MR Imaging
Sella Anterior pituitary Posterior pituitary Septum pellucidum Corpus callosum Stalk Optic nerves
1.1 Hypoplastic Hypoplastic Undescended Absent Partial Hypoplastic Hypoplastic
1.2 Normal Hypoplastic Undescended Absent Hypoplastic Hypoplastic Hypoplastic
II. 1 Normal Normal Normal Normal Normal Normal Kinked
II.2 Normal Normal Normal Normal Normal Normal Normal
III Hypoplastic Hypoplastic Undescended Normal Normal Hypoplastic Normal
IV Hypoplastic Hypoplastic Undescended Normal Normal Hypoplastic Normal
1537.3.2  Discussion
The R120C mutation found in patients 1.1 and 1 .II was the first reported mutation in HESXJ 
and was implicated in the etiology of SOD in humans (Dattani et al.  1998). Since then both, 
homozygous  and heterozygous  mutations  in HESX1  have been associated with markedly 
variable phenotypes in humans. Although reported heterozygous HESX1 mutations  S170L 
and T181A are,  in general,  associated with milder phenotypes and incomplete penetrance 
with most affected individuals inheriting the mutation from one of their unaffected parents 
(Thomas et al. 2001), two further heterozygous mutations [a deletion at nucleotide position 
1684  (Cohen  et  al.  2003)  and  a  de  novo  2bp  insertion  (Tajima  et  al.  2003)]  have  been 
identified in patients presenting with a more severe phenotype of SOD with GH deficiency, 
hypoplasia of the  anterior pituitary and optic nerves  and midline  forebrain abnormalities. 
The patient with the insertion mutation also exhibited evidence of gonadotrophin deficiency 
and hypothyroidism. A similar variability has been observed in patients with homozygous 
HESXJ mutations. Apart from the first report by Dattani at al (Dattani et al. 1998), 5 patients 
have been described with 4 different homozygous mutations. One patient presented with a 
milder  phenotype  of  evolving  CPHD,  anterior  pituitary  hypoplasia  and  no  optic  nerve 
abnormalities (Carvalho et al.  2003),  and 2 sibs were reported with CPHD,  aplasia of the 
anterior pituitary,  coloboma  of the right optic  nerve  and left-sided diaphragmatic  hernia. 
One sib also had aortic coarctation (Sobrier et al. 2005). More recently 2 unrelated patients 
have  been  described  with  a  life-threatening  neonatal  condition  associated  with  anterior 
pituitary  aplasia,  panhypopituitarism,  a  normal  posterior  pituitary  and  no  optic  nerve 
abnormalities (Sobrier at al. 2006).
154There is a poor genotype-phenotype correlation in patients with mutations in HESX1 within 
this  study cohort  as  well.  The brothers  from pedigree  II presented with peak  serum GH 
concentrations  of  14.5  mU/L  and  20.5  mU/L  with  an  evolving  severity  of  GHD  and 
gradually decreasing concentrations of GH with age. Patient III however had severe GHD at 
diagnosis  (1.1  mU/L)  with repeat concentrations  at end of his  growth of 0.9  mU/L.  MR 
imaging in these patients, with the same genotype, was also variable. Patients II. 1   and II.2 
essentially demonstrated  a normal  MR scan  apart from patient  II. 1  demonstrating kinked 
optic  nerves.  Patient  III,  however,  demonstrated a hypoplastic pituitary sella and anterior 
pituitary, an undescended posterior pituitary and a hypoplastic stalk. There was also a poor 
correlation between the genotype and the neuroanatomical phenotype within families with 
the same mutation. The pituitary sella was hypoplastic with partial agenesis of the corpus 
callosum in patient 1.1  but normal with hypogenesis of the corpus callosum in patient 1.2. 
Similarly,  kinked  optic  nerves  revealed  on  MR  imaging  in  Patient  II. 1   were  not 
demonstrated in patient II.2.
MR imaging did not reveal MFD in patients with heterozygous mutations unlike previous 
reports (Cohen et al. 2003; Tajima et al. 2003). However, these abnormalities have not been 
reported  in  some  patients  with  homozygous  HESX1  mutations  as  well.  Patients  with 
homozygous mutations present with a more severe endocrine phenotype as compared with 
those with heterozygous mutations, with evolving CPHD (Carvalho et al. 2003;  Sobrier et 
al. 2005) or complete panhypopituitarism with pituitary aplasia (Sobrier et al. 2006).
155Patient  II. 1,  with  a  heterozygous  S170L  mutation had  clinical  optic  nerve  dysplasia  and 
kinked optic nerves on MR imaging, a phenotype similar to but milder than that observed in 
patients  1.1  and  1.2  with  SOD.  Patient  II.land  patient  IV,  with  IGHD,  also  had  digital 
anomalies as have been previously observed in patients with SOD (Pagon and Stephan 1984; 
Orrico et al. 2002; Harrison et al. 2004).
A  novel  E149K  heterozygous  missense  mutation  that  led  to  functional  compromise  was 
identified in patient IV [McNay et al, 2006, in press]. While both the patient and his brother 
have inherited this mutation from their mother, they inherited different paternal haplotypes. 
His brother, mother and a son are unaffected carriers of the mutation. It is possible that this 
may represent variable penetrance or the patient may have inherited an as yet unidentified 
HESX1 mutation from his father resulting in a phenotype due to compound heterozygosity.
1567.4  MUTATIONS WITHIN PROP1
7.4.1  Patient phenotypes
Of 233  patients  screened,  mutations in PROPl  were detected in  15 patients  [12 males,  3 
females] from 8 pedigrees yielding a frequency of  6.4% [Table 7.4, page 162]. In addition, 
a further patient from pedigree IV who presented with a height of -4.5 SDS at 60 years of 
age, was found to have GH, TSH and gonadotrophin deficiencies, but had died of ischaemic 
heart disease shortly after presentation.  DNA was not available from this patient.  Patients 
from pedigrees III, IV, V, VI, VII and VIII were siblings.
There  was  a wide  range  in the  age  at  initial presentation.  The mean  age  at diagnosis  of 
hypopituitarism was made at 17.5 ± 17.0 years. 5 patients [II, IV. 1, IV.2, VII. 1, VII.2] were 
diagnosed late with CPHD, at ages 29.0 years, 50 years, 55 years, 26.3 years and 22.3 years. 
Short stature (mean height SDS -6.6 ±1.8  SDS) was the reason for presentation in all  15 
patients.  Patient  IV. 1   diagnosed  at  50  years  of age  also  had hypoglycaemic  seizures  at 
presentation. 8/15 patients (patients I, II, V.l, V2, VI. 1, VI.2, VII. 1, VII.2), all with the same 
mutation,  a  homozygous  13bp  deletion  (112-124A),  were  of Asian  origin  (6  Indian,  2 
Pakistani). The remaining patients were Caucasian; siblings from pedigree III harbouring a 
homozygous  lbp deletion (150AA) were from Russia, brothers from pedigree IV and those 
from pedigree  VIII  harbouring the  common  2-bp  deletion within  exon  2  (301-302AAG) 
were from the UK and Poland respectively. Mode of inheritance was autosomal recessive in 
all patients.
157All  15 patients had CPHD, evolving in the case of patient VIII.3 and possibly in patient II. 
GHD was present in all patients (precise GH concentrations unavailable in 2 patients) with a 
mean serum GH concentration of 1.7 ±  1.3 mU/L. GHD was evident in  14/15 patients at 
initial  presentation.  Patient  VIII.3,  when  tested  in  infancy,  had normal  pituitary function 
tests at one year of age but was found to be GHD at 5 years of age. Patient II was initially 
investigated in Afghanistan and details of investigations performed were not available. He 
received  thyroxine  treatment  but  continued  to  be  severely  growth  retarded  until  the 
diagnosis of GHD at the age of 29 years.
TSH deficiency was present in 14/15 (93%) patients. The mean serum TSH concentration in 
patients with hypothyroidism was 3.0 ±  1.5 mU/L. Patient VII. 1   with no clear evidence of 
TSH  deficiency,  had  a  free  thyroxine  concentration  at  the  lower  end  of normal  at  13.1 
pmol/L with a serum TSH concentration of 2.9 mU/L at the age of 26.3  years.  Similar to 
GH, TSH deficiency was evolving in Patient VIII.3. Patient V.l  had a marginally elevated 
serum TSH concentration of 6.1 mU/L at diagnosis.
The  serum  prolactin  concentrations  were  normal  (100-500  mU/L)  in  8/15  patients 
(chronological age range  11.0-58.0 years), although it was in the lower range of normal in 
50%  of them  (100  -182  mU/L).  Seven  of  15  (47%)  patients  were  prolactin  deficient, 
evolving in patient VIII.3, 9 years after the diagnosis of GH and TSH deficiencies.
Siblings  from pedigree  III have not had testing for gonadotrophin deficiency.  4/10 males 
with confirmed gonadotrophin deficiency had evidence of undescended testes. Patient II also 
had micropenis and gynaecomastia, brothers from pedigree IV had genitalia that were near
158ambiguous  and  patient  VIII. 1   had  needed  bilateral  orchidopexies  in  the  past.  Although 
gonadotrophin  deficiency  has  not  been  confirmed  in  patient  I  in  view  of his  age,  he 
presented  with  a  micropenis  and  bilaterally  undescended  testes  and  preliminary 
investigations revealed peak serum FSH and LH concentrations of 0.7 U/L and 0.2 U/L [ 9 
years of age].
Hypocortisolemia was documented in 3/15 patients (20%). Both brothers from pedigree IV 
presented with hypocortisolaemia at initial presentation at ages of 50 years and 55  years. 
Patient V.2 had normal cortisol secretion initially but was found to be deficient at the age of 
17 years after a tonic clonic  seizure at the time of dental extraction.  7/12 patients without 
cortisol deficiency are now adults and continue to have normal cortisol secretion.
Results  of MR  imaging,  particularly with respect to  anterior pituitary morphology,  were 
variable among 11 patients in whom it was performed [Table 7.5, page  163]. The posterior 
pituitary, pituitary stalk, septum pellucidum, corpus callosum and optic nerves were normal 
in all patients apart from patient I in whom, although morphologically normal, the pituitary 
stalk  was  anteriorly  displaced,  and  the  posterior  pituitary  appeared  compressed. 
Abnormalities of the anterior pituitary and pituitary sella were demonstrated in  100% and 
45.5%  of patients.  MR  imaging  in  patient  I  revealed  an  enlarged  sella  turcica  with  a 
markedly enlarged anterior pituitary (8.6 mm) (Argyropoulou et al.  1991), with enhancing 
lesions  suggestive  of  possible  haemorrhage  [Figure  7.2  (i)  a].  Repeat  MR  imaging 
performed 4,  12 and 21 months after the first scan showed significant waxing and waning in 
the size of the anterior pituitary mass at 6.8 mm, 8.3 mm and 4.2 mm respectively [Figure
7.2  (i)b, (i) c, (i) d].
159Figure  7.2:  Magnetic  resonance  imaging  in  two  patients  with  a  13  bp  deletion  in 
PROP1 illustrating variability between genotype and phenotype between pedigrees.
(i) Patient 1 (ii) Patient 2.
160Figure 7.3:  Magnetic  resonance  imaging in  siblings IV.l  and  IV.2  with  301-302AAG 
deletion  in  PROP1  illustrating  variability  between  genotype  and  phenotype  within 
pedigrees, (i) Patient IV.l (ii) Patient IV.2.
0)  (ii)
Four patients  [patients  II,  IV.2,  V.2  and  VII.2]  had  a  very  thin rim of barely discernible 
anterior pituitary tissue, 2 of whom had an enlarged and 2 of whom had a normal pituitary 
sella. MR imaging of patient II is shown in Figure 7.2 (ii). Anterior pituitary tissue appeared 
dysgenetic  with  a  shallow  pituitary  fossa  in  patient  IV.l  but  Mr  imaging  of his  brother 
revealed a thin rim of anterior pituitary tissue within an enlarged pituitary sella [Figure 7.3].
The anterior pituitary in the remaining 5 patients (patients III, VII. 1, VIII. 1, VIII.2, VIII.3) 
was  hypoplastic  in  appearance,  although  the  sella  was  enlarged  in  patient  VII. 1.
161Table 7.4: Clinical and endocrine data of patients with mutations in PROP1
Ethnic
origin
Sex At diagnosis Endocrinology Mutation
Height
(SDS)
Age
(years)
Peak
GH
(mU/L)
FT4
(pmol/L)
TSH
(mU/L)
PRL
(mU/L)
Cortisol
(nmol/L)
Peak
(U/L)
Basal Peak LH FSH
I Asian M -4.5 9 2.1 6.7 2.2 322 393 693 0.7 0.2 112-124A
II Asian M -7.3 29 0.6 5.3 1.6 136 499 997 0.2 0.5 112-124A
III.l Caucasian F -6.0 6.6 1.5 Low Low 78 379 N/A N/A N/A 150AA
III.2 Caucasian M N/A N/A Low L L L N N N/A N/A 150AA
IV.l Caucasian M -6.0 50 1.5 9.3 1.7 182 308 352 1.0 0.3 301-302AAG
IV.2 Caucasian M -6.2 55 D 5.3 1.3 126 L 138 2.5 0.9 301-302AAG
V.l Asian F -5.1 10.5 2.4 L 6.1 100 N N 2.3 3.0 112-124A
V.2 Asian M -5.7 7.4 1.2 L 4.7 72 59 352 0.1 0.2 112-124A
VI. 1 Asian M -6.7 8.0 2.4 62* 4.0 N N N L L 112-124A
VI.2 Asian F -6.5 6.0 1.8 52* 3.0 N N N L L 112-124A
VII.l Asian M -5.5 26.3 1.5 13.1 2.9 40 368 737 1.2 1.5 112-124A
VII.2 Asian M -6.2 22.3 1.5 8.0 3.1 38 158 598 0.4 0.5 112-124A
VIII. 1 Caucasian M N/A 8.3 1.8 55.9* 1.9 36 269 585 0.6 0.6 301-302AAG
VIII.2 Caucasian M N/A 1.0 3.3 62.4* 0.8 256 490 740 0.6 0.1 301-302AAG
VIII.3 Caucasian M N/A 5.0 5.7 6.7 2.5 60 366 909 N/A N/A 301-302AAG
N/A not available; * total thyroxine; M, male; F, female; GH, growth hormone; TSH, thyrotrophin; FSH, follicle stimulating hormone; 
LH, luteinising hormone; PRL, prolactin; L, low.
162Table 7.5: Magnetic resonance [MR] imaging in patients with mutations in PROP1
MR Imaging
Sella Anterior pituitary Posterior pituitary Pituitary stalk
I Enlarged Enlarged Normal Normal
II Enlarged Thin rim Normal Normal
III.1 Normal Hypoplastic Normal Normal
III.2 N/A N/A N/A N/A
IV.l Hypoplastic Hypoplastic/dysgenetic Normal Normal
IV.2 Enlarged Thin rim Normal Normal
V.l N/A N/A N/A N/A
V.2 Normal Thin rim Normal Normal
VI. 1 N/A N/A N/A N/A
VI.2 N/A N/A N/A N/A
VII. 1 Enlarged Hypoplastic Normal Normal
VII.2 Normal Thin rim Normal Normal
VIII. 1 Normal Hypoplastic Normal Normal
VIII.2 Normal Hypoplastic Normal Normal
VIII.3 Normal Hypoplastic Normal Normal
N/A not available
1637.4.2  Discussion
Mutations within PROPI  are reported to be the  commonest genetic  cause of CPHD with 
incidence rates quoted between 50-100% in familial cases of CPHD (Deladoey et al.  1999; 
Mody et al. 2002). PROPI mutations were identified in 15 patients with hypopituitarism in 
this  study  cohort  (6.4%)  (Turton  et  al.  2005a).  No  mutations  were  identified  in patients 
screened with IGHD or in those with morphological abnormalities of the posterior pituitary 
and/or pituitary stalk.  The true prevalence of mutations in PROPI  in patients with CPHD 
without  posterior  pituitary  and pituitary  stalk  abnormalities  was  11/37  (30%),  as  37/233 
patients  screened had CPHD and MR available that did not demonstrate pituitary stalk or 
posterior  pituitary  abnormalities.  Of  15  patients  in  whom  mutations  were  identified,  13 
patients would be classified as familial cases. As the cohort screened included 44 familial 
cases,  the  prevalence  of PROPI  mutations  in  sporadic  hypopituitarism  was  only  1.1% 
(2/189)  and  increased  to  29.5%  (13/44)  in  familial  hypopituitarism.  The  reason  for  the 
discrepancy  in  incidence  of mutations  between  various  reports  is  unclear.  All  mutations 
identified in the present study were homozygous,  in keeping with other reports (Wu et al. 
1998;  Agarwal  et  al.  2000;  Riepe  et  al.  2001).  Eight  patients  from  5  pedigrees  of 
Indian/Pakistani origin harboured an identical mutation (112-124A) suggesting the presence 
of a  possible  founder  mutation  in  PROPI  within  the  Indian  subcontinent  (Turton  et  al. 
2005a).
The  present  findings,  like  other  previously  published  studies,  show  marked  phenotypic 
variability  in  patients  with  PROPI  mutations.  For  example,  patient  VII.I  displayed  a 
borderline free thyroxine concentration with a normal serum TSH concentration despite all 
other patients  demonstrating central  hypothyroidism.  Patients  I,  II,  IV.l,  IV.2  and  VIII. 1
164showed  probable  early-onset  gonadotrophin  deficiency  demonstrated  by  genital 
abnormalities at birth.  Prolactin concentrations were highly variable ranging from 38-322 
mU/L.  Patients  III.l,  III.2,  V.II,  VII.I,  VII.2,  VIII.I  and  VIII.3  demonstrate  prolactin 
deficiency with variable  concentrations  whilst patients  1,  II,  IV.l,  IV.2,  V.l,  VI. 1,  VI.2, 
VIII.2 maintain normal concentrations to date. Three patients, V.2 on repeated assessment 
and two older patients, IV.l  and  1V.2, manifested frank cortisol deficiency as observed in 
some other patients with mutations in PROPI  (Agarwal et al. 2000; Pemasetti et al. 2000; 
Vallette-Kasic  et al. 2001). No other patient within this cohort harbouring the same  13 bp 
mutation  as  detected  in  patient  V.2  demonstrated  hypocortisolemia  although  it  has  been 
reported previously (Agarwal et al. 2000). The endocrine phenotype within families with the 
same  mutation was  also  variable,  as observed in pedigree VIII where only patient VIII.3 
revealed evolving hormonal deficiency. There was a poor correlation between the genotype 
and  neuroradiological  phenotype  between  patients  and  within  families  with  an  identical 
mutation  in  PROPI.  MR  imaging  of patient  I  revealed  an  enlarged  pituitary  gland  that 
waxed  and  waned  in  size,  not  reported  previously,  before  undergoing  virtual  complete 
involution 20 months after the first scan.  Patients II and VII.I, with the same mutation as 
patient 1.1, also had an enlarged sella but with a hypoplastic rim of anterior pituitary tissue 
that may possibly be  explained by prior pituitary enlargement.  Although  evolving ACTH 
deficiency during a period of pituitary involution has been suggested (Pemasetti et al. 2000), 
ACTH deficiency was not evident in these 3 patients. Of 3 patients with ACTH deficiency, 
patient IV.l  had a hypoplastic anterior pituitary but an enlarged pituitary sella, which could 
be explained by prior pituitary enlargement and subsequent involution. The other 2 patients, 
however, demonstrated hypoplastic sellae.
1657.5  MUTATIONS WITHIN POU1F1
7.5.1  Patient phenotypes
Eight patients [4 males, 4 females] belonging to 6 unrelated families, from a cohort of 129 
patients  screened,  were  found  to  harbour mutations  in POU1F1  yielding  a  frequency  of 
6.2%  [Table 7.6, page  169]. Pedigrees I,  II and III were Maltese in origin, patient IV and 
patients from pedigree V were from the UK and patient VI was Russian. The mean age at 
diagnosis  [0.6  ±0.8  years]  was  significantly  [<0.05]  earlier  than  that  for  patients  with 
mutations in PROPI.  Short stature [mean height -5.2 ±1.9 SDS], poor growth and failure to 
thrive were the reasons  for seeking medical attention in 4 patients  [II,  III,  IV,  V.2] while 
patients 1.1, V.l and VI were diagnosed due to prolonged unconjugated hyperbilirubinaemia. 
Patient 1.2 was asymptomatic but was investigated at birth in view of the diagnosis of CPHD 
in his older brother.
A homozygous  E230K mutation  [substitution of a glutamate residue by lysine at position 
230]  was  found  in  patients  II  and  III.  Both  brothers  from  pedigree  I  were  compound 
heterozygotes for two mutations: E230K inherited from the mother and R172Q [substitution 
of an arginine residue by glutamine at position  172]  inherited from the father.  Mutational 
analysis  of POU1F1  in  patient  VI  also  revealed  compound  heterozygosity:  the  E230K 
mutation [inherited from the mother and maternal grandmother]  and insA791  in exon 6 of 
the gene, the latter either inherited from the father [paternal DNA not available] or a de novo 
mutation. Patients IV, V.l and V.2 were heterozygous for a R271W point mutation.
166CPHD was present in all 8 patients. Profound GHD was diagnosed in all 7 patients tested, 
with a mean peak serum GH concentration of 1.4 ± 1.2 mU/L. Patient 1.2 has not, as yet, had 
GH provocation testing.  The diagnosis of GHD was made within 3  years in all 7 patients, 
and within the first year of life in 3/7 patients.
TSH  deficiency manifested itself earlier than GHD in 4 patients.  Compared with patients 
with mutations in PROPI  [2.8 ±1.5 mU/L], the mean serum TSH concentration in patients 
with  mutations  in  POU1F1  [0.8  ±  0.9  mU/L]  was  significantly  lower  [p=0.002].  TSH 
deficiency was present in 7/8 patients and had manifested itself within the first year of life in 
all 7 patients. Patient II had a borderline free thyroxine [FT4] when investigated for failure 
to thrive at 4 months of age. Although diagnosed with profound GH deficiency at the age of 
2.4 years, her TRH test was normal. Repeat dynamic pituitary function testing at 16.3 years 
off all  treatment  confirmed GH,  partial  TSH  and prolactin deficiencies.  She  is now aged 
20.5  years  with  a  serum  FT4  concentration  that  is  normal  at  15.6  pmol/L  without  any 
thyroxine treatment.
No patient was confirmed to have cortisol or gonadotrophin deficiencies although 2 patients 
received  hydrocortisone  replacement  treatment  and  one  patient  had  puberty  induced, 
temporarily.  Patient IV demonstrated borderline hypocortisolaemia [unstimulated and peak 
serum cortisol concentrations of 335 nmol/L and 426 nmol/L respectively]  at the age of 2 
years when the diagnosis of severe GH and prolactin deficiencies was made. Hydrocortisone 
replacement  was  commenced  at the  age  of 6.5  years  in  view  of symptoms  of fatigue  in 
conjunction  with  previously  documented  borderline  cortisol  insufficiency.  He  also  had 
bilaterally undescended testes and was presumed to be gonadotrophin deficient and puberty
167was induced at 11  years of age with Sustanon treatment. However, when re-investigated off 
all  replacement  treatment  at  the  end  of  his  statural  growth,  GH,  TSH  and  prolactin 
deficiencies  were  re-confirmed but he  mounted  a  satisfactory  serum  cortisol  response to 
insulin-induced  hypoglycaemia  [626  nmol/L]  and  a  normal  gonadotrophin  response  to 
LHRH [LH  15.1  U/L, FSH 5.8 U/L] with a serum testosterone concentration of 15 nmol/L. 
Patient V.2  also demonstrated a partial cortisol response to metyrapone at  11  years of age 
that resulted in  substitution with cortisone  acetate treatment.  When full dynamic pituitary 
testing was  repeated  as  an  adult  off all replacement treatment,  GH and TSH deficiencies 
were re-confirmed but cortisol secretion was normal.
The  mean  serum prolactin concentration in patients was  48.5  ± 48  mU/L  and was  again 
significantly  lower  [p=0.05]  than  that  of patients  with  mutations  in PROPI  [120.5  ±91 
mU/L]. Patients III and V.2 had borderline low unstimulated serum prolactin concentrations. 
In  spite  of that  patient  V.2  presented  with  failure  of lactation  and  an  absent  prolactin 
response to stimulation with a TRH test confirming prolactin deficiency.
Results of MR imaging were available in 7/8 patients [Table 7.7, page  170]. Neuroimaging 
revealed normal posterior pituitary, pituitary stalk, septum pellucidum, corpus callosum and 
optic  nerve  morphology  in  all  7  patients.  The  anterior  pituitary  was  hypoplastic  in  6/7 
patients and normal in patient V. 1.
168Table 7.6: Clinical and endocrine data of patients with mutations in POU1F1.
Ethnic origin Sex Presentation Endocrinology Mutation
Height
(SDS)
Age
(years)
Peak GH 
(mU/L)
FT4
(pmol/L)
Unstimulated Cortisol
(nmol/L)
Peak
(U/L)
TSH
(mU/L)
PRL
(mU/L)
Basal Peak LH FSH
1.1 Caucasian M -3.6 0.1 3.9 5.2 0.1 14 675 1380 29.8 3.9 E230K / R172Q
1.2 Caucasian M -2.3 0.1 N/T 2.6 0.1 10 N/T N/T N/T N/T E230K/R172Q
II Caucasian F -5.8 2.4 0.3 15.6 0.3 14 578 745 40.1 6.1 E230K
III Caucasian M -5.6 1.0 2.1 7.8 2.7 120 543 895 N/T N/T E230K
IV Caucasian M -7.8 0.5 0.9 37.7* 1.0 44 464 626 15.1 5.8 R271W
V.l Caucasian F N/A 0.3 0.9 9.1 0.9 50 300 1150 12 30 R271W
V.2 Caucasian F N/A 0.2 0.9 20.5* 1.0 124 N/A 725 30 5.0 R271W
VI Caucasian F -5.9 0.3 <0.7 Low 0.1 12 430 N/A N/A N/A E230K / insA778
N/A not available; * total thyroxine; M, male; F, female; GH, growth hormone; TSH, thyrotrophin; FSH, follicle stimulating hormone; 
LH, luteinising hormone; PRL, prolactin; AP, anterior pituitary; PP posterior pituitary; H, hypoplastic; N, normal
169Table 7.7: Magnetic resonance [MR] imaging in patients with mutations in POU1FL
MR Imaging
Anterior pituitary Posterior pituitary Pituitary stalk
1.1 Hypoplastic Normal Normal
1.2 N/A N/A N/A
II Hypoplastic Normal Normal
III Hypoplastic Normal Normal
IV Hypoplastic Normal Normal
V.l Normal Normal Normal
V.2 Hypoplastic Normal Normal
VI Hypoplastic Normal Normal
N/A not available
1707.5.2  Discussion
The incidence of POU1F1  mutations in patients with GH, TSH and prolactin deficiencies 
may be as high as 50% (Brown et al.  1998). The present study suggests that the prevalence 
of mutations in POU1F1  in patients with sporadic hypopituitarism is 3.8%  [4 of 105] but 
increased to  16.7% [4 of 24] in familial cases of CPHD as 24 of 129 patients screened had 
evidence of familial disease. No mutation was identified in patients with IGHD or those with 
abnormalities of the posterior pituitary and pituitary stalk.
A novel mutational “hot-spot” within POUIF1 [E230K] was identified in 5 individuals from 
4 different pedigrees. Of these, 3 pedigrees originated from Malta, suggesting that a founder 
effect cannot be excluded. Two novel mutations [ins778A and R172Q] were also identified 
in compound heterozygosity with E230K (Turton et al. 2005b).
Phenotypic  variability in patients  with POU1F1  mutations,  as with mutations  in PROPI, 
was present  mainly with respect  to  the presence  of central  hypothyroidism and prolactin 
deficiency.  Deficiencies  of  GH,  TSH  and  prolactin  were  more  severe  in  patients  with 
mutations in POU1F1  as compared with mutations in PROPI  as was the age at diagnosis. 
All patients with POU1F1 mutations in the present study tested for GHD showed profound 
GH deficiency. Previous reports have suggested that TSH deficiency is invariably associated 
with mutations within POU1F1  (Pfaffle et al. 1999). Patient II with an identical genotype to 
Patient III [E230K] had preserved thyroxine secretion until 20.5 years of age unlike Patient 
III who developed TSH deficiency at 1.0 year of age. Prolactin deficiency was not complete 
in all patients.  Six patients demonstrated severe prolactin deficiency while the remaining 2
171patients had a serum prolactin concentration in the lower range of normal at 120 mU/L and 
124  mU/L.  The  latter patient,  however,  presented  with  failure  of lactation  illustrating  a 
possible role of hormone-receptor interaction resulting in this inter-individual variation in 
phenotype.  In contrast to  patients with  mutations within PROPI,  patients with mutations 
within POU1F1 did not manifest gonadotrophin and cortisol deficiency.
Whereas  MR scanning revealed a  small,  normal  or enlarged anterior pituitary in patients 
with  mutations  within PROPI,  the  anterior pituitary was  either hypoplastic  or normal  in 
patients  with  mutations  within  POU1F1.  Two  patients  were  successfully  weaned  off 
hydrocortisone  treatment  following  mutational  screening.  These  findings  illustrate  the 
importance  of careful  phenotypic  characterization  and  genetic  analysis  in  patients  with 
hypopituitarism.
1727.6  MUTATIONS WITHIN GH1
7.6.1  Patient phenotypes
14 patients [11  males, 3  females] from 7 unrelated families, of 103 patients screened, were 
found to have mutations within the  GH1  gene yielding a frequency of 13.6%  [Table 7.8, 
page 175]. Apart from patient IV, all patients had an affected family member.
Three brothers from pedigree II, from Pakistan, harboured a 6.7 Kb homozygous deletion in 
the GH1  gene indicating an autosomal recessive mode of inheritance.  Mutational analysis 
revealed heterozygous intronic point mutations, predicted to result in abnormal splicing, in 
the majority of the remaining patients: IVS3 +2nt in patient 1.1 and her son 1.2, IVS3 +6nt in 
patient III. 1   and her father III.2, and IVS3 +lnt in patient IV, VI. 1   and his son VI.2 , VII. 1  
and his mother VII.2.  Patient V.l  and his  son V.2 were found to harbour a heterozygous 
point mutation  [A>C] resulting in substitution of a glutamate residue by alanine at the 2nd 
base  of exon  3,  in  an  exon  splice  enhancer,  likely to  result  in  aberrant  splicing as well. 
These  heterozygous  mutations  indicated  an  autosomal  dominant  mode  of  inheritance 
resulting in type IIIGHD. All patients with these splice site mutations, apart from pedigree I 
from Denmark, were from the UK.
All  14 patients presented with  short stature and poor growth,  at a mean age of 4.7 ± 3.8 
years with  a mean  height of -6.2  ±1.7  SDS.  Patient VI. 1   was  diagnosed with  IGHD  in 
childhood for which he received GH treatment from the age of 7.5 years until  18 years of 
age.  He  continued  to  be  GHD  as  an  adult  with  low  serum  IGF1  concentrations  and  an 
elevated serum cholesterol. However, he was more recently found to develop CPHD with
173infertility secondary to gonadotrophin deficiency [low basal serum gonadotrophin and serum 
testosterone  concentrations],  a  borderline  cortisol  response  and  prolactin  deficiency 
suggesting evolving hormonal deficiencies. No other patient has demonstrated abnormalities 
of any other pituitary hormones and five patients have reached adulthood.
Patient  V.l  was  diagnosed  with  IGHD  at  the  age  of 7.3  years  with  a  peak  serum  GH 
concentration of 4.2 mU/L. He has since demonstrated fluctuating serum GH concentrations 
on longitudinal testing. He was treated with pituitary-derived hGH between the ages of 8.3 
years to 9.7  years, however,  given the association between Creutzfeldt-Jacob disease with 
pituitary-derived GH,  the  latter was discontinued.  He was re-commenced on recombinant 
hGH  at  10.1  years  of age until  16.2  years of age.  Repeat GH provocation testing at  16.6 
years,  19.9 years and 29 years revealed GH concentrations of 8.4 mU/L, 24.6 mU/L and < 
0.8  mU/L.  His  serum  IGF1  concentrations  have  however  been  very  low.  Similar  to  his 
endocrine  findings,  results  of his neuroimaging have been conflicting.  A CT  scan at 7.3 
years  of age  was  reportedly  normal.  A  repeat  CT  scan  performed  at  16.2  years  of age 
revealed  anterior pituitary hypoplasia  and  a  MR  scan  performed  at  25  years  of age  was 
reported to be normal.
Apart from patient V.l  with the unusual  MR imaging and patient IV whose MR imaging 
revealed  an  empty pituitary  sella  with  extension  of chiasmatic  cistern  into  the  sella,  the 
anterior pituitary in the remaining patients was either hypoplastic [patients III. 1, III.2, V.2, 
VI. 1,  VI.2  and  VII.1]  or  normal  [Patient  1.1,  Table  7.8,  page  175].  There  were  no 
abnormalities  within  the  posterior  pituitary,  pituitary  stalk,  septum  pellucidum,  corpus 
callosum or optic nerves.
174Table 7.8: Clinical features, endocrinology and magnetic resonance imaging in patients with mutations in GHL
Sex Ethnic
origin
Presentation Endocrinology Anterior 
pituitary 
on imaging
Mutation
Age
(yrs)
Height
(SDS)
Weight
(SDS)
Peak
GH
(mU/L)
Basal
TSH
(mU/L)
FT4
(pmol/L
)
PRL
(mU/L)
Cortisol
(nmol/L)
Peak
(U/L)_
Basal Peak LH FSH
1.1 M Caucasian 1 -4.6 N/A 0.7 N N N N N N/T N/T N IVS3+2nt
1.2 F Caucasian 8 N/A N/A D N N N N N N N N/A IVS3+2nt
II.1 M Asian 4.0 -8.5 -6.6 D N N N N N N/T N/T N/A 6.7Kb deletion
II.2 M Asian 6.0 -8.6 -8.5 D N N N N N N/T N/T N/A 6.7Kb deletion
II.3 M Asian 3.0 -8.1 -6.2 D N N N N N N/T N/Y N/A 6.7Kb deletion
III.l F Caucasian 1.25 -6.1 -5.0 <0.3 2.3 101* N 155 718 N N H IVS3+6nt
III.2 M Caucasian 14.8 -7.2 -3.3 9.2 2.5 13.3 106 N 831 9.3 24.4 H IVS3+6nt
IV M Caucasian 1.6 -5.4 -5.0 3.9 1.5 16 260 474 1194 N N A IVS3+lnt
V.l M Caucasian 7.3 -4.3 -3.7 4.2 N N 700 N N N N N E58A/E32A
V.2 M Caucasian 5.7 -5.0 N/A 4.2 N N N N N N/T N/T H E58A/E32A
VI. 1 M Caucasian 2.3 -4.4 -3.2 <0.6 0.9 16 90 388 504 L L H IVS3 +lnt
VI.2 M Caucasian 7.5 N/A N/A 2.1 N N N N N N N H IVS3 +lnt
VII.l M Caucasian 1.5 N/a N/a 5.4 N N N N N N/T N/T H IVS3 +1 nt
VII.2 F Caucasian 2.5 N/A N/A D N N N N N N N N/A IVS3 +1 nt
N/A not available; N/T, not tested; * total thyroxine; M, male; F, female; GH, growth hormone; TSH, thyrotrophin; FSH, follicle 
stimulating hormone; LH, luteinising hormone; PRL, prolactin; D, deficient; N, normal; H, hypoplastic; A, absent.
1757.6.2  Discussion
IGHD may be inherited in an autosomal recessive [type I GHD], autosomal dominant [type 
II GHD] or X-linked recessive [type III GHD] manner. Type 1  A, type II and rarely, type IB 
can  be  due  to  mutations  in  GH1  gene.  Type  IB,  is  however,  more  commonly  due  to 
mutations in GHRHR. Some forms of the X-linked type of GHD are now believed to be due 
to mutations in SOX3.  Heterozygous mutations in HESX1 can also lead to IGHD (Brickman 
et al. 2001; Thomas et al. 2001).
14 patients  from a cohort of 103  patients with IGHD were found to harbour mutations in 
GH1 resulting in a prevalence of 13.6%. 32/103 patients had a history of familial GHD and 
hence the prevalence of GH1  mutations in familial GHD increased to 40.6%. No patients 
with IGHD within the present study were found to harbour mutations in GHRHR. Splice site 
mutations  in  GH1  were  the  commonest  [64.3%  of  all  mutations]  resulting  in  type  II 
autosomal  dominant  GHD.  Additionally  both  patients  in  pedigree  V  harboured  a 
heterozygous point mutation (A>C) resulting in the substitution of a glutamate residue by 
alanine at the 2nd base of exon 3. Although this potentially results in the substitution of an 
amino acid, it is more likely that the phenotype is due to aberrant splicing.  Splice site and 
exon splice enhancer mutations within exon 3 can lead to a total skipping of exon 3 and loss 
of amino acids 32-71  from the mature 22kD GH protein. This leads to a truncated 17.5kDa 
product which has a dominant negative effect preventing the production, storage and release 
of the normal  wild-type  22kDa hGH  from the  other allele with  a  consequent deleterious 
effect  on  pituitary  somatotrophs.  The  17.5kDa  isoform  is  retained  in  the  endoplasmic 
reticulum,  disrupts  the  Golgi  apparatus  and  reduces  the  stability  of the  22kDa  isoform,
176which becomes unavailable for exocytic release (Hayashi et al.  1999; Graves et al. 2001). 
This phenomenon is  further accelerated by the  GHRH drive,  macrophage response to the 
dying defective somatotrophs and the type of mutation, most effective in the IVS3+1  splice 
site  mutation.  Patients  with  this  type  of  IGHD  show  variably  reduced  serum  GH 
concentrations but usually respond well to exogenous GH therapy. Patient V.l demonstrated 
variable concentrations of GH at different times of provocation testing. This could be as a 
result  of this  dominant  negative  effect,  which  is  accentuated when the patient  is  off-GH 
treatment.  The  assay  would  pick  up  greater  concentrations  of the  mutant  17.5kDa  GH 
molecules along with reduced concentrations of the normal 22kD protein, provided that the 
17.5kDa form of hGH  is secreted from the pituitary gland and this remains to be proven. 
The variability in the ratios of 17.5kDa to 22kDA GH proteins produced could also be an 
important  contributor  to  the  extent  of pituitary  gland  damage  and  hence  the  variability 
observed in the anterior pituitary size in these patients.
The phenomenon of evolving CPHD in patients with type II IGHD was evident in patient 
VI. 1   [Turton et al., in press] and it has been recently documented in a murine model as well 
as other human patients (McGuinness et al.  2003;  Mullis et al.  2005;  Salemi et al.  2005). 
The  phenomenon  of  evolving  CPHD  could  be  attributed  to  an  invasion  by  activated 
macrophages  leading  to  a  significant  bystander  endocrine  cell  killing,  which  in  time 
compromises cellular repletion of other cell lineages and ultimately to additional endocrine 
deficits,  as observed in transgenic mice.  Early treatment with rhGH in these patients may 
prevent  the  progressive  dysfunction  of the  somatotrophs  and possibly other cell  lines  by 
suppressing the GHRH drive and hence production of the mutant 17.5 kD protein, although 
this remains to be proven.
1777.7  MUTATIONS WITHIN SOX3
7.7.1  Patient phenotypes
Mutations in SOX3 were found in 5.3% of selected males with hypopituitarism. Inheritance 
was X-linked recessive. A submicroscopic duplication of Xq27.1  including the SOX3 gene, 
the smallest reported to date (685.6 Kb), was found in one pedigree from Finland, which 2 
half-brothers had inherited from their unaffected mother. An expansion by 7 alanines of the 
first polyalanine tract was identified in a consanguineous Asian family from Qatar with 3 
affected males (A(7)240A 241  ins) leading to reduced transcriptional activation and impaired 
nuclear localisation of the mutant protein.
Pedigree I: Two half-brothers, patients 1.1  and 1.2, had a history of hypoglycaemia at birth. 
Patient 1.1  then remained asymptomatic until 7 years of age when he presented with short 
stature  [[Table  7.9,  page  181].  He  was  diagnosed  with  GHD,  borderline  serum  FT4 
concentrations [6.6-13.3 pmol/L] with a serum TSH concentration of 2.8 mU/L, but normal 
serum prolactin and cortisol concentrations.  He underwent spontaneous puberty.  His half- 
brother  patient  1.2  was  found  to  have  severe  cortisol,  TSH,  GH  and  gonadotrophin 
deficiency  at  2  months  of  age  [height  -3.8  SDS].  He  had  hypoplastic  genitalia  with 
undescended testes and a micropenis. The anterior pituitary was hypoplastic in both patients 
on  MR  imaging  and  the  posterior pituitary was  undescended  in patient  1.2  and partially 
descended in patient 1.1  [Table 7.10, page  182].  The pituitary stalk was hypoplastic  in its 
lower half in patient 1.1  but absent in patient 1.2. A cyst was noted within the splenium of the 
corpus  callosum only in the patient  1.1  while the septum pellucidum was normal  in both 
[Figure 7.4]. Psychomotor development, apart from hyperactivity in patient 1.2, was normal.
178Pedigree II:  These siblings were bom to first-degree consanguineous Qatari parents. All 3 
brothers, patients  II. 1,  II.2,  and II.3, presented with short stature at 3.0, 4.5  and 2.7  years 
with heights of -2.5 SDS, -2.5 SDS and -1.3 SDS [Table 7.9, page 181]. All 3 brothers were 
found  to  have  undescended  testes;  the  younger  2  patients  also  had  a  micropenis.  All  3 
patients  had  GH,  TSH,  ACTH  and  gonadotrophin  deficiencies.  An  evolving  hormone 
deficiency was observed only in patient II. 1   with GHD diagnosed at presentation, followed 
by TSH deficiency at 6.2 years and gonadotrophin and ACTH deficiencies at the age of 15 
years.  Patient II.2, however,  was diagnosed with GH, ACTH and TSH deficiencies at 6.0 
years of age. A 3-month course of Sustanon led to an increase in the size of the phallus but 
he required pubertal  induction  at  13.5  years  of age  in view  of gonadotrophin deficiency. 
Patient  II.3  was  found to  have GH,  TSH  and ACTH deficiencies at initial investigations. 
Although the testes descended into the scrotum in response to 3 weeks of human chorionic 
gonadotrophin  treatment,  the  serum  testosterone  response  was  poor.  He  too  required 
pubertal induction. Neurodevelopment of all brothers is normal. A CT scan was reported as 
being normal in patient II. 1.  MR imaging of the younger brothers, patients II.2 [Figure 7.4 
(iii)] and II.3  [Figure 7.4 (iv)] revealed a hypoplastic anterior pituitary in the sella that was 
severely attenuated in II.2,  a hypoplastic stalk that was particularly difficult to visualize in 
II.3 and an undescended posterior pituitary in both [Table 7.10, page 182].
Their heterozygous mother is of normal height. A further male sibling presented at 9 years 
of age with GHD [peak GH 8.4 mU/L] and probable gonadotrophin deficiency [peak serum 
LH and FSH < 0.5 IU/L]. Serum FT4 [13.3 pmol/L], prolactin [170 mU/L] and basal cortisol 
[335 nmol/L] concentrations were normal. DNA was unavailable from this child.
179Figure 7.4: Variability in magnetic resonance imaging in patients with abnormalities 
within SOX3. (i) Patient 1.1 (ii) patient 1 .II (iii) patient 2.II (iv) patient 2.Ill
(iv)
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180Table 7.9: Clinical and endocrine data of patients with abnormalities within SOX3.
Presentation Endocrinology
Sex Ethnic
origin Age Height Weight
Peak
GH
mU/L
FT4
Basal Peak
Mutation
(yrs) SDS SDS pmol/L
TSH
mU/L
PRL
mU/L
Cortisol
nmol/L
LH
U/L
FSH
U/L
1.1 M Caucasian
7.0 -2.8 -0.9 3.0 13.3 2.8 124 934 5.0 4.5
685.6 Kb 
Xq27.1 duplication
1.2 M Caucasian 0.2 -3.8 -1.5 3.9 8 0.01 1710 70 0.8 0.5
685.6 Kb 
Xq27.1 duplication
II. 1 M Asian 3.0 -2.5 N/A 5.1 6.6 0.08 N/A 55 L L A(7)240a241 ins
II.2 M Asian 4.5 -2.5 N/A 2.1 9.3 3.3 146 108 0.5 0.5 A(7)240a241 ins
II.3 M Asian 2.7 -1.3 0.7 2.1 6.6 2.8 N/A 88 1 <1 A(7)240a241 ins
M, male; F, female; GH, growth hormone; TSH, thyrotrophin; PRL, prolactin; FSH, follicle stimulating hormone; LH, luteinising 
hormone; AP, anterior pituitary; PP posterior pituitary; SP, septum pellucidum; CC, corpus callosum; N/A, not available; L, low, H, 
hypoplastic; N, normal; U, undescended; P, partial; A, absent;
181Table 7.10: Magnetic resonance imaging in patients with abnormalities within SOX3.
Anterior pituitary Posterior pituitary Pituitary stalk Corpus callosum Septum pellucidum
1.1 Hypoplastic Partially undescended Partially hypoplastic Cyst in the splenium Normal
1.2 Hypoplastic Undescended Absent Normal Normal
II.l N/A N/A N/A N/A N/A
II.2 Hypoplastic Undescended Hypoplastic Normal Normal
II.3 Hypoplastic Undescended Hypoplastic Normal Normal
N/A not available
1827.7.1  Discussion
X-linked  hypopituitarism  is  a  rare  and  variable  condition.  Recent  studies  implicated 
duplications at Xq26-27 in the aetiology of this form of hypopituitarism (Hamel et al.  1996; 
Hoi  et  al.  2000;  Solomon  et  al.  2002).  The  duplication  found  in  pedigree  I  refines  the 
critical  interval  to  a  685.6  Kb  region  containing  SOX3  and  two  other  transcripts  not 
expressed in the infundibulum (Woods et al. 2005). Overdosage as a result of duplications, 
and underdosage as a result of a polyalanine expansion, within SOX3,  are both associated 
with similar phenotypes, predominantly that of infundibular hypoplasia with variable effects 
on  the  corpus  callosum  suggesting  that  gene  dosage  of SOX3  is  critical  for  the  normal 
development of the diencephalon and the infundibulum in humans.
Five patients  [from 2  pedigrees]  of 78 patients  screened were found to have mutations in 
SOX3,  indicating a mutation frequency of 5.3%.  The underlying mechanism whereby both 
under- and over-dosage of SOX3 can lead to a disease phenotype remains, as yet, unknown. 
Mice  deleted  for  Sox3  are  affected  by  a  variable  reduction  in  growth  rate,  pituitary 
concentrations of GH, TSH, LH and FSH and display craniofacial defects with dysgenesis of 
the corpus callosum (Rizzoti et al. 2004).  The similarity between the null mutant mice and 
phenotype  of  patients  described  suggest  that,  both,  the  polyalanine  expansion  and 
duplication in SOX3 results in a loss of function, though a gain of function effect cannot be 
excluded  in  the  latter  case.  Anterior  pituitary  hypoplasia  and  an  undescended  posterior 
pituitary possibly reflect the effects of infundibular hypoplasia.
183There  was  variability  in  both  the  endocrine  phenotype  and  findings  on  MR  imaging  in 
patients  and  within  families  with  abnormalities  of  SOX3,  although  the  variability  in 
phenotype between the  two  half-brothers  in pedigree  I  may reflect differences  in  genetic 
background from their different fathers. Patient 1.1   had a milder phenotype with a later age 
at onset of hypopituitarism in contrast to his brother. Patient 1.1  also had variable thyroxine 
concentrations that may highlight the possibility of evolving TSH deficiency. The genotype 
- phenotype  correlation in pedigree  II was more complete,  possibly related to the genetic 
homogeneity of the consanguineous union of their parents.
None of the patients manifested any craniofacial defects or evidence of mental retardation as 
previously reported in a pedigree with a longer polyalanine expansion (Laumonnier et al. 
2002). The lack of learning difficulties in patients from the present study could be explained 
by differences in the genotype or alternatively may reflect variation in the penetrance of the 
central nervous system defects as shown in the murine model (Rizzoti et al. 2004).
184CHAPTER 8
EVALUATION OF PITUITARY HORMONE SECRETION
8.1  INTRODUCTION
Evaluation of pituitary hormone secretion is essential in the following settings:
- in a patient with known pituitary dysfunction of one hormone abnormality to evaluate rest 
of the pituitary function,
- in the follow-up of a patient with combined pituitary hormone deficiency [CPHD] to assess 
for evolving endocrine disease,
- in a new patient suspected of having hypopituitarism and/or
- in a patient “at-risk” of hypopituitarism with abnormalities such as optic nerve hypoplasia 
[ONH].
Secretion of hormones is a complicated process in which the hypothalamo-pituitary [H-P] - 
target  gland  axis  is  subject  to  complex  feedback  mechanisms.  The  diagnosis  of 
hypopituitarism in patients is not straightforward and a simple assessment of unstimulated 
hormonal secretion is often not adequate to make a precise diagnosis. The H-P-target gland 
axis can be activated by various pharmacological and physiological stimuli that have formed 
the basis  of tests used in the  evaluation of hormone  secretion and have been  extensively 
studied.  Previous  studies  have  attempted  to  differentiate  patients  as  having  “pituitary” 
disease strictly implying a quantitative abnormality associated with low pituitary hormone 
secretion  and an absent or blunted  response  to  external  stimulation,  with  “hypothalamic” 
disease postulated to be a qualitative abnormality due to a prolonged lack of hypothalamic
185releasing hormones resulting in reduced pituitary cell content and a delayed rise in pituitary 
hormone  concentration  on  stimulation  (Milner  and  Herber  1983).  However,  separating 
patients based on this cellular differentiation is not always possible. “Provocative” tests have 
numerous  other  limitations  as  well.  The  tests  are  expensive,  complicated  to  perform, 
uncomfortable  to  the  patient,  require  supervision  in  specialized  endocrine  centres  with 
trained personnel, detailed protocols and require good laboratory facilities. Interpretation of 
hormone  concentrations  following stimulation needs to be made in light of the hormonal 
assay in use and endogenous hormonal rhythmicity. Some provocative agents used act at the 
upper  end  of  the  dose  response  curve  and  are  influenced  by  external  factors  altering 
hormone response. Provocative testing with some agents reflects a non-physiological milieu 
that may bear no resemblance to the endogenous state of the patient. Finally, there is a lack 
of  a  “gold  standard”  test  in  detecting  several  hormone  deficiency  states  resulting  in 
difficulties with comparison of test performance.
The diagnosis  of growth hormone deficiency  [GHD]  in children has  always been fraught 
with problems.  The  GH-insulin  like  growth  factor  1   [IGF1]  axis  can be  stimulated with 
various provocative agents such as insulin, glucagon, arginine, and clonidine. Various cut­
offs  have  been  used  to  define  GHD  generally  at  a  value  of  20  mU/L  based  on  test 
performance  and  likelihood of detecting  serious  deficiency.  Some provocative tests  have 
poor specificity but overall the insulin induced hypoglycaemia [IIH] test is considered as the 
“gold standard”  for assessing both the GH-IGF1  axis and the H-P-adrenal axis. However, 
the test can be extremely unsafe in infants and young children (Shah et al.  1992; Hurel et al. 
1996). Glucagon stimulation induces GH and cortisol release although the exact mechanism 
remains obscure and may be related to a glucagon-induced catecholamine release (Goodwin
186et al. 1976) or an indirect effect via the hypothalamus. A good correlation has been reported 
previously between peak serum GH and cortisol concentrations in response to  stimulation 
with  glucagon  and  IIH  (Spathis  et  al.  1974;  Orme  et  al.  1996).  Chanoine  et  al reported 
asymptomatic hypoglycemia at least once between  120 and 180 minutes in 11% of infants 
who  underwent  glucagon  provocation  and  the  elevation  in  serum  GH  and  cortisol 
concentrations  may  therefore  reflect  response  to  hypoglycaemia  (Chanoine  et  al.  1995). 
However,  the  glucagon  test  is  also  known  to  be  potentially  hazardous  and  should  be 
performed with caution (Shah et al.  1992). To resolve some of the controversies surrounding 
the  diagnosis  of GHD,  the  Growth Hormone Research  Society and National  Institute for 
Clinical Excellence have both set guidelines for its diagnosis.
In  contrast  to  the  diagnosis  of GHD,  there  is  no  overall  consensus  for  the  diagnosis  of 
thyrotrophin [TSH], corticotrophin [ACTH] and gonadotrophin deficiency and the diagnosis 
can become particularly difficult in patients with borderline results. TSH releasing hormone 
[TRH]  releases  preformed  TSH  from the pituitary into  the  circulation  and also  increases 
TSH synthesis. Administration of TRH in normal individuals produces a consistent rise in 
serum TSH concentration with a peak concentration at 20 minutes followed by a decrease in 
measured concentrations at 60 minutes. The test has been used as an adjunct in the diagnosis 
of central hypothyroidism [CH]. An absent or impaired response is believed to be indicative 
of primary pituitary disease  and a prolonged lack of TRH  in patients  with hypothalamic 
disease has  been postulated to  result  in  a delayed rise  in  serum TSH  concentration.  The 
optimal  method  for establishing  the  diagnosis  of ACTH  deficiency also  remains  unclear 
inspite  of its  potentially  serious  consequences  such  as  hypoglycaemia,  consequent  brain 
damage and even death particularly in newborns and infants.  The standard Synacthen test
187(SST) was first used in clinical practice as a direct measure of adrenal function (Wood et al. 
1965)  It  has  since,  by  implication,  been  used  to  evaluate  H-P-adrenal  axis  integrity  in 
patients  with  H-P  disorders,  with  good  correlation  between  peak  serum  cortisol 
concentrations at 30 minutes after Synacthen and those achieved in response to the IIH test, 
considered  to  be  the  “gold-standard”  (Kehlet  et  al.  1976;  Nelson  and  Tindall,  Jr.  1978; 
Lindholm et al.  1978; Lindholm and Kehlet 1987; Stewart et al.  1988; Jackson et al.  1994; 
Hurel et al.  1996; Abdu et al.  1999; Gonzalbez et al. 2000). Unlike the IIH test, the SST is 
safe  and  relatively  easy  to  perform  in  young  infants,  although  it  has  been  reported  to 
generate normal responses in patients with subtle adrenal insufficiency (Cunningham et al. 
1983; Broide et al.  1995).  Previous data have suggested that unstimulated serum luteinising 
hormone  [LH]  and  follicle  stimulating  hormone  [FSH]  concentrations  are  not  reliable 
parameters to test pituitary gonadotrophin reserve particularly in children (Lovrencic et al. 
1975; Dickerman et al.  1979;  Kletter et al.  1996). Pituitary stimulation with LH releasing 
hormone  (LHRH)  is  an  established  method of assessing gonadotrophin reserve  in  adults 
with hypopituitarism and at puberty, although conflicting results have been well documented 
in  distinguishing  adolescents  with  hypogonadotrophic  hypogonadism  [HH]  and 
constitutional  delay of puberty (Job  et  al.  1977;  Ehrmann  et  al.  1989;  Ghai  et  al.  1995; 
Kauschansky  et  al.  2002).  Post-LHRH  measurement  of serum reproductive  hormones  in 
infants with H-P disorders may help to identify those with gonadotrophin deficiency at an 
early stage.
This part of the study was undertaken in order to assess the usefulness of currently used tests 
to diagnose hormone deficiency.
1888.2  THYROTROPHIN [TSH] DEFICIENCY
Serum TSH and thyroxine  [T4]  concentrations of 54 patients with central hypothyroidism 
[CH] were analysed retrospectively. In order to determine whether TRH tests have a role to 
play  in  supporting  the  diagnosis  and  in  differentiating  between  “pituitary”  and 
“hypothalamic”  CH,  serum  TSH  responses  to  stimulation  with TRH  were  retrospectively 
analysed in 30 of 54 patients.
8.2.1  Patient Selection
Diagnosis of CH was based on subnormal  serum T4 concentrations  [free T4 (FT4) <12.0 
pmol/L  or  total  T4  (TT4)  <65  nmol/L]  with  either  an  inappropriately  low  serum  TSH 
concentration  [<5  mU/L],  thereby  ruling  out  primary  hypothyroidism,  or  biochemical 
evidence of other pituitary hormone deficiencies.
Based on findings on their MR scans, they were divided into 2 groups:
•  Group A (n=24); patients with no midline forebrain defects [MFD; Appendix V-6],
•  Group B (n=30); patients with MFD [Appendix V-7].
The TRH test was performed according to the standardised protocol within the department 
[See Appendix IV].
1898.2.2  Methods and controls
Unstimulated serum TSH concentrations of patients were compared with that of:
(1)  93  short  normal  children  [mean  age  of 9.9  (±  3.0)  years  (M:F  1:1)]  who  were 
investigated for short stature between 1985-1992 with normal results. These children 
were followed-up until adulthood to ensure normal growth and spontaneous puberty.
(2)  38 consecutive newborns with congenital primary hypothyroidism.
30 of 93 normal children underwent a TRH test. The 10th and the 90th centiles of the ATSH 
[difference  between the  peak  stimulated  and  unstimulated  serum  TSH  concentrations]  in 
these children were 4.5 mU/L and  17.8 mU/L respectively and were arbitrarily selected to 
delineate a “normal” range.
Based on the “normal” range, serum TSH responses of patients were grouped as:
•  absent  or  blunted  response  (ATSH<  4.5  mU/L)  with  peak  serum  TSH  at  20 
minutes
•  normal response (ATSH 4.5 -  17.8 mU/L) with peak serum TSH at 20 minutes
•  exaggerated response (ATSH > 17.8 mU/L) and peak serum TSH at 20 minutes
•  delayed  response  with  peak  serum  TSH  concentration  at  60  minutes.
190Table 8.1: Clinical characteristics of patients with central hypothyroidism [CH].
Group A, patients with CH and no midline forebrain defects (MFD); Group B, patients with CH and MFD.
n= M:F
ratio
Age at first 
presentation 
(yrs)
Age at 
diagnosis 
of CH 
(yrs)
Patients with 
evolving CH 
(n=)
FT4
(n=44,
pmol/L)
TT4
(n=10,
nmol/L)
Unstimulated
TSH
(mU/L)
Number of patients 
with deficiencies of
GH ACTH Gn AVP
Group A 24 3:1 2.9 ±3.2 3.4 ±4.1 2 7.7 ±  1.8 53.6 ±  9.8 2.5 ±  1.5 20 19 10 0
Group B 30 3:2 1.212.0
2.313.7
6 8.6 ±  1.5 50.8 ±  9.1 3.1 ±  2.5 28 23 15 7
P 0.02 0.31 - 0.07 0.65 0.31 0.7 0.7 0.6 0.04
M, males; F, females;1  Chronological age at first presentation;2  Chronological age at diagnosis of CH; p, probability value; FT4, free 
thyroxine; TT4, total thyroxine; TSH, thyrotrophin; GH, growth hormone; ACTH, corticotrophin; GN, gonadotrophin; AVP, arginine 
vasopressin
1918.2.3  Results
8.2.3.1  Patient characteristics
Clinical characteristics of patients from both groups are shown in Table 8.1. Two patients 
had isolated TSH deficiency. Patient 16, group A, presented with growth failure in infancy 
and apart from CH, he had normal  anterior pituitary function.  He responded to thyroxine 
treatment and continued to have profound TSH deficiency on retesting in adulthood.  MR 
scan was normal. Patient 34, group B, had holoprosencephaly [HPE] and has not developed 
any other hormone deficiency. 40% of group B patients were diagnosed with CH and other 
hormone  deficiencies  within the  first month of life  as compared with  12.5%  in group A 
(p=0.05).  Evolving TSH deficiency was evident in 8 individuals, patients  13  and  18 from 
group  A  and patients  25,  29,  38,  46,  49,  53  from group  B,  up to  11.8  years  after initial 
presentation.
8.2.3.2  Basal serum  TSH concentrations
There were no  significant differences between the serum concentrations of FT4, TT4 and 
unstimulated  serum  TSH  concentrations  of both  groups  [See  Table  8.1].  Although  the 
majority (90.7%) of patients had unstimulated serum TSH concentrations less than 5 mU/L, 
elevated concentrations were observed in 5 patients (patients 22, 32, 40, 52, 54), four with 
SOD  [Figure 8.1]. The relationship between serum FT4 and unstimulated serum TSH was 
shifted to the left as compared with euthyroid individuals [Figure 8.2]. A similar relationship 
was observed between serum TT4  and basal  serum TSH  concentration  (data not shown). 
Patients with primary hypothyroidism had a markedly elevated serum TSH concentration at 
diagnosis.
192Figure 8.1: Unstimulated serum thyrotrophin concentrations in patients with central 
hypothyroidism. Horizontal bar represents cut-off at 5 mU/L
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thyrotrophin concentrations in patients with central hypothyroidism (CH, n=44, red 
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1938.2.3.3 Thyrotrophin releasing hormone stimulated serum  TSH responses
A TRH test was performed in 30 patients and 30 controls. The remainder (24/54) did not 
undergo a TRH test and were commenced on thyroxine treatment based on low serum FT4 
or TT4 concentrations. Serum TSH responses to TRH stimulation in relation to the “normal” 
range are shown in Figure 8.3. Males and females did not respond differently to stimulation.
Figure 8.3: Change in serum thyrotrophin concentration (ATSH) following stimulation 
with TSH releasing hormone in central hypothyroidism [CH] but no midline forebrain 
defects  [MFD, group A]  and CH with MFD  [group B). Horizontal lines depict the  10th 
and 90th percentiles  of the  change  in  serum TSH  concentration in controls.  Blue circles 
represent  patients  with  peak  serum  TSH  concentration  at  20  minutes  and  green  circles 
represent patients with peak serum TSH concentration at 60 minutes.
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194Patients with  exaggerated or  delayed  responses  showed  significantly higher unstimulated 
serum TSH  concentrations  as  compared  with  those who  had  an  absent/blunted response 
(p=0.02), a normal response (p=0.02) or controls (p=0.003) [Figure 8.4]. A normal TRH test 
was observed in 7 patients in spite of subnormal serum thyroxine concentrations in patients 
from both groups (patients 4, 6,  19, 34, 36, 47, 53).  Seven patients (patients 12,  13,  16,  18, 
20,  21,  24)  in  Group  A  demonstrated  an  absent/blunted  response  as  compared with two 
patients from group B (patients 25, 42). Five patients had an exaggerated response. Of these, 
the  majority  (80%)  were  in  group  B  (patients  28,  46,  48,  51).  A  delayed response  was 
observed in significantly greater number of patients [30%] compared with controls [6.7%].
Figure 8.4: Unstimulated serum thyrotrophin concentrations in patients and controls 
who underwent a thyrotrophin releasing hormone test (horizontal line represents the 
mean for each group).
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1958.2.3.4  Differentiation between “pituitary” and “hypothalamic” CH
MR imaging was normal in 3 patients, patient  16 with idiopathic isolated TSH deficiency 
and  patients  10  and  15  with  CPHD.  Abnormalities  in  the  remaining  patients  included 
anterior pituitary hypoplasia (n=39),  an undescended posterior pituitary (n=24), an absent 
septum  pellucidum  or  absent/hypoplastic  corpus  callosum  (n=22),  an  absent/hypoplastic 
stalk (n=21), ONH (n=23) and HPE (n=2).
The unstimulated serum TSH concentration or the ATSH did not differ significantly between 
patients with anterior pituitary hypoplasia or a normal anterior pituitary. Only 50% of the 
patients  with  anterior  pituitary  hypoplasia  and  no  midline  or  stalk  abnormalities 
demonstrated  an  absent  /  blunted  serum  TSH  response.  A  delayed  serum  TSH  rise  was 
demonstrated in 41.7% of cases with stalk abnormalities but also seen in 22.2% of patients 
who had a normal stalk. This difference was not statistically significant.
The mean serum prolactin concentration was 1088 ± 830 mU/L in those with an absent / thin 
stalk  as  compared  with  501  ±  390  mU/L  in  those  with  a  normal  stalk  but  again  this 
difference did not reach statistical significance (p=0.06). Only 7.7% [n=13] of patients with 
MFD demonstrated an absent/blunted serum TSH response as compared with 47% [n= 17] of 
patients without such a defect (p=0.05).
1968.2.4  Discussion
Only 30% of patients in this study demonstrated an absent or blunted serum TSH response 
characteristic of “pituitary” disease. A further 30% of cases had a delayed “hypothalamic” 
response  and an  exaggerated serum TSH response was present in  16.7% of patients.  The 
majority (77.8%) of patients who demonstrated a delayed serum TSH peak had exaggerated 
concentrations  on  stimulation  (ATSH>17.8  mU/L).  Only  50%  of patients  with  anterior 
pituitary hypoplasia,  and no  stalk  or  midline  defects,  demonstrated  an  absent  or blunted 
response.  Stalk  disruption  suggestive  of  H-P  disconnection  and  hence  “hypothalamic” 
disease was  evident in a total of 12/30 patients who underwent the TRH test. Of these,  a 
delayed response was  observed in only 41.7%  and such a response was also observed in 
22.2% of patients who did not have stalk disruption. These data suggest that differentiation 
between  “pituitary”  and  “hypothalamic”  disease  is  difficult  to  discern,  at  least  based  on 
current assessments. This observation is supported by Cohen et al (Cohen et al.  1995) who 
reported a patient with CH due to a mutations in POU1F1 who demonstrated a delayed TSH 
rise after TRH stimulation. A similar response was reported in a patient with a mutation in 
PROP1  (Vieira  et  al.  2003).  Both  PIT1  and  PROP1  are  pituitary-specific  transcription 
factors and are not associated with a hypothalamic phenotype.  Hence,  a pituitary cause of 
CH cannot be ruled out on the basis of a delayed serum TSH response.
Unstimulated  serum  TSH  concentrations  ranged  from  0.04-11.0  mU/L  in  this  study  as 
compared with  1.0-3.8 mU/L in controls.  Of 5 patients with elevated unstimulated serum 
TSH  concentrations,  an  absent  pituitary  stalk  suggestive  of “hypothalamic”  disease  was 
documented  in  only  one patient.  The  exact mechanism underlying  elevated  unstimulated
197serum TSH concentrations in CH remains unknown, although some studies have postulated 
that the TSH measured in these patients may be biologically inactive (Horimoto et al. 1995). 
This  explanation may also  apply in  7 patients who  demonstrated a “normal”  serum TSH 
response  in spite  of developing CH.  Four of 5  patients  (80%) with elevated unstimulated 
serum  TSH  concentrations  at  diagnosis  had  SOD,  a  complex  phenotype  that  is  highly 
variable,  evolving and with hypothalamic  dysfunction.  A TRH test was performed in  14 
patients with SOD within this cohort. Of 4 patients with elevated unstimulated serum TSH 
concentrations, only one had been investigated using a TRH test, the response to which was 
delayed. Patients with SOD who had abnormalities of the septum pellucidum and/or corpus 
callosum were  less  likely to  demonstrate an  absent/blunted response (7.7%)  as compared 
with those without these abnormalities (47%). Evolving hypothyroidism was more common 
in patients with SOD.
Isolated TSH deficiency was rare in the cohort.  The high incidence of CPHD in patients 
with  CH  highlights  the  need  to  investigate  the  H-P  axis  carefully  for  other  endocrine 
abnormalities.  It is clear from the present data that a normal TRH test, observed in 23.3% of 
patients with CH does not exclude abnormalities of the H-P-thyroid axis. Regular evaluation 
of the serum FT4 (or TT4) concentrations can often reveal the diagnosis. The TRH test is of 
limited use in patients in whom other biochemical or neuroradiological H-P abnormalities 
have  been  demonstrated.  There  is  considerable  overlap  between  patients  with  “pituitary” 
disease and those with “hypothalamic” disease in terms of the serum TSH response to TRH 
(Mehta et al. 2003).
1988.3  CORTICOTROPHIN DEFICIENCY
This section of the study was a prospective analysis undertaken to ascertain the usefulness of 
the short Synacthen test [SST] as a marker of endogenous cortisol secretion. Serum cortisol 
concentrations obtained after Synacthen stimulation were compared with those obtained on 
spontaneous secretory profiles in children with and “at-risk” of hypopituitarism [including 
disorders  of eye,  forebrain  and pituitary].  Sub-optimal  endogenous  cortisol  secretion was 
accepted as an indirect marker of corticotrophin [ACTH] deficiency in these patients as it is 
a true reflection of the physiological milieu.
8.3.1  Patient selection and methods
28  consecutive patients  [male:  female ratio  0.9:1;  age range  0-5.1  years  (mean  1.0 ±  1.0 
years)]  investigated for ACTH deficiency from March 2002 until June 2004 were selected 
for  analysis.  All  patients  had  evidence  of  ONH,  MFD  or  other  pituitary  hormone 
deficiencies. The procedures for collection of blood for analysis of spontaneously secreted 
cortisol and performing the SST were based on standardized protocols within the department 
and are shown in Appendix IV.
Previously  published  data  in  28  short  normal  children  reported  a  mean  [average 
concentration  from  the  twelve  2-hourly  samples  obtained]  spontaneous  serum  cortisol 
concentration of 289 ± 72 nmol/L (Charmandari et al. 2002). Based on these studies, a “cut­
off’  of  145  nmol/L  or  -2SD  from  the  mean  in  normal  children  was  taken  as  a  normal
199spontaneous  serum  cortisol  concentration  for  the purpose  of this  analysis.  Patients  were 
defined as ACTH  deficient  and ACTH  sufficient if they demonstrated mean spontaneous 
serum  cortisol  concentrations  <  145  nmol/L  and  equal  or  >  145  nmol/L  respectively. 
Patients with a mean spontaneous  serum cortisol concentration > 3SD below the mean at 
73nmol/L were considered to have severe ACTH deficiency.
A normal SST was defined as a 30-minute [min]  serum cortisol concentration greater than 
540 nmol/L (Weintrob et al.  1998),  since the 30-min sample has been standardised against 
the IIH test.
8.3.2  Results
8,3,2.1  Mean spontaneous serum cortisol concentrations
Of 28 patients, none had a mean spontaneous serum cortisol concentration greater than the 
mean documented for normal children [289 nmol/L]. There were no significant gender- or 
age-related differences in mean spontaneous serum cortisol concentrations.  15 patients were 
ACTH deficient [Appendix V-8; Figure 8.5]. Of these, five were severely deficient  [-3SD]. 
The majority of these patients had SOD [patients 3-11,  12,  14,  15]; patient  13 had isolated 
ONH  and  patients  1   and  2  had  “idiopathic”  H-P  disease.  CPHD  was  documented  in  13 
patients with ACTH deficiency. Of 13 patients with ACTH sufficiency, 4 patients [patients 
16, 23, 25, 27] had other pituitary hormone deficiencies.
200Figure 8.5: Mean spontaneous serum cortisol concentration in study patients compared 
with 28 short normal children. Blue circles, patients with ACTH sufficiency; red circles, 
patients with ACTH deficiency.
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8.3.2.2  Efficacy o f the short Synacthen test
13 patients passed the SST, all of whom also achieved a 30-min increment > 200 nmol/L. Of 
the  15 patients who failed the SST, 9 patients achieved a 30-min increment > 200 nmol/L 
despite the 30-min absolute serum cortisol < 540 nmol/L. 26/28 patients demonstrated peak 
serum  cortisol  concentrations  at  60  min.  Basal,  30-min  and  60-min  serum  cortisol 
concentrations were significantly lower in patients with ACTH deficiency as compared with 
those without [Table 8.2]. There was a significant correlation (r=0.7, p<0.0001) between the 
30-min SST and the mean spontaneous serum cortisol concentrations.
201Table  8.2:  Short  Synacthen  test  and  0800  hour  serum  cortisol  concentrations  in 
patients with corticotrophin sufficiency and deficiency.
Serum cortisol concentration (nmol/L) at
0 minutes  30 minutes  60 minutes 0800 hour
ACTH deficient 
ACTH sufficient
82 ± 68*  376 ± 239*  468 ± 322* 
196 + 93*  717 ± 156*  865 ±183*
89 ± 63.9* 
283.6 ±108.4*
* Level of statistical significance p<0.001
8.3.2.3  0800-hour serum  cortisol concentrations
There was a  significant correlation between the 0800-hour [h]  and the mean spontaneous 
serum cortisol concentration [r=0.8, p<0.01, Figure 8.6]. A significant correlation was also 
observed  between  the  0800h  serum  cortisol  concentration  and  the  0-min  SST  (r=0.7, 
p<0.0001), 30-min SST (r=0.5, p=0.003) and 60-min SST (r=0.5, p<0.0001) serum cortisol 
concentrations  [Data  not  illustrated].  Mean  0800h  serum  cortisol  concentrations  were 
significantly lower in patients with ACTH deficiency [See Table 8.2].
202Figure 8.6: Relationship between 0800-hour and mean spontaneous serum cortisol 
concentrations (r=0.8, p<0.01)
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8.3.2.4  Comparison o f Test Performance
Using spontaneous cortisol secretion,  an indicator of the endogenous cortisol milieu as an 
indirect  marker of ACTH  secretion,  sensitivity  and  specificity of the  SST  in  diagnosing 
ACTH  deficiency was  80%  and  76.9%  respectively  [Figure  8.7].  The test detected  all  5 
patients with severe ACTH deficiency. 60-min SST serum cortisol concentration, although 
highly specific (100%), had a reduced sensitivity (66.7%). Of 3 patients [patients 10, 12, 15] 
with a false negative SST, patients  10 and  12 were symptomatic with fatigue, poor growth 
and recurrent hypoglycemia, and hydrocortisone treatment resulted in amelioration of their 
symptoms.  3  patients  [patients  16,  25,  27],  with  CPHD,  had a  false positive  SST.  Mean
203spontaneous serum cortisol in patient 16 was borderline [147 nmol/L]. Although patients 25 
(SOD) and 27 (“idiopathic” hypopituitarism) failed the SST, the 60-min concentrations were 
548 nmol/L and 645 nmol/L respectively. Both also achieved good 30-min increments [366 
nmol/L, 233 nmol/L respectively].
Figure 8.7: Correlation between mean spontaneous and 30-minute short Synacthen test 
[SST]  serum cortisol  concentrations. Data points to the left of the vertical line, patients 
with corticotrophin deficiency; data points below the horizontal line, patients who failed the 
SST. Green circles, patients with ACTH sufficiency and passed the SST; Red circles, patients with 
ACTH insufficiency and failed the SST; Black circles, patients with ACTH insufficiency but passed 
the SST, false negatives: Blue circles, with ACTH sufficiency but failed the SST, false positives.
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204Table 8.3: Cut-off values for 0800-hour serum cortisol concentration
0800 h serum cortisol concentration Sensitivity % Specificity %
100 60 100
125 66.7 92.3
150 73.3 92.3
175 93.3 92.3
200 93.3 69.2
225 100 61.5
A 0800h serum cortisol cut-off of 175 nmol/L provided optimal sensitivity and specificity 
[93.3%, 92.3% respectively]  as compared with mean spontaneous cortisol secretion [Table 
8.3]. The role of combined 0800h and 30-min SST serum cortisol was considered under two 
circumstances.  First, when both tests were required to be under their respective cut-offs to 
diagnose ACTH deficiency (“rule-in”) and second, when both tests were required to be over 
their respective cut-offs to exclude (“rule-out”) ACTH deficiency.  In the “rule-in” scenario 
the combination had a sensitivity of 73% and a specificity of 100% whereas in the “rule-out” 
situation the combination had a sensitivity of 69% and specificity of 100% [Figure 8.8].
205Figure 8.8: Combination of 0800-hour and 30-minute serum cortisol concentration 
after Synacthen (r=0.5, p=0.003). Red circles, patients with corticotrophin deficiency; blue 
circles, patients with corticotrophin sufficiency.
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8.3.3  Discussion
The  sensitivity  and  specificity  of  the  SST  as  compared  with  assessment  of  mean 
spontaneous  cortisol  secretion  were  80%  and  76.9%  respectively  (Mehta  et  al.  2005a). 
Several  different  “cut-off’  values  have  been  applied  to  the  30-min  SST  serum  cortisol 
concentration. This study used a “cut-off’ value of 540 nmol/L since this has been shown to 
perform well against the IIH test in children (Weintrob et al.  1998).  Raising this “cut-off’ 
value to  600  nmol/L  did not  improve  either the  sensitivity or the  specificity of the  test.
206Employing an increment at 30-min of 200 nmol/L or using the 60-min SST as a measure of 
normal cortisol secretion increased specificity (100% in both) at the expense of a reduction 
in  sensitivity  (40%,  66.7%  respectively).  Using  more  stringent  criteria  of both  30-min 
absolute  and  increment  in  serum  cortisol  concentration  did  not  improve  sensitivity  or 
specificity.
No patient in this study had mean spontaneous serum cortisol concentrations greater than the 
mean reported in normal children (Charmandari et al. 2002). It could be argued that this may 
be a result of the age difference between this cohort [median 0.7 yrs, range 0.03-5.1 yrs] and 
controls [median 7.7 yrs, range 4.9-9.3 yrs]. However, there are no age-matched data on 24 
h spontaneous serum cortisol concentrations in normal infants. From the 3rd month of life the 
rhythm of spontaneously secreted serum cortisol concentrations remains identical to that of 
1   and 3-year old children (Vermes et al.  1980). The mean gestational age of our cohort at 
birth was 38.3 ± 4.4 weeks and no patient investigated was bom prematurely (<36 weeks). 
Additionally, the present data did not suggest significant gender- or age-related changes in 
spontaneous or stimulated serum cortisol concentrations, both in the cohort as a whole and 
in the subgroup of patients with normal cortisol responses.
Ten patients passed both tests and 12 patients failed both tests. Of the latter, 10 patients with 
CPHD and abnormal H-P imaging had a 0800h serum cortisol concentrations <175 nmol/L, 
one  patient  with  TSH  deficiency  and  normal  MR  imaging  had  a  0800h  serum  cortisol 
concentration  of  28  nmol/L  and  one  patient  with  ONH,  no  other  pituitary  hormone 
abnormality and normal MR imaging failed both tests. Of 10 patients who passed both tests, 
6  patients  [with  ONH]  demonstrated abnormal  MR imaging but had no  evidence  of any
207pituitary hormone deficiency to date, 3 patients [with ONH] had both normal MR imaging 
and no  other hormone  deficiency and patient 23  had ONH with deficiencies of all  other 
pituitary  hormones.  The  30-min  absolute,  incremental  and  0800  serum  cortisol 
concentrations were 587 nmol/L, 440 nmol/L and 205 nmol/L respectively in patient 23. He 
has  no  symptoms  to  date  suggestive  of  adrenal  insufficiency  and  remains  well  on 
replacement treatment with recombinant human GH, thyroxine and desmopressin. However, 
regular  re-evaluation  of the  H-P-  adrenal  axis  will  be  required  in  order  to  diagnose  an 
evolving endocrinopathy at an early stage (Stanhope et al. 1984).
Three patients with ACTH deficiency, defined by spontaneous cortisol secretion, passed the 
SST  [false  negatives].  All  had  0800h  serum  cortisol  concentrations  <  175  nmol/L. 
Symptoms of fatigue, poor growth and recurrent hypoglycemia in 2/3 patients resolved on 
treatment with hydrocortisone.  A  further 3  patients with ACTH  sufficiency,  defined as a 
mean spontaneous serum cortisol concentration >  145 nmol/L, failed to respond to the SST 
[false positives]. All 3 patients had CPHD. Mean spontaneous serum cortisol concentration 
in one  of the  patients  (Patient  16)  with  SOD was  only  147  nmol/L  and this may reflect 
incipient ACTH deficiency. The other 2 patients (patients 25, 27) failed the SST based on 
30-min absolute serum cortisol concentration but had 60-min serum cortisol concentrations 
greater than 540 nmol/L, a 30-min rise greater than 200 nmol/L and 0800h serum cortisol 
concentrations greater than 175 nmol/L.
Although  the  circadian  rhythm  does  not  appear  until  3  months  of age  (Zurbrugg  1976; 
Vermes et al.  1980), an 0800h serum cortisol concentration of 175 nmol/L had a sensitivity 
and  specificity  of 93%  and  92.3%  respectively  as  compared  with  spontaneous  cortisol
208secretion.  “Cut-off’  values  for  young  children  are  unknown,  although  data  from  adults 
suggest that values <100 nmol/L are indicative of hypocortisolaemia.(Hagg et al.  1987; le 
Roux et al.  2002)  However,  there was  a wide range of mean  spontaneous  serum cortisol 
concentrations associated with a given 0800h value and the use of the latter alone.
Combining  the  0800h  serum  cortisol  concentration  with  the  30-min  SST  serum  cortisol 
response produced a “rule-in”, both tests failing to exceed their respective cut-offs, with a 
sensitivity  of 73%  and  a  specificity  of  100%.  In  “rule-out”  mode  when  both  tests  must 
exceed  their  respective  cut-offs,  the  sensitivity  was  69%  and  specificity  100%.  A 
combination approach has the advantage that it includes a marker of physiological secretion 
with a measure of cortisol reserve and be therefore, considered a suitable overall assessment 
of  the  H-P-  adrenal  axis.  Data  from  this  study  indicates  that  no  patient  with  ACTH 
sufficiency demonstrated both a 30-min SST serum cortisol concentration < 540 nmol/L and 
an 0800h serum cortisol concentration <175  nmol/L.  Conversely,  no patient with ACTH 
deficiency  achieved  both  a  30-min  SST-stimulated  serum  cortisol  concentration  >  540 
nmol/L and an 0800h serum cortisol concentration equal or > 175 nmol/L.
2098.4  GONADOTROPHIN DEFICIENCY
The  role  of the postnatal  surge  in reproductive hormone  secretion remains  unclear.  This 
increase is gender-specific.  Previous data have suggested that unstimulated serum LH and 
FSH  concentrations  are  not  reliable  parameters  to  test  pituitary  gonadotrophin  reserve, 
particularly  in  children.  The  present  study  was  undertaken  to  investigate  if luteinising 
hormone releasing hormone [LHRH]  stimulated serum LH and FSH responses continue to 
be gender-specific, to compare the rise in reproductive hormone secretion to those of normal 
pre-pubertal and pubertal children and to assess a possible role of the LHRH test in infancy.
8.4.1  Patient Selection and methods
30 consecutive patients [Table 8.4 and Appendix V-9] at LCPE who underwent a LHRH test 
within the first  18 months of life were selected for this study [mean age 7.3 ±5.2 months, 
age range 0.3-17.4 months, male to female ratio  1.3:1].  The LHRH test was performed in 
view of other pituitary hormone  deficiencies  and/or abnormal  H-P  structures or MFD on 
neuroimaging and hence risk of gonadotrophin deficiency. The LHRH test was carried out 
in accordance with the set protocol used within the department as shown in Appendix 9.7. 
There was no  significant correlation between age at testing with serum LH or serum FSH 
concentrations  at  0  minutes  [r=-0.2,  p=0.3;  r=-0.1,  p=0.4],  20  minutes  [r=-0.1,  p=0.6; 
r=0.01, p=1.0] or 60 minutes [r=-0.1, p=0.5; r=0.01, p=l .0] ruling out a bias due to the age 
at which the test was performed.
210Table 8.4: Clinical data, endocrinology and neuroimaging in patients who underwent 
the luteinising hormone releasing hormone test
Males Females
Number of patients (n) 17 13
Gestational age 39 ± 3 weeks 39 ± 4 weeks
Birth weight 2.9 ± 0.9 kgs 3.0 ± 0.9 kgs
ONH 47% 69%
Endocrinology: % of patients with deficiencies of
GH 75% 78%
TSH 47% 69%
ACTH 41% 61%
AVP 12% 15%
Serum prolactin concentration 754 ± 1554 mU/L 997 ± 767 mU/L
MR imaging
H-P abnormality 71% 92%
MFD 59% 85%
ONH,  optic  nerve  hypoplasia;  GH,  growth  hormone;  TSH,  thyrotrophin;  GH,  growth  hormone; 
ACTH,  corticotrophin;  AVP,  arginine  vasopressin;  MR,  magnetic  resonance;  MFD,  midline 
forebrain defect; H-P, hypothalamo-pituitary
8.4.2  Controls
LHRH-stimulated serum LH and FSH responses of 2 groups were used as controls:  (i)  18 
pre-pubertal normal  children  [male:  female  2:1,  age 8.3±2.0  years]  (ii)  9 pubertal normal 
children [male: female 8:1, age 12.7±2.0 years]. There were significant (p<0.05) differences 
between  serum  LH  concentrations  [unstimulated and  stimulated]  and unstimulated serum 
FSH  concentrations  between  pre-pubertal  and  pubertal  children.  Post-LHRH  serum  FSH 
concentrations,  however,  did  not  significantly  differ  between  both  control  groups.  Peak 
serum FSH concentrations were reached at 60 minutes in both groups of controls.
2118.4.3  Results
8,4.3A  Gender differences in serum gonadotrophin concentrations
Ten patients had normal endocrinology to date and the remaining 20 patients had evidence 
of other  pituitary  hormone  deficiencies,  55%  of whom  demonstrated  complete  anterior 
pituitary  hormone  dysfunction.  Unstimulated  gonadotrophin  concentrations  however,  did 
not significantly differ between patients with other pituitary hormone deficiencies [LH 0.9 ±
1.0  IU/L; FSH 2.4 ± 4.7 IU/L] as compared with those without [LH 0.7 ± 0.03; FSH 4.0 ± 
4.9]. Unstimulated serum LH and FSH concentrations did not differ significantly from age- 
matched controls (Andersson et al,  1998). There was a marked inter-individual variation in 
unstimulated serum FSH concentrations in both sexes [Figures 8.9 and 8.10].
Eight male patients were bom with bilaterally undescended testes and a micropenis. Mean 
unstimulated serum LH and FSH concentrations were not significantly (p=0.3) different in 
patients with genital abnormalities at birth [LH 0.7; FSH 0.6 IU/L] as compared with those 
with  normal  genitalia  [LH  1.2;  FSH  1.4  IU/L  respectively].  Females  demonstrated 
significantly greater unstimulated serum FSH concentrations as compared with males [Table 
8.5].  Differences  between  semm  LH  concentrations  were  however  not  statistically 
significant  between  sexes.  Both  semm  LH  and  FSH  responses  were  absent  in  16.7%  [3 
males, 2 females] of patients suggestive of gonadotrophin deficiency, all of whom had other 
pituitary  hormone  deficiencies.  Two  of the  3  male  patients  were  bom  with  bilaterally 
undescended  testes  and  a  micropenis.  Females  demonstrated  significantly  greater  serum 
FSH  responses  following  LHRH  administration  as  compared with males.  There  were  no 
significant sex-related differences in LHRH-stimulated semm LH responses [Table 8.5].
212Figure 8.9: Unstimulated serum luteinising hormone [LH] concentrations in patients 
compared with those from normative longitudinal data. Solid line, mean concentration; 
dotted lines, range (Andersson et al,  1998).
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213Figure 8.10: Unstimulated serum follicle stimulating hormone [FSH] concentrations in 
patients compared with those from normative longitudinal data. Solid line, mean 
concentration; dotted lines, range (Andersson et al, 1998).
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214Table 8.5:  Serum gonadotrophin concentrations following stimulation with luteinising 
hormone releasing hormone in patients, pre-pubertal and pubertal controls.
Luteinising hormone (IU/L) Follicle stimulating hormone (IU/L)
minutes minutes
0 20 60 0 20 60
Males
(n=17)
1.0 ± 1.1 7.0 ±9.8 5.5 ±7.7 1.0 ± 1.6 4.0 ±5.7 5.5 ±7.5
Females
(n=13)
0.7 ±0.1 5.1 ±5.3 5.4 ±5.3 5.5 ±6.3 23.3 ±22.3 32.0 ±31.9
Pre-pubertal
(n=18)
1.1 ±0.5 4.3 ±2.5 4.5 ±2.7 0.7 ± 0.3 4.4 ± 2.9 7.3 ±6.1
Pubertal
(n=9)
3.6 ± 1.5 31.0 ± 19.6 26.3 ± 15.0 3.5 ± 1.6 8.5 ±4.8 9.4 ± 6.3
8.4.3.2  Luteinising hormone releasing hormone test in infancy
To compare the rise in serum gonadotrophin concentrations between patients and controls, 5 
patients who demonstrated absent serum LH and FSH responses were excluded from further 
analysis.  Stimulated serum LH concentrations,  at 20 and 60 minutes respectively,  in both 
female [5.9 ± 5.3 IU/L, 6.3 ± 5.3 IU/L] and male [8.3 ± 10.4 IU/L, 6.6 ± 8.2 IU/L] patients 
did not differ significantly from pre-pubertal children [4.3 ± 2.5 IU/L, 4.5 ± 2.7 IU/L] and 
were significantly lower than those of pubertal children [31.0 ± 19.6 IU/L, 26.3 ± 15.0 IU/L; 
p<0.01] [Figure 8.11]. Stimulated serum FSH concentrations, at 20 and 60 minutes in males 
[4.9 ± 6.0 IU/L, 6.7 ± 7.9 IU/L] were also significantly lower than that of pubertal normal 
children.  However,  stimulated serum FSH concentrations in females at 20 and 60 minutes 
[27.5 ±21.7 IU/L, 37.8 ±31.3  IU/L], were significantly greater than those of pre-pubertal 
[4.4 ± 2.9 IU/L, 7.3 ± 6.1 IU/L; p<0.0005] and even pubertal [8.5 ± 4.8 IU/L, 9.4 ± 6.3 IU/L; 
p<0.05] individuals [Table 8.5 and Figure 8.12].Figure 8.11: Serum luteining hormone [LH] responses following LH releasing hormone 
[LHRH] stimulation. Male patients, blue circles; female patients, red circles; mean post- 
LHRH serum LH response in pubertal children, solid line; prepubertal children, dotted line.
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Figure 8.12: Serum follicle stimulating hormone [FSH] responses following LHRH 
stimulation. Male patients, blue circles; female patients, red circles; mean post-LHRH 
serum LH response in pubertal children, solid line; prepubertal children, dotted line.
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2168.4.4  Discussion
Fetal gonadotrophin secretion first becomes established during the 12th week of intrauterine 
life.  During  early  infancy,  there  is  an  increase  in both  FSH  and  LH  although  the  exact 
significance  of this  is  not  known.  Main  et  al  have  suggested  a  significant  role  for this 
postnatal surge in reproductive hormone secretion as a developmental window during which 
gonadotrophin  stimulation of the testes  is critical  to the normal  development of the male 
genitalia (Main et al. 2000). Apart from the increase in fetal Leydig cell function in the 3rd 
month  of  life  [followed  by  a  rapid  decrease]  as  reflected  in  the  serum  testosterone 
concentration, the rise in gonadotrophin secretion also affects Sertoli cell function. There is 
also some evidence for a role of gonadotrophins with respect to Leydig cell proliferation and 
germ cell differentiation in human infant testicular development.
The  increase  in reproductive hormones  is  gender-specific  in normal  infants  (Forest et al. 
1974; Winter et al.  1975; Forest et al.  1976; Winter et al.  1976; Forest et al. 1980; Burger et 
al.  1991; Andersson et al.  1998). Previous data have suggested that unstimulated serum LH 
and FSH concentrations are not reliable parameters to test pituitary gonadotrophin reserve, 
especially in children (Lovrencic  et al.  1975;  Dickerman et al.  1979;  Kletter et al.  1996). 
Post-LHRH  measurement  of serum reproductive hormones  in  infants  with  H-P  disorders 
may help to identify those with gonadotrophin deficiency and provide clues about gonadal 
development. Although 65% of males and 69% of females had evidence of other pituitary 
hormone deficiencies, an absent serum LH and FSH response was observed in only 16.7% 
of patients. All 5 patients had evidence of at least one other hormone abnormality. 2/3 males
217with absent LH and FSH responses were bom with undescended testes and a micropenis at 
birth.
Females  demonstrated  significantly  higher  unstimulated  semm  FSH  concentrations 
compared with males in keeping with other studies (Job et al.  1977; Andersson et al.  1998). 
Similar  gender-specific  differences  were  not  observed  in  unstimulated  serum  LH 
concentrations.  Inhibin  B  produced mainly by  Sertoli  cells  of the testis  in males  and by 
granulosa cells in females plays an important role in negative feedback regulation of the H- 
P-gonadal  axis.  Inhibin  concentrations  in  males  in  early  infancy have been  shown to  be 
unexpectedly  high,  into  the  supra-adult  range  and  persist  longer than  in the  female  and 
longer than the rise in semm gonadotrophins (Andersson et al.  1998). Gender differences in 
serum  FSH  responses  between  males  and  female  in  the  present  study  may  reflect  this 
physiological  difference.  LHRH  stimulated  serum  FSH  responses  were  markedly 
exaggerated in females with concentrations significantly greater than those observed in pre­
pubertal  and  even  pubertal  children.  Such  semm  FSH  responses  have  been  reported  in 
normal females although the concentrations did not exceed 20 U/L (Job et al.  1977). There 
was a marked inter-individual variation in the serum FSH responses in females but not in 
males, possibly indicative of a cyclic regulation (Chellakooty et al. 2003).
Reduced prenatal growth has been associated with FSH hypersecretion and reduced gonadal 
size in adolescent boys and girls. Ibanez et al have recently reported a 2- to 4- fold increase 
in  serum  unstimulated  FSH  concentrations  in  children bom  small  for gestation  age  than 
those bom of a normal size, in the 1st year of life (Ibanez et al. 2002). Longitudinal growth 
assessment was not undertaken in this group of patients and no patient was bom premature
218or small for gestation age. However, a postnatal growth restraint due to CPHD resulting in 
an  augmented  serum FSH  drive  to  maintain inhibin B  requirements  cannot be  excluded, 
although, this alone cannot explain the gender-specific serum FSH responses.
The present study has several drawbacks including the small size of the cohort and lack of 
proper control data at this age group. However, these preliminary data provide an interesting 
observation,  particularly with regard to  exaggerated FSH responses  in  females who need 
detailed evaluation and follow-up at puberty to investigate for gonadotrophin deficiency and 
an assessment of fertility at that stage. Based on further data from this study, early treatment 
with gonadotrophins  in  future patients  may induce  testicular  and penile  growth  in males 
(Main  et  al.  2002).  Whether  early treatment  may  also  prove  beneficial  in  the  long term 
towards adult male sexual and reproductive function in both sexes remains to be seen.
219CHAPTER 9
CONCLUSIONS
9.1  HETEROGENEITY OF CONGENITAL HYPOPITUITARISM
The clinical presentation of pituitary dysfunction varies with the age of the patient and the 
endocrine spectrum that ranges from growth hormone deficiency [GHD] in isolation through 
to combined pituitary hormone deficiency [CPHD]. Documentation of a deficiency in one 
pituitary hormone requires  evaluation of the others.  Briefly,  evaluation consists of a good 
history,  thorough  clinical  examination and assessment of the hypothalamo-pituitary  [H-P] 
axis,  both  its  function  and  morphology.  With  the  advent  of magnetic  resonance  [MR] 
imaging, it is now possible to relate neuroanatomy in patients with hormone deficiencies to 
the likely underlying pathophysiological process.  MR imaging also helps identification of 
patients  with  more  complex  phenotypes  such  as  septo-optic  dysplasia  [SOD]  and 
holoprosencephaly  [HPE].  In  recent  years,  considerable  progress  has  been  made  in  the 
understanding of pituitary gland development and the critical cascade of transcription factors 
responsible for the differentiation of pituitary cell types. Pituitary development is intricately 
linked to  that  of the  eye  and  forebrain  and  rodent pituitary development  has  provided  a 
useful  model  to  understand  the  pathophysiology  in  patients  with  hypopituitarism  and  in 
linking it to  defects  of the  forebrain  and the  eye.  Each cell  type of the anterior pituitary 
gland is  characterized by the  secretion of one or more  trophic  hormones that regulates a 
diverse  range  of  important  biological  processes  in  response  to  signals  from  the 
hypothalamus  and  peripheral  organs.  The  H-P  axis  is  constantly  subject  to  positive  and 
negative feedback mechanisms and the ability of an individual to respond to a variety of
220suppressive and stimulatory agents forms the basis of several dynamic pituitary tests that are 
used  to  assess  integrity  of  the  axis.  The  diagnosis  of hypopituitarism,  in  spite  of  the 
availability of a multitude of tests, is fraught with problems. Difficulties with diagnosis are 
compounded by variability in phenotype, evolving hormonal deficiencies and lack of “gold 
standards” with which to compare test performance.
This  study  was  undertaken  in  sub-groups  from  a  cohort  of  825  patients  with  variable 
hypopituitarism and developmental  defects of the eye and forebrain to test the hypothesis 
that  the phenotype  of a patient  with  hypopituitarism is  influenced by the position  of the 
abnormal  gene  within  the  pituitary  developmental  cascade  and  that  this  temporospatial 
positioning influences the morphology of the  H-P and midline forebrain structures  [MFS] 
and the endocrine  status of the  individual.  The aims of the  study were to define possible 
structure -   function  relationships  within  the  H-P  axis  in  order  to  determine  risk  factors 
associated with hypopituitarism, to investigate the influence of neuroanatomy on birth size 
and  early growth,  to  ascertain  the  optimal  tests  for assessing hormone  deficiency  and to 
establish genotype - phenotype correlations in patients with a genetic hypopituitarism.
Data from this study demonstrated a good relation between structure and function within the 
H-P  axis  and  MFS.  Overall,  abnormal  H-P  morphology  was  a  reasonable  indicator  of 
endocrine dysfunction as all patients with endocrine dysfunction demonstrated at least one 
H-P structural defect as compared with 76% of patients without endocrine dysfunction.  In 
particular,  the  presence  of  an  undescended  posterior  pituitary  offered  the  strongest 
association  with  hypopituitarism  with  an  odds  ratio  of 33.05  [95%  Cl  4.38,  249.45]  in 
patients with hypopituitarism as compared to those without.  Anterior pituitary hypoplasia
221also  occurred  6.7  [95%  Cl  2.63,  16.98]  times  more  commonly  in  patients  with 
endocrinopathies as compared with those without. Amongst patients with hypopituitarism, 
MFD and abnormalities of the pituitary stalk were significantly associated with the presence 
of CPHD over IGHD. This association was particularly significant for abnormalities of the 
corpus callosum as  they were observed in 23% of patients with CPHD as compared with 
4.5% of patients with IGHD with an odds ratio of 6.13  [95% Cl  1.37, 37.44]. Patients with 
optic  nerve  hypoplasia  [ONH]  who  demonstrate  anterior  pituitary  hypoplasia  and  an 
undescended  posterior  pituitary  were  found  to  be  significantly  at  risk  of  endocrine 
dysfunction  as  compared  with  children  with  ONH  and  normal  endocrinology.  Although 
MFD  occurred  with  an  odds  ratio  of  1.42  [95%  Cl  0.57,  3.55]  in  ONH  patients  with 
endocrine  dysfunction  as  compared  with  ONH  patients  with  normal  endocrinology,  the 
differences  did not reach  statistical  significance.  The endocrine  spectrum in hypopituitary 
patients  with  ONH  included  a  significantly  greater  prevalence  of  ACTH  and  AVP 
deficiencies as compared  with hypopituitary patients without ONH  [presumed “idiopathic” 
hypopituitarism].  There  was  a  significant  male  to  female  preponderance  in patients  with 
“idiopathic” hypopituitarism as compared with hypopituitary patients with ONH suggesting 
the possibility of a role for SOX3 or other unknown genes with an X-linked inheritance as 
the etiology in those patients currently labelled as “idiopathic”.
Birth  size  and  growth  in  infancy in  patients  with  congenital  GHD  with  or without  other 
pituitary hormones was also influenced by the neuroanatomical phenotype. Although birth 
size  in  patients  with  GHD,  on  the  whole,  was  not  reduced,  patients  with  the  mildest 
phenotype  of IGHD  were bom with  a greater birth length  SDS  than those with the most 
severe phenotype  characterized by CPHD  and midline defects.  Differences  in weight and
222body mass  index  [BMI]  were particularly significant as patients with  a severe phenotype 
[CPHD  +  midline  defects]  were  bom  heaviest,  with  greatest  BMI,  than  those  with  the 
mildest phenotype  with  IGHD.  GH  appeared to be critical  for early postnatal  growth  as 
length SDS decreased in all patients within 6 months of birth.  Trends within data from this 
study  suggest  that  this  growth  during  the  infancy  period  was  influenced  in  part  by  the 
complexity of the hypopituitary phenotype reflected by the presence of CPHD and midline 
defects. Patients with CPHD had a greater decrease in length as compared with patients with 
IGHD. Patients with CPHD and midline defects were longer, heavier and with greater BMI 
than CPHD patients without midline defects.
A retrospective evaluation of serum TSH response to stimulation with TRH in patients with 
central  hypothyroidism  revealed  that  responses  remained  normal  in  23.3%  of  patients 
limiting the role of the TRH test as a diagnostic tool in central hypothyroidism.  There was 
considerable overlap between stimulated serum TSH  responses  in patients with “pituitary” 
and those with “hypothalamic” disease, and a distinction between the two pathologies is not 
easy based  on  this  test.  In  patients  in  whom other biochemical  or neuroradiological  H-P 
abnormalities  have  been  demonstrated,  regular  evaluation  of  the  serum  thyroxine 
concentrations alone may reveal the diagnosis of TSH deficiency which is best made in the 
presence  of a  low  serum  thyroxine  concentration  in  the  face  of a  low,  normal  or  even 
modestly elevated unstimulated  serum  TSH  concentration.  It is  important to  establish the 
diagnosis of ACTH deficiency quickly in order to avoid the risk of hypoglycemia, adrenal 
crisis and mortality. A combination of the short Synacthen test and measurement of 0800- 
hour serum cortisol concentration, both of which are safe and relatively easy to perform in 
young  children,  represented  the  optimal  method  of  investigation  for  ACTH  deficiency.
223Patients  who  have  a  serum cortisol  concentration  <  540  nmol/L  at  30  minutes  following 
stimulation with  Synacthen and <  175 nmol/L at 0800 hours should receive glucocorticoid 
replacement. A reassessment of all individuals’ cortisol status should be performed at a later 
stage to identify those normal individuals who may have received treatment inappropriately 
as the sensitivity of the test remains below 85%. A high index of clinical suspicion should be 
exercised even in patients with normal test results in order to identify evolving H-P disease 
with  later onset  of ACTH  deficiency.  Preliminary data on  serum  LH  and  FSH  responses 
following  stimulation  with  LHRH  demonstrated  that  responses  are  gender  specific  with 
exaggerated serum  FSH  responses  in  females in infancy,  with concentrations  significantly 
greater than those in prepubertal and pubertal normal children.
Mutations  in  pituitary  transcription  factors  were  found  in  0.7%,  6.4%,  6.2%,  13.6%  and 
5.3% of hypopituitary patients  screened for mutations in HESX1,  PROP1,  POU1F1,  GH1 
and SOX3 respectively. On the whole, they were rare in sporadic hypopituitarism. As there 
was  a  significant  increase  in  the  male  to  female  ratio  in  patients  with  “idiopathic” 
hypopituitarism as compared with that in hypopituitary patients with ONH, identification of 
mutations  in  SOX3  and  other  unknown  genes  leading  to  an  X-linked  inheritance  of 
hypopituitarism  may  elucidate  the  genetic  basis  of this  male  preponderance  in  patients 
thought  to  have  idiopathic  disease.  There  was  a  poor  genotype  phenotype  correlation  in 
patients  with  genetic  hypopituitarism  both  between patients  and  within  families  with  the 
same  mutation.  Variability in  phenotype  was  most  obvious  in patients  with  mutations  in 
HESX1,  where the endocrine spectrum ranged from patients with IGHD, with and without
224ONH  to  SOD.  Neuroanatomical phenotype ranged from normal  MR imaging to that with 
complex abnormalities of the H-P axis and MFS. There was a similar variability in patients 
with mutations  in SOX3,  an  endocrine phenotype ranging  from  IGHD  to  evolving CPHD 
with variable  MR imaging abnormalities.  Patients with mutations  in PROP1  also  showed 
considerable  variability  in  phenotype  particularly  with  respect  to  ACTH  and  prolactin 
deficiencies and the size of the anterior pituitary gland.  A pituitary mass identified in one 
patient waxed  and  waned  in  size prior to  its  involution.  An  evolving nature  of hormone 
deficiencies in patients with PROP1 mutations suggests a progressive decline in the anterior 
pituitary axis indicating a need for continual monitoring of patients for the development of 
hormone  deficiency  that  may  not  be  apparent  at  initial  presentation.  TSH  and  prolactin 
deficiencies were not complete in all patients with mutations in POU1F1.  IGHD in patients 
with type II autosomal dominant GHD may also evolve leading to CPHD. Early treatment 
with recombinant human GH  [rhGH]  and avoidance of precipitate withdrawal of treatment 
following  attainment  of adult  height  in  these  patients  may  be  important  in  maintaining 
pituitary  function  by  providing  a  feedback  signal  to  reduce  the  GHRH  drive,  reduce 
somatotroph  proliferation  and  reduce  the  rate  of cell  destruction.  This  could  potentially 
reduce  pituitary  damage  and  hence  loss  of  other  endocrine  cells  types.  However,  this 
hypothesis remains to be proven.
It is however important to note that our knowledge of the field of pituitary development is in 
its embryonic stages and further research in the areas of clinical and molecular medicine will 
better clarify the ambiguities in the spectrum of hypopituitarism.
2259.2  SHORTCOMINGS OF THE PRESENT STUDY
A few criticisms could be made from these preliminary studies.  The study was performed 
retrospectively  and  hence  data  collection  was  not  systematic.  Although  patients  were 
selected  systematically,  there  is  likely to be  an  inherent  variability in the  anthropometry, 
biochemical  testing  and  hormone  assays  between patients  within  the  LCPE  and  between 
national and international centres. The population of children studied was highly selective, 
selecting only those with apparent pituitary pathology reflecting the nature of referrals to the 
LCPE and possibly to other centres. There was also a lack of true age-related control data as 
it  was  not  ethically  possible  to  undertake  pituitary  function  testing  and  MR  imaging  in 
normal  children.  Short normal  children who  had  undergone  investigations  as part of their 
diagnostic assessment and found to have no pathology were used as controls for the studies 
evaluating  pituitary  hormone  function.  These  children  have  been  followed  up  until 
adulthood  to  ensure  normal  growth  and  puberty.  Children  with  ONH  without  endocrine 
dysfunction were used as controls in the study identifying MR abnormalities associated with 
endocrine dysfunction. Not all patients were analysed longitudinally and hence an accurate 
assessment of evolving endocrine dysfunction was not possible. Although functional studies 
have provided insight into the effects of genetic mutations, it is difficult to assess its impact 
on the general population. Although this study is one of the largest documenting the detailed 
phenotype  and  prevalence  of mutations  in  pituitary  transcription  factors  in  patients  with 
hypopituitarism,  it  is  still  relatively  small  given  the  rarity  of these  conditions  and  it  is 
therefore  difficult  to  make  definitive  conclusions.  Long-term  follow-up  is  essential  to 
determine  the  likelihood  of evolving endocrinopathy and the  long-term outcome  of these 
patients.
2269.3  CLINICAL IMPACT OF PRESENT RESEARCH
This  study  has  led  to  the  implementation  of a  number  of recommendations  for  clinical 
practice  at  the  London  Centre  fpr  Paediatric  Endocrinology  LCPE].  As  structural 
abnormalities on magnetic resonance [MR] imaging significantly helped predict the risk of 
hypopituitarism  and  the  likelihood  of developing  combined  pituitary hormone  deficiency 
over isolated growth hormone deficiency, MR imaging is recommended in all patients with 
hypopituitarism and those “at-risk” of hypopituitarism. Patients with optic nerve hypoplasia 
and  abnormal  MR  imaging  should  receive  long-term  follow  up  as  they may demonstrate 
evolving endocrine dysfunction.
Analysis  of  tests  used  in  evaluating  pituitary  hormone  secretion  revealed  several 
shortcomings, particularly in infants and young childen, in whom some endocrine tests may 
prove hazardous and interpretation of results is often difficult. As the TRH test was found to 
be normal in several patients with central hypothyroidism, it was not deemed necessary for 
its diagnosis. Regular evaluation of free thyroxine concentration is recommended in patients 
who  demonstrate  other  pituitary  hormone  and/or  structural  brain  abnormalities.  A 
combination approach of measurement of 0800-hour serum cortisol concentration, a marker 
of  physiological  secretion,  with  measurement  of  post-Synacthen  serum  cortisol 
concentrations, a measure of cortisol reserve, was considered a suitable overall assessment 
of the H-P- adrenal axis in infants and young children. Patients who have a serum cortisol 
concentration < 540 nmol/L at 30 minutes following stimulation with Synacthen and <175 
nmol/L at 0800 hours should receive glucocorticoid replacement with a reassessment of all
227individuals’ cortisol status at a later stage. This study also illustrates that interpretation of the 
LHRH  test  in  infancy is  difficult,  and  long-term follow up of hypopituitary patients with 
“abnormal”  LHRH  tests  is  necessary  to  correlate  the  biochemistry  with  the  clinical 
phenotype.  The results of LHRH testing were particularly variable in female patients who 
demonstrated exaggerated serum FSH responses following stimulation.
Data from this study indicates that growth failure in infancy, as early as 6 months of age, 
may be  attributed  to  congenital  GHD.  In  patients  with  congenital  GHD,  identification  of 
other pituitary hormone  deficiencies  and  MFD  on  MR imaging helped predict those who 
would present earlier with more severe growth deceleration and those with a propensity for 
early weight gain respectively.
Although data from this study suggest a lack of complete genotype-phenotype correlation in 
patients  with  a  molecular  genetic  cause  for  hypopituitarism,  molecular  analysis  led  to 
several benefits. Given the difficulties with interpretation of current endocrine tests and the 
evolving nature of hypopituitarism, DNA analysis was found not only to be useful in a better 
understanding of H-P development, but also helpful in making a correct clinical diagnosis as 
observed in patients with a mutation in POU1F1 misdiagnosed with ACTH deficiency, in a 
patient with a “pituitary tumour”  who was found to harbour a mutation  in PROP1,  and in 
diagnosing evolving CPHD  in patients with  IGHD who  harbour a  splice  site mutation in 
GH1.
2289.4 IDEAS FOR FUTURE RESEARCH
This  study  demonstrates  the  striking  phenotypic  heterogeneity  in  patients  with 
hypopituitarism.  A vast proportion of patients with hypopituitarism did not have a known 
genetic cause, many of whom had extra-pituitary malformations, suggesting that unknown 
genes may not only be implicated in H-P but other organ development as well. Using mice 
expression and transgenic data, the next few years may see the identification of such novel 
genes.  In some patients with a proven genetic cause, the genotype alone could not explain 
the  variabilities  in the phenotype and identification of genetic  or environmental modifiers 
may  in  the  future  explain  this  phenotypic  variability.  Although  good  structure-function 
relationships are demonstrated within the H-P axis following MR imaging, several questions 
remain  unanswered.  In  particular,  the  contribution  of  hypothalamic  versus  pituitary 
dysfunction to the phenotye needs to be examined further.  It is possible that the arrival of 
higher resolution MR scanners providing thinner cuts in the future, may identify structures 
currently reported as “absent”, providing a better explanation for the phenotypic ambiguity 
observed  in  some  patients  e.g.  those  with  an  “absent”  pituitary  stalk  who  did  not 
demonstrate  panhypopituitarism,  those  with  an  “absent”  posterior  pituitary  who  did  not 
develop  diabetes  insipidus  or  those  with  anterior  pituitary  hypoplasia  who  have  normal 
pituitary  function  to  date.  Future  longitudinal  follow-up  studies  will  prove  beneficial  in 
identification  of  risk  factors  associated  with  evolution  of  the  endocrinopathy  and  in 
determining outcomes of morbidity in these patients.  Detailed phenotyping, genotyping and 
epidemiological  data  in  these  groups  of patients  may  shed  further  light  on  the  etiology, 
particularly with respect to the contribution of environmental and genetic factors leading to 
improved investigation and treatment of these patients.
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249APPENDIX
I.  CLINICAL DETAILS PROFORMA
PATIENT DNA SAMPLE NO.
NAME
DOB
HOSPITAL / CONSULTANT
SURNAME
SEX
HOSPITAL NO.
ANTENATAL HISTORY 
MATERNAL AGE 
MATERNAL SMOKING 
MATERNAL ALCOHOL 
CONSANGUINITY 
FAMILY HISTORY 
GESTATION AT BIRTH 
BIRTH WEIGHT 
NEONATAL COMPLICATIONS
YES  /  NO 
YES  /  NO 
YES  /  NO
DELIVERY 
BIRTH LENGTH
AGE AT DIAGNOSIS 
WEIGHT ON PRESENTATION 
DEVELOPMENT 
MID PARENTAL HEIGHT 
SPONTANEOUS PUBERTY
HEIGHT ON PRESENTATION
FINAL HEIGHT 
YES  /  NO
VISUAL ACUITY RIGHT EYE
RIGHT OPTIC DISC
ERG
OTHER OPHTHALMOLOGICAL FEATURES
VISUAL ACUITY LEFT EYE
LEFT OPTIC DISC
VER
FREE THYROXINE
BASAL TSH
BASAL PROLACTIN
GH PROVOCATION TEST TYPE
PEAK GH
BASAL CORTISOL
BASAL LH
BASAL FSH
DIABETES INSIPIDUS
PEAK TSH 
PEAK PROLACTIN
PEAK CORTISOL 
PEAK LH 
PEAK FSH 
YES  /  NO
HYDROCORTISONE TREATMENT (AGE) 
THYROXINE TREATMENT (AGE)
GH TREATMENT (AGE)
DDAVP TREATMENT (AGE)
SEX STEROIDS (AGE)
NEUROIMAGING RESULT
OTHER ASSOCIATED FEATURES 
CANDIDATE GENES TO BE TESTED 
DIAGNOSIS
250II.  PATIENT / PARENT INFORMATION SHEET
Title of Project: A genetic analysis of children with forebrain, eye and/or pituitary defects 
We would like to ask your permission to include your child in this project.
Investigator: Dr. M.T. Dattani
Introduction:  The  pituitary  gland produces  a  number  of hormones  that  are  essential  for 
growth  and normal  pubertal  development  of children.  In  some  children  who  suffer  from 
growth failure, the pituitary gland may be unable to produce growth hormone (GH) and/or 
other hormones. The gland may be very small or even absent. These children would need to 
be treated with the hormones that are missing. Occasionally, the small pituitary gland may 
be associated with developmental abnormalities affecting the eyes and the midline structures 
of the brain, when the condition is called septo-optic dysplasia or SOD. The reason for this 
association  of developmental  abnormalities  lies  in  the  close  relationship  between  normal 
pituitary,  forebrain  and  eye  development  in  man.  A  number  of genes  are  implicated  in 
controlling the  development  of these  structures,  and  these  include  P/77,  PROP1,  LHX3, 
LHX4 and HESX1.
The aim of the study: In this study, we aim to analyse the genes controlling the development 
of the pituitary gland. We have recently found that changes in a new gene called HESX1 are 
associated with SOD, pituitary hypoplasia and GH insufficiency or deficiency in man. We 
now  wish  to  screen  children  for  abnormalities  in  this  and  other  genes  important  for the 
normal development of the forebrain, eye and pituitary gland in man and mouse.
Why is the study being done? This study will help us to understand why children develop 
abnormalities of the forebrain, eyes and pituitary gland. Additionally, we will gain further 
insights  into the complex development of these structures.  Finally, knowledge of the exact 
genetic mechanism for the underlying disease will enable us to make an earlier diagnosis in 
further affected children from the same family,  and also to offer antenatal diagnosis.  This 
will reduce the complications that could potentially arise in children with these disorders.
How is the study being done? We need to take a small blood sample (2 teaspoonfuls) from 
your child. To minimise discomfort, we will perform the blood test using local anaesthetic 
cream prior to collection of blood. Full genetic analysis will be performed on these samples. 
This investigation will be performed by a member of the Paediatric Endocrinology team at 
Great Ormond  Street Children’s  Hospital  during one of your visits to the hospital.  Only a 
single sample of blood is required for the study. Where possible, the blood sample will be 
taken  at  the  same  time  as  other  tests  of pituitary  gland  function  which  may  need  to  be 
performed on your child from time to time in the out-patient clinic.
What are the risks and discomfort? No risk to the child can be foreseen. There is discomfort 
from a  single  needle prick  for blood sampling,  but this will be minimised by using  local 
anaesthetic cream.
251What are the potential benefits? This study may help us to understand why your child has 
developed  their  medical  condition.  Additionally,  we  may be  able  to  make  the  diagnosis 
earlier, and where one child in the family already has the disorder, we may be alerted so that 
an earlier diagnosis is made in future children.
Who will have access to the case/research records? Only the researcher and a representative 
of the Research Ethics Committee will have access to the data collected during the study.
What  are  the  arrangements for  compensation?  The  project  has  been  approved  by  an 
independent  research  ethics  committee  who  believe  that  it  is  of  minimal  risk  to  you. 
However, research can carry unforeseen risks and we want you to be informed of your rights 
in the unlikely event that any harm should occur as a result of taking part in this study. Only 
the work of the academic staff on this project is covered by a compensation scheme, which 
may apply in the event of any significant harm occurring to your child as a result of taking 
part in this study. Under this scheme, it would not be necessary for you to prove fault. You 
might  also  have  the right to  claim damages  in  a court of law.  This would require you to 
prove fault on the part of the Hospital/Institute and/or any manufacturer involved.
Do I have to take part in this study? No. If you decide, now or at a later stage, that you do 
not wish to participate in this research project, that is entirely your right, and will not in any 
way prejudice any present or future treatment.
Who do I speak to if  problems arise? Please contact Dr. Dattani or Dr Mehta directly with 
any problems relating to the study. If you have any complaints about the way in which this 
research project has been, or is being conducted, please, in the first instance, discuss them 
with the researcher. If the problems are not resolved, or you wish to comment in any other 
way,  please  contact  the  Chairman  of the  Research  Ethics  Committee,  by  post  via  the 
Research  and  Development Office,  Institute  of Child  Health,  30  Guilford  Street,  London 
WC1N  1EH,  or if urgent,  by telephone on 020  7242  9879  ext.  2620,  and the  Committee 
administration will put you in contact with him.
252III.  CONSENT FORM
Great Ormond Street Hospital for Children NHS Trust and Institute of Child Health
Research Ethics Committee
Consent Form for parents or guardians of Children Participating in Research Studies
Title: A genetic analysis of children with forebrain, eye and / or pituitary defects
NOTES FOR PARENTS OR GUARDIANS
1.  Your child has been asked to take part in a research study.  The person organising that 
study is responsible for explaining the project to you before you give consent.
2.  Please  ask  the  researcher any questions  you  may  have  about  this project,  before  you 
decide whether you wish to participate.
3.  If you decide, now or at any other stage, that you do not wish your child to participate in 
the research project, that is entirely your right, and if your child is a patient it will not in 
any way prejudice any present or future treatment.
4.  You  will  be  given  an  information  sheet,  which  describes  the  research  project.  This 
information sheet is for you to keep and refer to.  Please read it carefully.
5.  If you have any complaints about the way in which this research project has been or is 
being conducted, please,  in the first instance, discuss them with die researcher.  If the 
problems are not resolved, or you wish to comment in any other way, please contact the 
Chairman of the Research Ethics Committee, by post via The Research and Development 
Office, Institute of Child Health, 30 Guilford Street, London WC1N 1EH or if urgent, by 
telephone on 020 7905  2620 and the committee administration will put you in contact 
with him.
I/W e______________ being the parent(s)/guardian(s)  of  _______  agree  that the  Research
Project  named  above  has  been  explained  to  me  to  my/our  satisfaction,  and  I/We  give 
permission for our child to take part in this study.  I/We have read both the notes written above 
and the Information Sheet provided, and understand what the research study involves.
SIGNED (Parent (s)/Guardian (s))  PRINTED  DATE
SIGNED (Researcher)  PRINTED  DATE
253IV.  PROTOCOLS USED FOR EVALUATING PITUITARY FUNCTION
(A)  Short (Standard) Synacthen test
Test  procedure:  A  cannula  should  be  inserted  at  least  1   hour  prior  to  the  test  being 
performed. The test should ideally be performed at 0900, and fasting is not required.
Synacthen  dose:  Synacthen  (Novartis  Pharma  AG,  Stein,  Switzerland)  Doses  are 
administered  IM  or  IV  (dilute  in  2  ml  normal  saline  and  give  slowly  over  2  minutes). 
Anaphylaxis has been reported, but it is extremely rare.
Age Dose
< 6 months 62.5 micrograms
6-24 months 125 micrograms
> 2 years 250 micrograms
Sampling: Serum cortisol should be measured at 0, 30 and 60 minutes.
(B)  Spontaneous Cortisol Day Curve
Prior arrangements: Inform the laboratory
Test  Procedure  and  Sampling:  Patients  to  be  admitted  early  in  the  morning  and  an 
indwelling  intravenous  catheter  to  be  inserted  2  hours  prior  to  blood  sampling.  Blood 
samples to measure spontaneous cortisol secretion to be drawn at 2-hour (h) intervals from 
lOOOh until 0800h the following day.
The 0800h sample was used in analysis of the role of this timed sample in the assessment of 
the  H-P-A  axis.  The  mean  spontaneous  serum  cortisol  concentration  is  calculated  as  the 
average concentration from the 12 samples obtained.
254(C)  LHRH test
Test procedure: Collect basal (time 0) samples. Then administer LHRH [Gonadarelin (HRS, 
Intrapharm, UK)] 2.5 micrograms/kg by IV bolus (maximum of 100 micrograms).
Sampling:  Basal  (time 0)  plasma  LH,  FSH,  oestradiol  or testosterone.  Repeat plasma LH 
and FSH at 20 and 60 minutes.
(D)  TRH Test
Test procedure: TRH 7 micrograms/kg (max of 200 micrograms) slow IV (over 3 minutes).
Sampling:  Basal  free  T4,  TSH  as well  as  free  T3.  Repeat TSH  at  20  and  60 minutes.  If 
clinically indicated, prolactin or growth hormone may need to be measured as well.
(E)  Intramuscular Glucagon stimulation test for GH secretion
Glucagon Dose:  100 micrograms/kg IM (maximum lmg if <90kg; 1.5mg if >90kg).
Timing of test samples:
Time (minutes) BM stix Glucose GH Cortisol
-30 □ □ □ □
0 □ □ □ □
30 □ □ □
60 □ □ □
90 □ □ □
120 □ □ □ □
150 □ □ □ □
180 □ □ □ □
255(F) Insulin tolerance test (ITT) for GH & cortisol secretion
Test Procedure:
-  If the BM stix reading at 0 minutes is under 2.6 mmol/1, then no dose of insulin should 
be administered. Sampling for hormone levels should proceed as per protocol, but the 
study should be continued for 60 minutes only. Glucose should be administered orally 
as described below.
-  If the  BM  stix  level  is between  2.6  -  3.5  mmol/1  then 0.1  IU/kg  of soluble  insulin 
should be administered intravenously as a bolus.
-  If the BM stix level is > 3.5 mmol/L, then the dose of insulin should be increased to
0.15  IU/kg  of  soluble  insulin,  UNLESS  the  child  is  suspected  of  suffering  from 
panhypopituitarism  or  in  children  post-cranial  surgery  or  post-cranial  radiotherapy 
(which includes total body irradiation), when the child should only receive 0.1  IU/kg 
of soluble insulin.  Consider administering IV hydrocortisone (<  3  years:  50 mg; > 3 
years:  100 mg) at the end of the test.
-  The  dose  may  need  to  be  increased  in  patients  with  diabetes  mellitus,  insulin 
resistance,  pre-treatment  acromegaly,  pre-treatment  Cushing  syndrome,  obesity,  or 
when the test is being repeated due to a failure to achieve hypoglycaemia at the first 
attempt.
-  NB: The dose of insulin should NEVER exceed 10 units
Timing of test samples:
Time (minutes) BM stix Glucose GH Cortisol
-30 (before insulin) □ □ □ □
0 (before insulin) □ □ □ □
20 □ □
30 □ □ □ □
60 □ □ □ □
90 □ □ □ □
120 □ □ □ □
Failure  to  reach  a  low  blood  glucose  at  30  minutes:  If the  BM  stix  has  not  gone  <2.6 
mmol/L, or < 50% basal blood glucose, and the child is asymptomatic, wait for 30 minutes 
but do NOT repeat insulin under any circumstances. Continue the test as per protocol.
256(G) Combined pituitary function test
Give the following successively:
Insulin (0.1 -  0.15 IU/kg IV) or glucagon (100 micrograms/kg IM, maximum 1  mg). 
GnRH (LHRH) 2.5 micrograms/kg IV (maximum 100 micrograms).
•  TRH 7 micrograms/kg IV slowly over 3 minutes (maximum 200 micrograms).
Timing of test samples:
Time
(minutes)
BM
stix Glucose Cortisol GH LH FSH TSH Prolactin
-30 □ □ □ □
0 □ □ □ □ □ □ □ □
20 □ □ □ □ □ □
30 □ □ □ □
60 □ n □ □ □ □ □ □
90 □ □ □ □
120 □ □ □ □
And continuing if glucagon has seen used:
150 □ □ □ □
180 □ □ □ □
(H)  Water deprivation test
Fluids must not be limited before the test, but tea and coffee must be excluded overnight. A 
light breakfast with minimal fluid (in the form of water) may be taken early in the morning 
before the test. Weigh the child, and calculate 5% of the body weight.
Test Procedure:
Time Wt (kg) HR BP Urine volume Specific gravity Notes
T = 0 0830
4  44
T = lhr 0930
" ”* ■ *   ........
T = 2hr 1030
4  44
J
3
C
O
I
I
H 1130
44
H
I
I
3
*
1230
*  4*
H
I
I
L
/
>
5
*
1330
•  **
T = 6hr 1430
44
T = 7hr 1530
4  44
257*Blood and **urine specimens to be sent for Na+ and osmolality. Stop the test and proceed to 
the second part of the test (i.e. the DDAVP test) if one of the following occurs:
1.  The patient’s weight falls by 5% from the starting weight.
2.  Serum osmolality rises  (>  295  mOsm/kg),  in the  face of an inappropriately dilute 
urine (< 300 mOsm/kg).
3.  If the patient becomes clinically dehydrated.
Stop the test and do not proceed to the DDAVP test if:
1.  Any urine osmolality exceeds 750 mOsm/kg.
2.  At 1530 hours, even if the above criteria have not been met.
(I)  DDAVP TEST
The DDAVP test follows the 7-hour water deprivation test. Administer either IM or 
intranasal DDAVP at a dose of:
Age DDAVP dose
Nasal Intramuscular
< 2 years 5 micrograms each nostril 0.05 microgram
2 -8  years 7.5 micrograms each nostril 0.1 microgram
>8 years 10 micrograms each nostril 0.2 microgram
A light meal may be taken and the patient is allowed to drink fluids in volumes strictly equal 
to the previous hour’s urine output. Over the next 4 hours, record urine volume and specific 
gravity, body weight, BP, HR, and the patient’s thirst.
The test ends when of the following occurs: After 4 hours; Urine specific gravity > 1.014.
Sampling at the end of the test: Blood and urine samples taken for sodium and osmolality, 
fluid restricted to the previous hour’s urine output. Serum U&Es need to be checked on the 
following morning.
258(J) Protocol for investigation of children with suspected SOD
The following investigations are required for the evaluation of a child with SOD:
1.  Assessment  of  cortisol  secretion  in  the  form  of  a  cortisol  day-curve  and/or  a
physiological/standard Synacthen test is required.
2.  Random serum prolactin -  if low, then a formal TRH provocation test
3.  Thyroid function tests -  if both the plasma thyroxine (free or total) and TSH are low, 
then formal provocation with TRH may be indicated.
4.  Plasma LH and FSH may be helpful in the first  18 months of life and then again at 
the  time  when  puberty  normally  commences.  Some  of these  children  may  have 
precocious puberty and a GnRH (LHRH) test may then be indicated.  An HCG test 
may be indicated in boys with undescended testes to assess testicular function.
5.  Paired  plasma  and  urine  osmolalities,  preferably  first  thing  in  the  morning,  if a 
diagnosis of diabetes insipidus is a possibility.
6.  Other tests should include a full blood count, U&E and a karyotype.
7.  Growth should be carefully monitored. If the growth velocity is reduced, assessment 
of GH  and cortisol  secretion  should be  considered  using one of a number  of GH 
provocation tests e.g. insulin-induced hypoglycaemia or a glucagon test.
8.  Neuroradiological imaging in the form of an MRI scan with pituitary views.
9.  Ophthalmologic  assessment  with  visual  evoked  responses  (VER)  and 
electrophysiology (e.g. ERG).
10. Referral to an appropriate Developmental Paediatrician.
11.DNA  analysis.  To  be  sent  to  Dr  Mehul  Dattani  (Professor  in  Endocrinology, 
Biochemistry,  Endocrinology  and  Metabolism  Unit,  Institute  of Child  Health,  30 
Guilford Street, London WC1N 1EH. Email address: mdattani@ich.ucl.ac.uk)
259V.  EXPANDED PATIENT DATA
Abbreviations used in this section:
A absent
Ab abnormal
ACTH corticotrophin
AP anterior pituitary
AVP arginine vasopressin
C cavum
CC corpus callosum
CH central hypothyroidism
E enlarged
F female
FSH follicle stimulating hormone
GH growth hormone
Gn gonadotrophins
H hypoplastic
HPE holoprosencephaly
EH luteinising hormone
260
M male
MR magnetic resonance
N normal
N/A not available
N/T not tested
ONH optic nerve hypoplasia
PP posterior pituitary
Pt patient number
PRL prolactin
TSH thyrotrophin
SP septum pellucidum
SST short Synacthen test
U undescended
A delta TSHV-l  MR imaging and endocrinology in patients with hypopituitarism.
Pt  sex  Presentation  Deficiencies of
Age
(years)
Height
(SDS)
Weight
(SDS)
GH TSH ACTH Gn
1 M 8.3 -4.8 -2.1 + - - -
2 M 8.0 -5.9 -1.5 + - - -
3 M N/A N/A N/A + - - -
4 M 5.6 -5.6 -0.8 + - - -
5 M 5.0 -6.9 -4.7 + - - -
6 F 16.2 -4.4 0.1 + - - +
7 M 0.2 -6.0 0.1 N/T + + -
8 F 2.0 -7.5 -2.7 + + - N/T
9 M 0.0 N/A N/A N/T + - N/T
10 F 6.0 -2.5 3.7 + - - +
11 M 1.3 -9.1 -4.8 N/T + + N/T
12 M 0.0 N/A N/A + + + +
13 F 1.2 -9.3 -3.8 + + - N/T
14 M N/A N/A N/A + - - -
15 M 2.3 -5.9 -1.7 + - - -
16 F 3.8 -8.0 3.4 - - -
17 M 2.0 -7.1 -4.3 + - - -
18 M 3.6 -6.4 -3.7 + - - -
19 F 5.8 -8.9 -4.6 + - - -
20 M 10.5 -7.7 -2.1 + - - -
21 F 4.0 -5.7 -1.2 + - - -
22 F 6.1 -7.4 -3.1 + - - -
23 M 8.6 -8.1 -5.8 + - - -
24 M 4.0 N/A N/A + - -
261
  Prolactin  ONH________MR imaging_______
AVP  (mU/L)  AP  PP  SP  CC  Stalk
- 520 - N N N N N
- 210 - N N N N N
- 230 - N N N N N
- 240 - N N N N N
- 540 - N N N N N
- 440 - N N N N N
- 280 - N N N N N
- 150 - N N N N N
+ 480 - N N N N N
+ 270 - N N N N N
- 1664 - N N N N N
- 412 - N N N N N
- 67 - N N N N N
- N/A - H N A N N
- 142 - H N N N N
- 150 - H U N N N
- N/A - H N N N N
- 110 - H N N H N
- N/A - H N N N N
- 178 - H U N N N
- 345 - H N N N N
- 129 - H N N N N
- 95 - H U N N N
_ N/A - H U N N AV-l  (continued]
Pt  s e x ______ Presentation________________ Deficiencies of      Prolactin ONH________ MR imaging_______
Age  Height  Weight  GH  TSH  ACTH  Gn  AVP  (mU/L)  AP  PP  SP  CC  Stalk
(years)  (SDS)  (SDS)
25 M 4.9 -6.7 -3.1 + - - - - 160 - H N N N N
26 M 5.7 -6.9 -4.2 + - - - - 614 - H U N N A
27 F 2.7 -7.4 -3.3 + - - - - 147 - H N N N N
28 M 6.0 -6.5 -0.7 + - - - - 857 - H N N N N
29 M 3.4 -5.7 -3.8 + - - - - 124 - H U N N N
30 M 5.1 -5.5 -2.2 + - - - - 112 - H N N N N
31 M 10.3 -6.4 -1.3 + - - - - N/A - H U N N A
32 M 5.0 -7.7 N/A + - - - - 228 - H U N N A
33 F 3.8 -8.0 -4.0 + - - - - 648 - H u N N A
34 M 11.0 -6.8 -2.7 + - - - - N/A - H N N N N
35 M 3.0 N/A N/A + - - - - 216 - H u N N N
36 M 1.6 -5.4 -5.0 + - - - - 260 - A N N N N
37 M 4.5 N/A N/A + - - - - 192 - H N N N N
38 M 17.3 -5.8 0.5 + - - - - 222 - H N N N A
39 M N/A N/A N/A + - - - - N/A - H N N N N
40 F 1.3 -6.1 -4.6 + - - - - N/A - H N N N N
41 F 11.0 -4.9 0.2 + - - - - N/A - H N N N N
42 M 6.9 -7.5 -4.0 + - - - - N/A - H N N N N
43 M 6.0 -2.8 N/A + - - - - N/A - H U N N H
44 M 3.0 -6.0 -1.5 + - - - - 34 - H U N N N
45 M N/A N/A N/A + - - - - 1400 - H N N N N
46 F 3.5 -5.6 -1.8 + - - - - 410 +BL H U A N A
47 M 0.5 -6.9 -4.2 + - - - - 296 +BL H N A H H
48 F 0.6 -3.9 -0.2 + - - - - 485 +BL H U N N A
262V-l  [continued]
Pt  Sex  Presentation  Deficiencies of
Age Height Weight GH TSH ACTH Gn
(years) (SDS) (SDS)
49 F 8.5 -5.8 N/A + - - -
50 M 7.6 -6.6 -2.9 - - -
51 F 2.0 N/A N/A + - - -
52 M 3.1 -6.7 -3.6 + - - -
53 F 1.5 -8.7 -3.3 + + + +
54 M 0.5 -5.1 -1.2 + - + +
55 F 0.3 -5.1 -2.0 + + + +
56 M 0.6 -3.1 0.3 + + +
57 F 0.9 -0.3 4.2 + - + N/T
58 F 0.1 -6.1 -0.8 + + + +
59 M 3.6 -5.3 -1.9 N/T - + N/T
60 M 2.9 -8.3 -3.6 + + N/T
61 M 0.5 -5.0 -1.5 + + + +
62 F 1.9 -4.4 0.4 + + + N/T
63 M 2.0 N/A N/A + + + +
64 M 0.2 -9.0 -4.1 + + + -
65 F 10.9 -4.2 -0.7 + + + +
66 M 0.8 -4.8 N/A + + + +
67 F 1.0 -6.2 -2.9 + + + N/T
68 M 0.4 -3.9 -0.7 N/T + + N/T
69 M 0.6 -8.0 -6.7 + + + +
70 M 0.4 -5.6 -0.9 + + + N/T
71 F 0.0 -4.9 -1.4 + + + -f
72 M 3.5 -6.4 -2.8 I I - N/T
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Prolactin  ONH     MR imaging_______
AVP  (mU/L)  AP  PP  SP  CC  stalk
- 300 +BL H N A N H
- N/A +BL H N N N H
- 192 +UL H U N N A
- 278 +BL H N N N A
- 98 +BL H N N A A
+ 644 +BL H N A A A
- 567 +BL H U A N N
- N/A +BL N U C H H
- 270 +BL H A N H A
+ 1360 +BL H U A N H
+ N/A +BL H U N A N
- 1223 +BL H N N A N
- 206 +BL H U C N H
- 248 +UL H U N N A
- 1336 +BL H N A N N
+ 355 +BL H N A A N
- 106 +BL N U A N N
- 1875 +BL H N N A N
- 665 +UL H U N N A
- N/A +UL A U N H N
- 1260 +BL H N N N A
- 661 +BL H A N H H
- 2160 +BL H A A H H
. N/A ■ i BL N N N N 1 1V-l  [continued]
Pt  Sex    Presentation_________________Deficiencies of_________   Prolactin  ONH________ MR imaging
Age
(years)
Height
(SDS)
Weight
(SDS)
GH TSH ACTH Gn AVP (mU/L) AP PP SP CC stal
73 M 1.3 -2.9 2.8 + + - - + 114 +BL H U N N A
74 M 0.5 -2.2 1.0 + + + - + 900 +BL H N A N N
75 F 0.6 -3.9 0.0 + + + - - 448 +BL H U A N A
76 M 9.2 -3.0 2.4 + - + N/T - 766 +BL H N C N H
77 F 4.5 -3.5 2.7 + + + - + 343 +BL H U C A A
78 F 0.3 -5.7 -3.2 - + + + - N/A +BL H N N A N
79 M 0.1 -4.5 -1.0 + + + + - N/A +BL H U N N A
80 M 10.7 -5.6 -1.2 + - + - + N/A +UL H U A N A
81 F 0.5 -1.4 -4.1 + + + N/T + 160 +BL H u A N A
82 F 0.8 -6.7 -4.0 + + + - - 12 +BL H u N N A
83 M 0.9 -3.2 -0.3 + + + N/T - 555 +BL H N A N N
84 F 5.0 N/A N/A + + + - - 489 +BL H N N N A
85 M 1.0 N/A N/A + - + N/T + N/A +BL H N A N N
86 F 2.3 -7.3 -1.3 + + + N/T - 407 +BL H U A N A
87 F 0.0 N/A N/A + + + - + 812 +BL H N N A N
88 F 3.6 -6.9 -4.0 + + + N/T - 2947 +BL N U A A A
89 M 0.1 -5.2 -0.6 + + + - - N/A +BL H N A N N
90 M 0.5 N/A N/A + + + + + N/A +BL H N A N N
91 F 0.2 -6.2 -1.3 N/T + + N/T - N/A +UL H N A H N
92 M 11.3 N/A N/A + + + N/T + 202 +BL H E A N A
93 F 2.2 -5.1 N/A + - + N/T + 432 +BL A U N A N
94 M 3.3 -5.7 -1.6 + - + N/T - N/A +BL H U N N N
95 F 2.8 -5.7 0.9 + + + N/T - N/A +BL A N A N A
96 M 0.2 -6.0 -1.3 + + + N/T - 669 +BL H U N N A
264V-l  [continued]
Pt  Sex  ______ Presentation_________________Deficiencies of__________ Prolactin  ONH________ MR imaging
Age
(years)
Height
(SDS)
Weight
(SDS)
GH TSH ACTH Gn AVP (mU/L) AP PP SP CC stal
97 M 1.0 -4.8 -1.6 + + + + - 316 - H U N N A
98 M 0.6 N/A N/A + + + + - N/A - H u N N A
99 M 3.0 -4.8 0.3 + + + + - N/A - H u N N A
100 M 3.4 -4.9 0.2 + + - N/T - 441 - N u N N A
101 M 4.9 -6.7 -2.1 + + - N/T - 264 - H u N N A
102 M 2.0 -7.9 -4.9 + + - N/T - 196 - H u N N A
103 M 1.8 -2.5 1.7 N/T + + N/T - 558 - H u N H A
104 M 1.6 -4.3 -0.1 + - + N/T - 70 - H N N N A
105 M 10.8 -7.7 -4.5 + + + + - N/A - H u N N A
106 F 3.9 -9.5 -5.4 + + + + - 158 - H u N N A
107 M 0.0 N/A N/A + + + + + N/A - H N N N A
108 F 2.5 -7.5 -3.9 + + - N/T - 537 - H N N N N
109 M 4.5 N/A N/A + + - - - 298 - H N N N N
110 M 0.1 -7.9 -2.1 + + + + - 132 - H U N A A
111 M 3.0 -9.9 -6.8 + - - + - 153 - H N N N A
112 M 0.5 -7.8 -4.9 + + - - - 44 - H N N N N
113 M 0.6 -4.7 -1.8 + - - + + 151 - H N A N N
114 M 2.9 -6.8 -4.1 + + + N/T - 446 - H U N N A
115 M 0.4 -6.8 -1.6 + + + + - N/A - H U N N A
116 M 3.2 -5.3 0.9 + - - + - 281 - H u N N N
117 M 9.0 -4.5 -3.8 + + - + - 323 - E N N N N
118 M 4.5 -6.2 -1.7 + + + + - 735 - H N N N A
119 M 6.8 -6.1 -2.9 + + + + - 475 - N U N N A
120 M N/A N/A N/A + + + + _ 11 - H u N N N
265V-l  (continued]
Pt Sex Presentation Deficiencies of Prolactin
(mU/L)
ONH MR imaging
Age
(years)
Height
(SDS)
Weight
(SDS)
GH TSH ACTH Gn AVP AP PP SP CC stalk
121 F 0.1 -4.9 -1.0 4 + + 4 - 3280 - H U N N N
122 F 0.0 -3.1 1.5 + + + 4 - 667 - N U N A A
123 M N/A N/A N/A + - + - - N/A - H u N N A
124 F 0.5 -3.7 0.6 4 + 4 N/T - 810 - H u N N N
125 M 10.0 N/A N/A + + 4 - - 336 - H u N N N
126 M 7.0 -6.0 -2.2 + + 4 4 - 1051 - H u N N A
127 F N/A N/A N/A + + 4 4 - N/A - H u N N A
128 M 3.0 -7.6 3.7 + + 4 N/T - N/A - N u N N A
129 M N/A N/A N/A 4 4 - - - N/A - H N N N A
130 F 0.7 -4.2 -0.8 4 4 t N/T - 242 - H u N N N
131 M 4.8 -7.0 -3.1 + - 4 - - 591 - N u N N A
132 F N/A N/A N/A 4 + 4 4 - N/A - H N N A N
133 M 5.3 -5.1 1.1 4 + 4 N/T - 477 - N u N N A
134 M 1.9 -7.1 -2.7 + - - 4 - 105 - H u N N A
135 M 0.5 -6.8 -4.2 + 4 4 4 - N/A - H N N N A
136 M 0.3 -5.7 -0.9 + + 4 4 - 19 - H N N N N
137 M 11.3 -6.5 -2.6 + 4 - - - 732 - H N N N N
266V-2  “Control” group B: Patients with optic nerve hypoplasia and normal endocrinology
Pt sex Age at Deficiencies of Prolactin ONH MR imaging
presentation GH TSH ACTH  Gn AVP (mU/L) AP PP SP CC Stal
138 M 3.6 N/T - - - 152 +UL H N N N N
139 M 2.4 N/T - - - 60 +BL H N A N H
140 F 4.0 - - - - 117 +BL H N N N N
141 M 1.5 N/T - - - 213 +BL N A A N H
142 M 1.4 N/T - - - 191 +BL N N A H H
143 M 5.2 N/T - - - 189 +BL H N N N N
144 M 6.0 N/T - - - 174 +UL H N N N H
145 F 0.8 N/T - - - N/A +BL H N N N H
146 F 0.9 N/T - - - N/A +BL H N A H N
147 F 0.6 N/T - - - 401 +BL N N N H N
148 M 0.3 N/T - - - 423 +BL N N A A N
149 F 0.3 N/T - - - 338 +BL N N N H N
150 F 0.2 N/T - - - 277 +BL H N A H N
151 M 5.7 - - - - 55 +BL H N N N N
152 M 1.1 - - - - 86 +BL H N C A N
153 F 1.6 N/T - - - 322 +BL N N N N H
154 M 0.4 N/T - - - N/A +BL H A N N H
155 F 0.9 N/T - - - 196 +BL N N A H N
156 F 1.6 N/T - - - 300 +UL H N N N H
157 F 0.6 N/T - - - 261 +BL H A N N N
158 M 6.5 N/T - - - 487 +BL N N N N H
159 F 0.5 N/T - - - 573 +BL N N A H N
160 M 0.6 N/T - - - 220 +BL H N A H N
161 F 1.1 N/T - - - 322 +BL N N C H H
162 F 0.2 N/T _ _ _ 2082 +BL N N A N N
267V-2 [continued]
Pt Sex  Age at 
presentatioi
Deficiencies of Prolatin
(mU/L)
ONH MR imaging
n  GH TSH ACTH Gn AVP AP PP SP CC stalk
163 M 0.7 N/T - - - - 344 +BL H A A H H
164 M 0.2 N/T - - - - 244 +BL H A A N H
165 F 1.6 N/T - - - - 241 +BL H A C N H
166 M 0.7 - - - - - 254 +BL N N A N N
167 M 1.1 N/T - - - - 208 +BL H U N H H
168 M 3.4 - - - - - 170 +UL N N N A N
169 F 0.9 N/T - - - - 1812 +UL H N N H H
170 M 2.0 - - - - - 572 +UL H N N N H
2681
2
3
4
5
6
7
8
9
10
11
12
Patients with isolated GH deficiency and no midline defects on MR scanning (Group A).
sex Birth (SDS) MPH
SDS
age at GH 
treatment 
(years)
Peak
GH
(mU/L)
Deficiencies of MR imaging
weight length BMI TSH ACTH Gn AVP PRL
(mU/L)
AP PP SP/CC  Stalk ONHHPE
F -1.6 0.7 -2.7 -1.7 3.8 7.1 - - N/T - 150 N U N N
M -0.3 -1.0 0.7 -2.0 3.0 1.0 - - N/T - N/A H N N N
M 0.1 1.0 -0.4 -0.2 2.9 19.8 - - N/T - 306 N N N N
F -2.4 -1.7 -2.3 -2.3 6.1 2.6 - - N/T - N/A H N N N
F -0.7 1.9 -2.1 -1.1 2.0 7.9 - - N/T - 974 N N N N
M -2.1 -1.9 -1.6 -1.9 4.9 12.0 - - N/T - 171 H N N N
F 0.0 0.0 0.3 -1.4 4.2 7.0 - - N/T - 648 H N N Ab  -
M -1.8 -1.5 -1.4 -0.7 3.8 6.9 - - N/T - 215 H U N N
M -1.3 -0.8 -1.0 -0.7 4.9 17.6 - - N/T - 144 N N N N
M -0.7 -1.0 0.0 0.9 2.2 1.3 - - N/T - 259 H N N N
F -0.5 N/A N/A -2.4 2.8 0.5 - - - - 199 H N N N
M -1.6 -1.7 -0.9 -1.1 5.6 11.0 - - N/T - 540 N N N N
269V-4
~pt~
~TT
14
15
16
17
18
19
20
21
22
Patients with CPHD but no midline defects on MR scanning (Group B].
sex  Birth (SDS)  MPH  age at GH  Peak
  —---- --------— S D S   treatment  GH  -
weight  length  BMI  (mlJ/L)  TSH
M -4.0 -2.0 -6.0 -0.4 2.5 15.8 +
M -0.8 -1.4 0.3 -1.2 1.1 0.9 -
M -1.0 0.8 -1.8 -1.8 2.0 1.0 +
M 0.4 -1.3 2.0 0.3 3.0 2.8 +
M -0.4 2.1 -1.8 -0.4 2.0 1.7 +
F 0.2 -1.6 1.9 0.2 0.7 N/T +
F 1.3 N/A N/A 0.0 2.0 N/T +
F 0.5 -0.5 1.5 0.3 1.7 3.4 +
F 0.0 0.0 0.4 -0.2 2.2 1.2 +
M -1.1 -1.0 -0.5 0.6 1.0 N/T +
Deficiencies of  MR imaging
ACTH  Gn  AVP  PRL  AP  PP  SP/CC  Stalk  ONH  HPE 
__________________(mU/L)________________________________
- N/T  - 196 H U N Ab - -
+ + 70 H N N Ab - -
- - 44 H N N N - -
+ + 446 H U N Ab - -
+ + 1887 H U N Ab - -
+ N/T  - 3280 H u N N - -
+ + 810 H u N N - -
- N/T  - 67 H N N N - -
+ + 242 H u N N - -
+ + 19 H N N N _ _
270V-5  Patients with CPHD and midline defects on MR scanning [Group C)
Pt sex Birth (SDS) MPH  age at GH 
SDS  treatment 
(years)
Peak
GH
(mU/L)
Deficiencies of MR imaging
weight length BMI TSH ACTH  Gn AVP PRL
(mU/L)
AP PP SP/CC Stalk ONH HPE
23 F 1.7 1.5 1.5 0.2 2.6 1.7 + + + - 98 H N Ab Ab + -
24 F -1.0 N/A N/A -1.2 1.2 6.4 - + N/T + 644 H N Ab Ab + -
25 M 0.6 -2.2 3.1 0.7 3.1 2.9 + + N/T - 343 H N Ab N - +
26 F -0.2 -1.3 1.1 -1.5 2.0 20.0 - - - + 419 N N Ab N - +
27 M -1.2 0.0 -1.6 -0.5 2.5 N/T + + N/T - N/A N N Ab N + -
28 F 0.3 -1.5 2.0 0.6 1.2 5.4 + + + + 1360 H U Ab Ab + -
29 M -0.1 -1.2 1.2 -0.5 2.0 5.7 + + N/T - 266 N N Ab N + -
30 M -0.3 -1.6 1.2 0.7 1.8 5.2 + + - + 355 N N Ab N - -
31 M -1.0 -0.8 -0.5 0.9 1.6 10.5 + + + - 665 H U N Ab + -
32 M -0.7 -4.6 3.5 -1.6 1.0 6.5 + + + - 1260 H N N Ab + -
33 M -0.6 N/A N/A -2.0 1.5 8.4 + + N/T - 661 H U Ab N + -
34 F -1.3 -1.6 -0.3 -0.3 1.2 11.5 + + - - 2160 H N Ab N + -
35 M 0.4 -2.1 2.8 -0.2 0.6 N/T + + N/T - 132 H U Ab Ab - -
36 M -0.7 -1.0 0.0 -0.7 2.0 2.2 + + N/T + 900 N N Ab N + -
37 F 0.6 N/A N/A 1.4 1.5 6.9 + + - - 448 H U Ab N + -
38 M 0.2 -0.1 0.5 0.1 2.3 9.3 + + + - N/A H U N Ab + -
39 F 1.9 N/A N/A 0.0 4.0 18.6 + + N/T + 166 H u Ab Ab + -
40 M 1.6 0.5 1.9 -0.6 1.5 9.0 + - N/T - 555 H N Ab N + -
41 F 0.1 -1.1 1.3 0.5 1.0 6.7 + + + - 667 N N Ab N - -
42 F -0.8 -3.1 1.7 0.0 3.3 N/T + + N/T - 392 H U Ab Ab + -
43 M 0.2 -1.0 1.3 -0.6 1.1 20.0 + + - - N/A H N Ab N + -
44 M -1.0 N/A N/A 0.1 1.9 10.3 + + - - 669 H U N N + -
271V-6  Patients with central hypothyroidism without midline defects (Group A)
Pt Sex Age at (yrs) FT4 TT4 TSH (mU/L) Deficiencies of PRL MR imaging
diagnosis  CH  lPmol/L') (nmoi/L.) Unstimulated Peak Delayed A GH ACTH Gn AVP AP PP SP/CC stalk ONH
1 M 5.0 5.0 6.6 - 2.2 N/T + + + - 316 H u N Ab -
2 M 0.6 0.6 - 62.0 3.6 N/T + + N/T - N/A H u N Ab -
3 M 2.0 2.0 8.7 - 2.3 N/T + - N/T - 196 H u N Ab -
4 M 11.0 11.0 7.3 - 1.5 15.0 - 13.5 + N/T - 366 H u N Ab -
5 F 6.1 6.1 5.5 - 1.0 N/T + + N/T - 158 H u N Ab -
6 M 0.5 0.5 9.9 - 3.1 13.1 - 10.0 N/T + + - 222 H N N N -
7 F 1.2 1.2 11.5 - 2.1 25.9 + 23.8 + - - - 537 H N N N -
8 M 1.5 1.5 - 38.0 1.0 N/T + + - - 44 H N N Ab -
9 M 2.9 2.9 6.9 - 3.2 31.2 + 28.0 + + - - 446 H u N Ab -
10 M 0.0 0.0 7.7 - 0.3 N/T N/T + - - 1664 N N N N -
11 M 0.4 0.4 9.0 - 3.0 41.2 -+ 38.2 + + + - 1887 H U N Ab -
12 M 9.0 9.0 6.9 - 2.2 4.8 - 2.6 + - + - 323 H N N N -
13 M 0.3 3.7 - 60.0 1.0 1.0 - 0.0 + + + - 735 H N N Ab -
14 M 6.3 6.3 - 58.0 2.8 20.7 + 17.9 + + + - 475 N U N Ab -
15 F 0.0 0.0 6.4 - 3.6 49.3 - 45.7 + + + - 87 N N N N -
16 M 2.5 2.5 5.1 - 1.4 1.4 - 0.0 - - - - N/A N N N N -
17 F 0.0 0.0 5.9 - 0.0 N/T N/T + + - 1163 H U N N -
18 M 10.0 16.0 - 50.0 2.2 4.0 - 1.8 + + - - 336 H U N N -
19 M 7.0 7.0 8.4 - 2.6 14.0 - 11.4 + + + - 1051 H u N Ab -
20 M 3.0 3.0 8.8 - 3.3 6.5 - 3.2 + + - - N/A N u N Ab -
21 F 1.2 1.2 5.0 - 2.1 3.7 - 1.6 + - N/T - 67 H N N N -
22 F 0.7 0.7 6.9 - 7.7 N/T + + - - 242 H u N N -
23 M 0.1 0.1 9.6 - 4.1 N/T + + N/T - N/A H N N Ab -
24 M 0.3 0.3 10.2 - 3.3 6.6 - 3.3 + + + - 14 H N N N -
272V-7  Patients with central hypothyroidism and midline defects (Group B)
Pt  Sex  Age at (yrs)  T4  TSH (mU/L)  Deficiencies of  PRL  MR imaging
Initial  CH  FT4  TT4  Unstimulated Peak Delayed  A  GH  ACTH  Gn  AVP (mU/L)  AP  PP SP/CC  stalk  ONH
diagnosis  (pmol/L) (nmol/L)  peak
25 F 1.5 6.0 - 48.0 3.5 4.5 -
26 M 0.0 0.0 7.0 - 1.2 N/T
27 M 0.0 0.0 8.8 - 2.1 N/T
28 F 0.0 0.0 10.4 - 3.1 25.3 -
29 F 0.4 1.0 - 54.0 4.6 N/T
30 M 0.6 0.6 8.4 - 4.9 N/T
31 F 0.0 0.0 10.2 - 4.1 48.9 +
32 M 3.8 3.8 10.4 - 9.1 N/T
33 F 0.0 0.0 7.6 - 0.3 N/T
34 M 0.0 0.0 8.8 - 0.9 12.6 -
35 M 0.0 0.0 10.8 - 3.7 N/T
36 M 2.0 2.0 7.0 - 1.3 8.8 -
37 M 0.2 0.2 7.0 - 2.2 26.3 +
38 F 7.6 12.0 11.4 - 0.9 N/T
39 M 0.0 0.0 7.8 - 2.0 N/T
40 F 0.0 0.0 6.9 - 11.0 N/T
41 M 4.3 4.3 8.6 - 1.2 N/T
42 M 0.6 0.6 - 45.0 0.2 0.2 -
43 F 0.0 0.0 6.4 _ 1.7 27.9 +
1.0 + - + - 98 N N Ab N +
+ - + + N/A H N N Ab +
+ + - - 343 H N Ab N -
22.2 + + + - 567 H U Ab N +
+ + + + N/A H N N N +
+ + N/T - N/A N N Ab N +
44.8 + + + + 1360 H U Ab Ab +
+ - N/T - 1223 H N Ab N +
N/T + - - N/A N U Ab N -
11.7 N/T - - - 410 N N Ab N -
+ + N/T - 266 H N Ab N +
7.5 + + + - 1336 H N Ab N +
24.1 + + - + 355 H N Ab N +
+ + + - 106 N U Ab N +
+ + + - 1875 H N Ab N +
+ + N/T - 665 H U N Ab +
+ - + - N/A N N N N +
0.0 + + + - 1260 H N N Ab +
26.2 + + + _ 2160 H N Ab N +
273V-7 (continued]
Pt Sex Age at (yrs) T4 TSH (mU/L) Deficiencies of PRL MR imaging
Initial
diagnosis
CH FT4  TT4 
(pmol/L) (nmol/L)
I nstimulated Peak Delayed 
peak
A GH ACTH Gn AVP (mU/L) AP PP SP/CC Stalk ONH
44 M 0.1 0.1 - 42.0 5.0 N/T + + N/T - N/A H u Ab Ab -
45 M 0.3 0.3 9.9 - 2.8 N/T + + - + 900 N u N N +
46 F 0.1 11.9 6.5 - 1.8 20.5 - 18.7 + - - + 343 H u Ab Ab +
47 M 4.5 4.5 9.8 - 1.4 9.9 - 8.5 + + + - N/A H u Ab Ab +
48 M 4.0 4.0 7.0 - 2.3 23.6 - 21.3 + + - - N/A H N N N +
49 F 0.0 1.0 9.0 - 2.2 N/T + + + - 667 N N Ab N -
50 F 3.6 3.6 8.0 - 1.3 11.5 + 10.2 + + N/T - 2947 N u Ab Ab -
51 M 0.0 0.0 - 65.0 4.1 22.4 - 18.3 + + - - N/A H N Ab N +
52 M 0.5 0.5 9.1 - 6.3 13.1 + 6.8 + + - + N/A N N Ab N +
53 F 2.0 12.0 9.7 - 1.6 10.2 - 8.6 + - + - N/A H N Ab N -
54 M 0.0 0.0 9.4 - 5.5 N/T + + + - 669 H U N N
774V-8  Clinical, MR imaging and endocrine data in patients analysed to assess the efficacy of the short Synacthen test
Pt. Sex Age at Cortisol (nmol/L) Deficiencies of PRL MR imaging
test
(years)
Mean  SST (minutes) 
spontaneous  0  30  60
0800
hour
GH TSH Gn AVP  (mU/L)  AP PP SP/CC stalk ONH
1 M 0.6 28 28 98 100 28 N/T + N/T - 1664 N N N N -
2 F 0.3 28 28 64 69 28 N/T + N/T - 1163 N U N N -
3 M 0.4 39 75 214 229 52 + + - + 355 H N Ab N +
4 F 0.1 55 157 268 284 28 + + N/T - 448 H U Ab N +
5 F 0.1 68 8 259 259 28 + + - - 567 H U Ab N +
6 M 0.5 73 59 314 409 76 + - N/T + 644 H N Ab Ab +
7 M 0.3 78 28 28 28 28 + + N/T - 669 N U N N +
8 F 1.1 83 60 320 492 131 N/T + N/T - 270 H N Ab N +
9 F 2.4 83 82 358 510 56 N/T + N/T - 407 N N Ab N +
10 M 0.5 98 56 728 766 61 + + N/T - 266 H N Ab N +
11 M 1.0 99 274 469 478 162 + + + + 900 N N Ab N +
12 F 0.2 120 41 752 1141 153 + + - - 11 H N N Ab +
13 F 1.6 120 101 488 652 221 N/T - N/T - 300 N N N N +
14 M 0.9 141 88 525 680 157 + + N/T - 555 N N Ab N +
15 F 0.8 142 145 736 901 122 N/T - - - 277 H U Ab N +
16 M 5.1 148 90 457 596 233 + + N/T - 1223 H N Ab N +
17 F 0.1 157 55 823 1133 440 N/T - - - 1811 N N N N +
18 F 0.5 171 121 871 1048 121 N/T - N/T - 338 N N Ab N +
19 F 1.0 174 175 896 935 268 N/T - N/T - 503 N N N N +
20 M 0.7 198 229 842 862 193 N/T - - - 344 N N Ab N +
21 F 0.8 199 326 722 780 457 N/T - N/T - 401 N N Ab N +
22 M 1.8 204 191 730 930 315 N/T - - - 213 H U Ab Ab +
23 M 1.4 205 145 586 779 215 + + + + 114 H U N Ab +
24 M 0.5 220 353 742 930 311 N/T - - - 220 N N Ab N +
25 F 0.0 228 116 480 549 193 + + + - 2160 H N Ab N +
26 F 1.8 238 288 830 1053 375 N/T - N/T - 188 N N N N +
27 M 2.3 243 273 505 647 403 + - + - 70 N N N Ab -
28 F 0.9 258 183 800 968 175 N/T - - - 455 H N N N +
775V-9  Clinical, neuroradiological and endocrine data of patients who underwent the LHRH test
Pt. sex age at LH (U/L) at minutes FSH (U/L) at minutes genital Deficiencies of PRL MR imaging
test (yrs) 0 20 60 0 20 60 abnormality GH TSH ACTH AVP AP PP SP/CC stalk ONH
1 M 4.4 0.7 5.3 3.7 0.9 4.2 4.2 - N/T - - - 317 N U Ab N -
2 F 3.9 0.7 2.0 1.9 1.1 8.4 17.6 - + + + - 28 H N Ab N +
3 F 0.7 0.7 0.7 0.7 0.2 1.7 2.4 - + + + + 1360 H N Ab Ab +
4 F 2.9 0.7 14.2 15.7 4.3 14.9 22.4 - - + + - 2005 N N Ab N -
5 M 3.0 5.1 37.5 21.9 6.8 16.4 22.8 - N/T + + - 247 N U N N -
6 M 17.4 0.7 2.0 1.8 0.3 1.0 3.6 + + - - - 659 H U Ab Ab +
7 M 4.6 1.1 6.9 5.8 1.0 2.0 3.4 + + + + + 355 H u Ab N +
8 M 7.6 0.7 2.6 1.9 0.2 1.6 1.6 - + - + - 423 N u Ab N -
9 M 5.0 0.7 0.7 0.7 0.2 0.2 0.2 + N/T + - - 222 H u N N -
10 F 9.2 0.7 7.6 4.9 5.4 39.7 48.2 - N/T - - - 277 H u Ab N +
11 F 0.3 0.7 0.7 0.7 0.3 3.5 3.4 - + + + - 2160 H u Ab N +
12 M 16.8 0.7 2.5 1.6 0.6 3.8 4.2 - + + - + 114 H N N Ab +
13 F 7.4 0.7 13.0 11.7 15.8 44.0 49.1 - + + + + 448 H N Ab Ab +
14 M 14.9 0.7 6.4 6.8 0.8 2.1 3.8 + - - - - 86 H U Ab N +
15 M 11.5 0.7 0.7 0.7 0.2 0.9 1.6 - + - - - 90 H u N N -
16 M 15.0 0.7 0.7 0.7 0.2 0.2 0.2 - + + + - 636 H u N N -
17 M 6.0 0.7 0.7 0.7 0.2 0.2 0.2 + + + + - 1887 H N N Ab -
18 M 3.1 0.7 11.8 8.6 1.1 19.6 23.1 + - - - - 166 N u Ab N +
19 M 12.7 0.2 1.1 0.8 0.6 2.1 2.5 + + + + - N/A H N Ab Ab +
20 F 11.1 0.7 8.5 5.2 3.4 48.4 66.1 - N/T - - - 456 H U Ab Ab +
21 F 2.3 0.9 5.9 4.9 14.9 28.2 32.5 - + + - - 12 H N N Ab +
22 M 6.3 0.8 24.6 27.9 2.8 9.7 16.5 - N/T - - - 220 H U Ab N +
23 F 8.8 0.5 0.5 0.5 0.3 0.3 0.3 - + + + - 667 N U Ab N -
24 M 8.3 0.7 5.8 4.0 0.4 1.3 1.5 - N/T - - - 344 H N Ab Ab +
25 F 2.4 0.7 0.7 0.7 0.6 3.6 4.1 - + + + - 1319 N N N Ab -
26 M 9.9 0.7 6.6 4.2 0.6 2.0 2.8 - - - - - 254 N U Ab N -
27 F 0.7 0.7 0.7 0.7 0.2 0.2 0.2 - N/T + + - 1777 N N Ab N +
28 F 1.2 0.7 0.7 10.9 15.4 56.9 91.4 - N/T - - - 1812 H U Ab Ab +
29 F 16.7 0.7 11.4 11.6 9.6 52.9 78.6 - - - - - 101 N U Ab N -
30 M 5.9 0.7 2.7 2.4 0.8 1.3 1.6 + + + + - 14 H u N N -
276